Method for producing terpene compounds by biocatalysis

By using diphosphate removers from the protein tyrosine phosphatase family, the problem of terpene diphosphate intermediate cleavage was solved, enabling efficient biocatalytic synthesis of terpene compounds, particularly the production of coparol and lysine diol, providing a new method for the preparation of the high-value flavoring ingredient Ambrox.

CN112334581BActive Publication Date: 2024-11-12FIRMENICH SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980043113.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-10
Filing Date
2019-07-10
Publication Date
2024-11-12
Estimated Expiration
2039-07-10

AI Technical Summary

Technical Problem

The lack of enzymes in the current technology that can specifically cleave terpene diphosphate intermediates such as CPP and LPP leads to low efficiency in the biocatalytic synthesis of terpene compounds.

Method used

The diphosphate remover enzyme of the protein tyrosine phosphatase family, especially peptides with terpenoid diphosphate phosphatase activity, is used to cleave terpenoid diphosphate bonds to achieve the biocatalytic synthesis of terpenoid alcohols.

Benefits of technology

A more cost-effective method is provided for the efficient biocatalytic synthesis of intermediate terpenoid compounds, such as copalol and lysine diol, of high-value fragrance ingredients like Ambrox.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112334581B_ABST
    Figure CN112334581B_ABST
Patent Text Reader

Abstract

Provided herein is a biocatalytic method for producing terpene compounds by applying a novel phosphatase. The method allows for the complete biochemical synthesis of terpene compounds, such as copal and lisdendiolate, and their derivatives, which are used as valuable intermediates for the production of flavor ingredients such as ambroxan. Also provided are novel, completely biochemical, multi-step methods for the production of such compounds, as well as novel phosphatases and mutants and variants derived therefrom.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Provided herein are biocatalytic methods for producing terpene compounds using novel phosphatases. This method allows for the complete biochemical synthesis of terpene compounds, such as copalol and labdendiol, and their derivatives, which serve as valuable intermediates for the production of flavoring ingredients such as ambrox or γ-ambrol. Also provided are novel, completely biochemical, multi-step methods for producing such compounds, as well as novel phosphatases and mutants and variants derived therefrom. Background Art

[0002] Terpenes are found in most organisms (microorganisms, animals and plants). These compounds are composed of five-carbon units called isoprene units and are classified by the number of these units present in their structure. Therefore, monoterpenes, sesquiterpenes and diterpenes are terpenes containing 10, 15 and 20 carbon atoms, respectively. For example, sesquiterpenes are widely found in the plant kingdom. Many sesquiterpenoid molecules are well known for their flavor and aromatic properties as well as their cosmetic, medical and antibacterial effects. Many sesquiterpenoid hydrocarbons and sesquiterpenoid compounds have been identified.

[0003] The biosynthesis of terpenes involves enzymes called terpene synthases. These enzymes convert acyclic terpene precursors into one or more terpene products. Specifically, diterpene synthases produce diterpenes through the cyclization of the precursor geranylgeranyl diphosphate (GGPP). The cyclization of GGPP generally requires two enzyme polypeptides, i.e., type I and type II diterpene synthases that work in combination in two consecutive enzymatic reactions. Type II diterpene synthases catalyze the cyclization / rearrangement of GGPP caused by the protonation of the terminal double bond of GGPP, resulting in a cyclic diterpene diphosphate intermediate. This intermediate is then further converted by the cyclized type I diterpene synthase that catalyzes ionization.

[0004] Diterpene synthases are present in plants and other organisms and use substrates such as GGPP, but they have different product profiles. Genes and cDNAs encoding diterpene synthases have been cloned, and the corresponding recombinant enzymes have been characterized.

[0005] To date, no enzymes have been described that specifically or preferentially cleave or remove the diphosphate group from terpene diphosphate intermediates, in particular from cyclic terpene diphosphate intermediates, such as the diterpenes copalyl diphosphate (CPP) or lisdendiol diphosphate (LPP). In order to carry out such cleavage, chemical cleavage of the phosphate bond would be required.

[0006] The problem to be solved by the present invention is to provide a polypeptide which exhibits the enzymatic activity of a phosphatase which can be used for the enzymatic cleavage of terpene diphosphate bonds and allows the biocatalytic production of terpene alcohols. Summary of the Invention

[0007] The above problems were unexpectedly solved by providing a novel class of enzymes exhibiting terpene diphosphate phosphatase activity, which are selected from the subgroup of diphosphate removal enzymes of the large protein tyrosine phosphatase family. The use of such enzymes of the protein tyrosine phosphatase family as phosphatases, which utilize terpene diphosphates as substrates, in particular complex bicyclic compounds such as CPP and LPP, has not been described in the prior art.

[0008] This approach could provide a more cost-effective way to generate terpene intermediates such as copalol and lisdendiolate, which are building blocks for making high-value flavor ingredients such as Ambrox.

[0009] In some embodiments of the present invention, the biocatalytic production of acyclic terpene alcohols, such as farnesol or geranylgeraniol, from the corresponding diphosphate precursors is also provided.

[0010] The biocatalytic step can be coupled with several other preceding or consecutive enzymatic steps and allows providing a biocatalytic multi-step process for the complete enzymatic synthesis of valuable complex terpene molecules from their respective precursors. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 Copalol biosynthesis pathway. 1. Farnesyl pyrophosphate synthase. 2. Geranylgeranyl pyrophosphate synthase. 3. Copalyl pyrophosphate synthase. 4. Phosphatase.

[0012] Figure 2a GC-MS chromatograms of copalol production in E. coli cells. Top chromatogram: E. coli cells producing recombinant mevalonate pathway enzymes, CPP synthase, and AspWeTPP. Middle chromatogram: E. coli cells producing recombinant mevalonate pathway enzymes, CPP synthase, and TalVeTPP. Bottom chromatogram: Control analysis using E. coli cells producing recombinant mevalonate pathway enzymes and CPP synthase.

[0013] Figure 2b .Mass spectrum of copalol produced by E. coli cells (in Figure 1 Peak with retention time 16.7 in a) (A) and mass spectrum of authentic copalol (B).

[0014] Figure 3 . Production of copalol in engineered E. coli cells using TalVeTPP and AspWeTPP.

[0015] Figure 4. Copalol was produced in engineered E. coli cells using TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1.

[0016] Figure 5 Biosynthetic pathway of lysedil. 1. Farnesyl pyrophosphate synthase. 2. Geranylgeranyl pyrophosphate synthase. 3. Lisedil pyrophosphate synthase. 4. Phosphatase.

[0017] Figure 6 . Production of lisdendiol in engineered Escherichia coli cells using TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1.

[0018] Figure 7a GC-MS chromatograms of lisdendiol produced in E. coli cells. Upper chromatogram: E. coli cells producing recombinant enzymes of the mevalonate pathway, LPP synthase, and HelGriTPP1. Lower chromatogram: Control analysis using recombinant E. coli cells producing mevalonate pathway enzymes and LPP synthase.

[0019] Figure 7b .Mass spectrum of lisdendiol produced by E. coli cells (in Figure 6 Peak with retention time 18.2 in a) (A) and mass spectrum of authentic copalol (B).

[0020] Figure 8 Biosynthetic pathways for farnesol and geranylgeraniol. 1. Farnesyl pyrophosphate synthase. 2. Geranylgeranyl pyrophosphate synthase. 3. Phosphatase.

[0021] Figure 9 Production of farnesol and geranylgeraniol in engineered Escherichia coli cells using TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1.

[0022] Figure 10Comparison of farnesol, geranylgeraniol, copalol, and lisdendiolate production in engineered E. coli cells using TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1. Values ​​are relative to the maximum production of each compound, set to 100.

[0023] Figure 11 Production of terpene compounds in engineered E. coli cells transformed with plasmids CPOL-2 and LOH-2 and compared with cells producing LPP and CPP without expressing recombinant phosphatases.

[0024] Figure 12. Copalol produced in engineered cells. This figure shows GC-MS chromatograms of copalol produced by E. coli cells. These cells were engineered to produce copalyl diphosphate from the mevalonate pathway and to express protein tyrosine phosphatase and ADH enzymes. Each chromatogram indicates the different ADHs expressed in the cells.

[0025] Figure 13. GCMS chromatogram showing the formation of farnesaldehyde from farnesol in cells engineered to produce recombinant enzymes of the mevalonate pathway, CPP synthase, protein tyrosine phosphatase, and ADH.

[0026] Figure 14 GCMS analysis of the production of lisdendiol oxidation products in Escherichia coli cells engineered to produce recombinant enzymes of the mevalonate pathway, LPP synthase, protein tyrosine phosphatase, and ADH. Each chromatogram indicates the different ADHs expressed in the cells. The peaks for lisdendiol and its oxidation product are labeled 1 and 2, respectively.

[0027] Figure 15Schematic diagram of the chromosomal integration of genes encoding mevalonate pathway enzymes and the organization of two synthetic gene operons. mvaK1, a gene encoding mevalonate kinase from Streptococcus pneumoniae; mvaD, a gene encoding phosphomevalonate decarboxylase from Streptococcus pneumoniae; mvaK2, a gene encoding phosphomevalonate kinase from Streptococcus pneumoniae; fni, a gene encoding isopentenyl diphosphate isomerase from Streptococcus pneumoniae; mvaA, a gene encoding HMG-CoA synthase from Staphylococcus aureus; mvaS, a gene encoding HMG-CoA reductase from Staphylococcus aureus; atoB, a gene encoding acetoacetyl-CoA thiolase from Escherichia coli; and ERG20, a gene encoding FPP synthase from Saccharomyces cerevisiae.

[0028] Figure 16a Alignment of the amino acid sequence of the conserved motif region of terpene diphosphate phosphatases with the deduced consensus sequence. Conserved residues are indicated by white letters on a black background.

[0029] Figure 16b Alignment of the amino acid sequence of the conserved motif region of terpene diphosphate phosphatases with the deduced consensus sequence. Conserved residues are indicated by white letters on a black background.

[0030] Figure 17 The biosynthetic pathway of 18,13-epoxy-lisdane-15-aldehyde. Dashed arrows indicate multiple enzymatic steps. 1, phosphatase; 2, alcohol dehydrogenase. The following steps are nonenzymatic rearrangement reactions.

[0031] Figure 18 GC-MS analysis of copal and copaldiol produced using modified Saccharomyces cerevisiae strains expressing the GGPP synthase CrtE, the CPP synthase SmCPS2, the CPP phosphatase TalVeTPP, and one of the following alcohol dehydrogenases: AzTolADH1, PsAeroADH1, SCH23-ADH1, or SCH24-ADH1. DETAILED DESCRIPTION

[0032] Abbreviations used

[0033] ADH alcohol dehydrogenase

[0034] bp base pair

[0035] kb kilobase

[0036] CPP copalyl diphosphate

[0037] CPS copalyl diphosphate synthase

[0038] DNA deoxyribonucleic acid

[0039] cDNA complementary DNA

[0040] DMAPP Dimethylallyl diphosphate

[0041] DTT dithiothreitol

[0042] FPP Farnesyl diphosphate

[0043] GPP Geranyl diphosphate

[0044] GGPP Geranylgeranyl diphosphate

[0045] GGPS Geranylgeranyl diphosphate synthase

[0046] GC gas chromatography

[0047] IPP isopentenyl diphosphate

[0048] LPP Lipolytic Acid Diphosphate

[0049] LPS Lipidol diphosphate synthase

[0050] MS Mass Spectrometer / Mass Spectrometry

[0051] MVA mevalonic acid

[0052] PP diphosphate, pyrophosphate

[0053] PCR polymerase chain reaction

[0054] RNA ribonucleic acid

[0055] mRNA messenger ribonucleic acid

[0056] miRNA

[0057] siRNA Small interfering RNA

[0058] rRNA ribosomal RNA

[0059] tRNA transfer RNA

[0060] TPP terpene diphosphate

[0061] definition

[0062] As used herein, "diphosphate" and "pyrophosphate" are synonymous.

[0063] "Terpenyl" refers to acyclic and cyclic chemical hydrocarbon residues derived from the C5 structural unit isoprene, and in particular contains one or more such structural units.

[0064] "Bicyclic terpene" or "bicyclic terpene group" or "bicyclic diterpene" or "bicyclic diterpene group" refers to a terpene compound or terpene group residue that contains two carbon rings, preferably two fused carbon rings, in its structure.

[0065] A "hydrocarbyl" residue is a chemical group consisting essentially of carbon and hydrogen atoms and may be a cyclic (e.g., monocyclic or polycyclic) or acyclic, linear or branched, saturated or unsaturated moiety. It contains more than one, e.g., 2, 3, 4 or 5, but particularly 5 or more, carbon atoms, e.g., 5 to 30, 5 to 25, 5 to 20, 5 to 15 or 5 to 10 carbon atoms. The hydrocarbyl group may be unsubstituted or may carry at least one, e.g., 1 to 5, preferably 0, 1 or 2, substituents. The substituents contain one heteroatom, e.g., O or N. Preferably, the substituents are independently selected from -OH, C=O or -COOH. Most preferably, the substituent is -OH.

[0066] "Monocyclic or polycyclic hydrocarbon residues" contain 1, 2 or 3 fused (anellated) or non-fused, optionally substituted, saturated or unsaturated hydrocarbon ring groups (or "carbocyclic" groups). Each ring may contain, independently of one another, 3 to 8, in particular 5 to 7, more particularly 6 ring carbon atoms. As examples of monocyclic residues, mention may be made of "cycloalkyl" carbocyclic groups with 3 to 7 ring carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; and corresponding "cycloalkenyl" groups. "Cycloalkenyl" (or "mono- or polyunsaturated cycloalkyl") particularly represents monocyclic, mono- or polyunsaturated carbocyclic groups with 5 to 8, preferably up to 6, carbon ring members, such as monounsaturated cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

[0067] As examples of polycyclic residues, there may be mentioned groups in which one, two or three of these cycloalkyl and / or cycloalkenyl groups are linked together, e.g. fused, to form a polycyclic cycloalkyl or cycloalkenyl ring. As non-limiting examples, there may be mentioned a bicyclic decalinyl residue consisting of two fused 6-membered carbocyclic rings.

[0068] The number of substituents in such monocyclic or polycyclic hydrocarbon residues may be 1 to 10, in particular 1 to 5. Suitable substituents for such cyclic residues are selected from lower alkyl, lower alkenyl, alkylidene, alkenylidene, or residues containing one heteroatom such as O or N, for example -OH or -COOH. In particular, the substituents are independently selected from -OH, -COOH, methyl and methylidene.

[0069] The term "lower alkyl" or "short-chain alkyl" means a saturated, linear or branched hydrocarbon radical having 1 to 4, 1 to 5, 1 to 6 or 1 to 7, in particular 1 to 4, carbon atoms. By way of example, mention may be made of: methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4- methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl; and n-heptyl, and their mono- or polybranched analogs.

[0070] "Short-chain alkenyl" or "lower alkenyl" means a mono- or polyunsaturated, especially monounsaturated, straight-chain or branched hydrocarbon group having 2 to 4, 2 to 6 or 2 to 7 carbon atoms and one double bond at any position, for example C2-C6 alkenyl, for example vinyl, 1-propenyl, 2-propenyl, 1-methylvinyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, alkenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl -2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-2-butenyl 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2-methyl-2-propenyl.

[0071] An "alkylidene" group refers to a straight-chain or branched hydrocarbon substituent attached to the main body of the molecule by a double bond. It contains 1 to 6 carbon atoms. As examples of such "C1-C6 alkylidene", there may be mentioned methylidene (=CH2), ethylidene (=CH-CH2), n-propylidene, n-butylidene, n-pentylidene, n-hexylidene and their structural isomers, such as isopropylidene.

[0072] "Alkenylidene" means a monounsaturated analog of the above-mentioned alkanediyl group having more than 2 carbon atoms, and may be referred to as "C3-C6 alkenylidene." As examples, n-propenyl, n-butenyl, n-pentenyl, and n-hexenyl may be mentioned.

[0073] The unsaturated cyclic group may contain one or more, for example one, two or three, C=C bonds and be aromatic or, in particular, non-aromatic.

[0074] Specific examples of cyclic residues are groups of the formula Cyc-A-, wherein A represents a linear or branched C1-C4-alkylene bridge, in particular methylene, and Cyc represents a monocyclic or polycyclic, in particular bicyclic, saturated or unsaturated hydrocarbon residue, in particular a bicyclic annulated hydrocarbon residue, each ring containing 5 to 7, in particular 6 ring atoms, optionally substituted with 1 to 10, 1 to 5 substituents independently selected from C1-C4-alkyl, C1-C4-alkylene, C2-C4-alkenyl, oxo, hydroxy or amino, in particular C1-C4-alkyl such as methyl, and C1-C4-alkylene such as methylene. Cyc-A particularly represents a group of the formula IIIa, IIIb or IIIc:

[0075]

[0076] Typical examples of compounds containing such residues are those of formula (1) below, in particular copalol and lisdendiol and their stereoisomers.

[0077] Non-limiting examples of C1-C4 alkyl groups are methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl,

[0078] Non-limiting examples of C1-C4 alkylene groups are methylene (=CH2), ethylene (=CH-CH2), n-propylene, n-butylene and structural isomers thereof.

[0079] Non-limiting examples of C2-C4 alkenyl are ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl,

[0080] Non-limiting examples of C1-C4 alkylene are -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)2-CH(CH3)-, -CH2-CH(CH3)-CH2-.

[0081] The "precursor" molecule of the target compound described herein is preferably converted to the target compound by the enzymatic action of a suitable polypeptide that undergoes at least one structural change to the precursor molecule. For example, a "diphosphate precursor" (e.g., a "terpene diphosphate precursor") is converted to the target compound (e.g., a terpene alcohol) by enzymatic removal of the diphosphate moiety, e.g., by removal of a monophosphate or diphosphate group, with the aid of a phosphatase. For example, an "acyclic precursor" (e.g., an acyclic terpene precursor") can be converted to a cyclic target molecule (e.g., a cyclic terpene compound) in one or more steps by the action of a cyclase or synthase, regardless of the specific enzymatic mechanism of the enzyme.

[0082] "Terpene synthase" refers to a polypeptide that converts a terpene precursor molecule into the corresponding terpene target molecule, such as, in particular, a processed target terpene alcohol. Non-limiting examples of such terpene precursor molecules are, for example, acyclic compounds selected from farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP), or a mixture of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). In cases where the terpene obtained contains a diphosphate moiety, the synthase is referred to as a "terpene diphosphate synthase."

[0083] The term "terpene diphosphate synthase" or "polypeptide having terpene diphosphate synthase activity" or "terpene diphosphate synthase protein (matter)" or "having the ability to produce terpene diphosphate" relates to a polypeptide that can catalyze the synthesis of terpene diphosphate in the form of any stereoisomer or a mixture thereof, the synthesis starting from acyclic terpene pyrophosphate, in particular GPP, FPP or GGPP or IPP together with DMAPP. Terpene diphosphate may be the only product or may be part of a mixture of terpene phosphates. The mixture may contain terpene monophosphates and / or terpene alcohols. The above definition also applies to "bicyclic diterpene diphosphate synthases", which can produce bicyclic terpene diphosphates such as CPP or LPP.

[0084] As an example of such a "terpene diphosphate synthase" or "diterpene diphosphate synthase", copalyl diphosphate synthase (CPS) can be mentioned. Copalyl diphosphate may be the only product or may be part of a mixture of copalyl phosphates. The mixture may contain copalyl monophosphate and / or other terpene diphosphates.

[0085] As an example of such a "terpene diphosphate synthase" or "diterpene diphosphate synthase", lisdandiol diphosphate synthase (LPS) can be cited. Lisdandiol diphosphate may be the only product or may be part of a mixture of lisdandiol phosphates. The mixture may contain lisdandiol monophosphate and / or terpene diphosphate.

[0086] "Terpene diphosphate synthase activity" or "diterpene diphosphate synthase activity" (e.g., CPS or LPS activity) can be determined under "standard conditions" as follows: recombinant terpene diphosphate synthase-expressing host cells, disrupted terpene diphosphate synthase-expressing cells, fractions thereof, or enriched or purified terpene diphosphate synthase can be used to determine these activities at a temperature of about 20 to 45° C., for example, about 25 to 40° C., preferably 25 to 32° C., in a culture medium or reaction medium (preferably buffered) having a pH of 6 to 11, preferably 7 to 9, and in the presence of a reference substrate (here, in particular GGPP) added at an initial concentration of 1 to 100 μM, preferably 5 to 50 μM, in particular 30 to 40 μM, or produced endogenously by the host cell. The conversion reaction to form terpene diphosphate is carried out for 10 minutes to 5 hours, preferably about 1 to 2 hours. If no endogenous phosphatase is present, one or more exogenous phosphatases, such as alkaline phosphatase, are added to the reaction mixture to convert the terpene diphosphate formed by the synthase into the corresponding terpene alcohol. The terpene alcohol can then be determined using conventional methods, for example after extraction with an organic solvent such as ethyl acetate.

[0087] The term "protein tyrosine phosphatase" refers to a group of enzymes generally known to remove phosphate groups from phosphorylated tyrosine residues on proteins. A specific subgroup of this family described herein are enzymes that dephosphorylate phosphorylated terpene molecules.

[0088] The polypeptides of the present invention having terpene diphosphate phosphatase activity are identified as members of the protein tyrosine phosphatase family, particularly members of the Y-phosphatase 3 family with Pfam ID number PF13350. The following website can be used, for example, to scan the polypeptide for matches with the Pfam protein family feature database, particularly the Pfam 32.0 database version (September 2018):

[0089] http: / / pfam.xfam.org / search#tabview=tab0,

[0090] https: / / www.ebi.ac.uk / Tools / hmmer / search / hmmscan or

[0091] https: / / www.ebi.ac.uk / Tools / pfa / pfamscan / .

[0092] The term "Pfam" refers to a large collection of protein domains and protein families maintained by the Pfam Consortium, which is available on several sponsored World Wide Web sites, including: pfam.sanger.ac.uk / (Welcome Trust, Sanger Institute); pfam.sbc.su.se / (Stockholm Bioinformatics Center) and pfam.janelia.org / (Janelia Farm, Howard Hughes Medical Institute). The latest version of Pfam is Pfam 32.0 (September 2018), based on UniProt Reference Proteomes (El-Gebali S. et al, 2019, Nucleic Acids Res. 47, Database issue D427–D432). Pfam domains and families are identified using multiple sequence alignments and hidden Markov models (HMMs). Pfam-A family or domain assignments are high-quality assignments generated using representative members of a protein family through curated seed alignments and profile hidden Markov models based on the seed alignments (matches of a queried protein to a Pfam domain or family are Pfam-A matches unless otherwise stated). A complete alignment of the family is then automatically generated using all identified sequences belonging to the family (Sonnhammer (1998) Nucleic Acids Research 26, 320-322; Bateman (2000) Nucleic Acids Research 26, 263-266; Bateman (2004) Nucleic Acids Research 32, Database Issue, D138-D141; Finn (2006) Nucleic Acids Research Database Issue 34, D247-251; Finn (2010) Nucleic Acids Research Database Issue 38, D211-222). For example, by accessing the Pfam database using any of the above reference websites, a protein sequence can be queried against the HMM using the HMMER homology search software (e.g., HMMER2, HMMER3, or higher versions hmmer.janelia.org / ). Significant matches that identify the queried protein as a pfam family (or having a particular Pfam domain) are matches with a bit score greater than or equal to the collection threshold for the Pfam domain.Expected values ​​(e-values) can also be used as criteria for including a query protein in Pfam or determining whether a query protein has a specific Pfam domain, where the e-value is low, much less than 1.0, such as less than 0.1 or less.

[0093] "E value" (expected value) refers to the number of hits that would be expected to score equal to or higher than this value by chance alone. This means that a good E value that gives a reliable prediction is much less than 1. An E value around 1 is the expectation by chance. Therefore, the lower the E value, the more specific the search for the domain. Only positive numbers (as defined by Pfam) are allowed. The term "terpene diphosphate phosphatase" or "polypeptide having terpene diphosphate phosphatase activity" or "terpene diphosphate phosphatase protein" or "having the ability to produce terpene alcohols" relates to a polypeptide that is capable of catalyzing the removal of a diphosphate moiety or a monophosphate moiety (regardless of the specific enzymatic mechanism) to form a dephosphorylated compound, in particular the corresponding alcohol compound of the terpene moiety. The terpene alcohol may be present in the product in the form of any stereoisomer thereof or a mixture thereof. The terpene alcohol may be the only product or may be part of a mixture with other terpene compounds, such as dephosphorylated analogs of individual (e.g., non-cyclic) terpene diphosphate precursors of the terpene diphosphate. The above definition also applies to "bicyclic terpene-based diphosphate phosphatases," which produce bicyclic terpene alcohols such as copalol or lisdandiol. Each of the above phosphatases exemplifies a "diphosphate removal enzyme."

[0094] As an example of such a "terpene diphosphate phosphatase", copalyl diphosphate phosphatase (CPP phosphatase) may be mentioned. Copalyl diphosphate phosphatase may be the sole product or may be part of a mixture with dephosphorylated precursors (e.g., farnesol and / or geranylgeraniol); and / or by-products resulting from enzymatic side reactions in the reaction mixture, such as esters or aldehydes of such alcohols or other cyclic or acyclic diterpenes.

[0095] As another example of such an enzyme "terpene diphosphate phosphatase", lisdandiol diphosphate phosphatase (LPP phosphatase) may be mentioned. Lisdandiol may be the sole product or may be part of a mixture with dephosphorylated precursors (e.g., farnesol and / or geranylgeraniol); and / or by-products resulting from enzymatic side reactions in the reaction mixture, such as esters or aldehydes of such alcohols or other cyclic or acyclic diterpenes.

[0096] The terpene diphosphate was determined under the following standard conditions: Phosphatase"Activity" (such as CPP or LPP phosphatase activity): These can be determined using recombinant terpene diphosphate phosphatase-expressing host cells, disrupted terpene diphosphate phosphatase-expressing cells, fractions thereof, or enriched or purified terpene diphosphate phosphatase at a temperature of about 20 to 45° C., for example about 25 to 40° C., preferably 25 to 32° C., in a culture medium or reaction medium (preferably buffered) having a pH of 6 to 11, preferably 7 to 9, and in the presence of a reference substrate (here, for example, CPP or LPP) added at an initial concentration of 1 to 100 μM, preferably 5 to 50 μM, in particular 30 to 40 μM, or produced endogenously by the cell host. The conversion reaction to form terpene diphosphates is carried out for 10 minutes to 5 hours, preferably about 1 to 2 hours. The terpene alcohol can then be determined using conventional methods, for example after extraction with an organic solvent such as ethyl acetate.

[0097] Specific examples of suitable standard conditions can be taken from the experimental section below.

[0098] In the context of the present invention, "alcohol dehydrogenase" (ADH) refers to a polypeptide that + or NADP + As a cofactor, it has the ability to oxidize alcohols to the corresponding aldehydes. Such enzymes are EC family 1.1.1.1 (NAD + Dependency) or 1.1.1.2 (NADP + More particularly, the ADH of the present invention has the ability to oxidize copalol to copalaldehyde and / or oxidize lisdendiol to the corresponding aldehyde.

[0099] As used herein, "copalol" refers to (E)-5-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-en-1-ol; CAS Registry Number 10395-43-4.

[0100] As used herein, "copalaldehyde" refers to (2E)-3-methyl-5-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylenedecahydro-1-naphthyl]-2-pentenal.

[0101] As used herein, “lisdandiol” refers to (1R,2R,4aS,8aS)-1-[(E)-5-hydroxy-3-methylpent-3-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-2-ol; CAS Registry Number 10267-31-9.

[0102] As used herein, "mainosol" refers to 5-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-1-en-3-ol.

[0103] As used herein, (+)-manooloxy refers to 4-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylenedecahydro-1-naphthyl]-2-butanone.

[0104] As used herein, "Z-11" refers to (3S,5aR,7aS,11aS,11bR)-3,8,8,11a-tetramethyldodecahydro-3,5a-epoxynaphtho[2,1-c]oxepin (oxepin).

[0105] As used herein, "γ-ambrol" refers to 2-[(1S,4aS,8aS)-5,5,5a-trimethyl-2-methylenedecahydro-1-naphthyl]ethanol.

[0106] The ones used in this article It refers to 3aR,5aS,9aS,9bR)-3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan.

[0107] As used herein, "sclareolide" refers to 3a,6,6,9a-tetramethyldecahydronaphtho[2,1-b]furan-2(1H)-one.

[0108] As used herein, "DOL" refers to (1R,2R,4aS,8aS)-1-(2-hydroxyethyl)-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-2-ol...CAS No. 38419-75-9

[0109] As used herein, "farnesol" refers to (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol

[0110] As used herein, "geranylgeraniol" refers to (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol.

[0111] In general, the following meanings apply:

[0112] For compounds similar to Z11: the general formula is 8,13:13,20-diepoxy-15,16-dinorlabdane (or diepoxy-dinorlabdane):

[0113]

[0114] For similar Compounds with the general formula 8,12-epoxy-13,14,15,16-tetranorlabdane (or epoxy-tetranorlabdane):

[0115]

[0116] The terms "biological function," "function," "biological activity," or "activity" of a terpene synthase refer to the ability of a terpene diphosphate synthase as described herein to catalyze the formation of at least one terpene diphosphate from the corresponding precursor terpene.

[0117] The terms "biological function," "function," "biological activity," or "activity" of a terpene diphosphate phosphatase refer to the ability of a terpene diphosphate phosphatase as described herein to catalyze the removal of a diphosphate group from a terpene compound to form the corresponding terpene alcohol.

[0118] The "mevalonate pathway" (also known as the "isoprenoid pathway" or "HMG-CoA reductase pathway") is an essential metabolic pathway in eukaryotes, archaea, and some bacteria. The mevalonate pathway begins with acetyl-CoA, producing two five-carbon building blocks called isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). The key enzymes are acetoacetyl-CoA thiolase (atoB), HMG-CoA synthase (mvaS), HMG-CoA reductase (mvaA), mevalonate kinase (MvaK1), phosphomevalonate kinase (MvaK2), mevalonate diphosphate decarboxylase (MvaD), and isopentenyl pyrophosphate isomerase (idi). Coupling the mevalonate pathway with enzyme activities to produce the terpene precursors GPP, FPP, or GGPP, particularly FPP synthase (ERG20), allows recombinant cells to produce terpenes.

[0119] As used herein, the term "host cell" or "transformed cell" refers to a cell (or organism) that has been altered to harbor at least one nucleic acid molecule, for example, a recombinant gene encoding a desired protein or nucleic acid sequence that, when transcribed, produces a functional polypeptide of the present invention, i.e., a terpene diphosphate synthase protein or terpene diphosphate phosphatase as defined above. The host cell is particularly a bacterial cell, a fungal cell, or a plant cell or plant. The host cell may contain a recombinant gene or genes that have been integrated into the host cell's nuclear or organelle genome, for example, genes organized as an operon. Alternatively, the host may contain recombinant genes extrachromosomally.

[0120] The term "organism" refers to any non-human multicellular or unicellular organism, such as a plant or a microorganism. In particular, the microorganism is a bacterium, yeast, algae or fungus.

[0121] The term "plant" is used interchangeably to include plant cells, including plant protoplasts, plant tissues, plant cell tissue cultures to produce regenerated plants or plant parts, or plant organs such as roots, stems, leaves, flowers, pollen, ovules, embryos, fruits, etc. Any plant can be used to practice the methods of the embodiments herein.

[0122] "Capable of producing FPP" is meant when a particular organism or cell naturally produces FPP or when it does not naturally produce FPP but is transformed with a nucleic acid as described herein to produce FPP. Also encompassed by "organisms or cells capable of producing FPP" are organisms or cells that have been transformed to produce higher amounts of FPP than the naturally occurring organism or cell.

[0123] "Capable of producing GGPP" is meant when a particular organism or cell naturally produces GGPP or when it does not naturally produce GGPP but is transformed with a nucleic acid as described herein to produce GGPP. Also encompassed by "organisms or cells capable of producing GGPP" are organisms or cells that have been transformed to produce higher amounts of GGPP than the naturally occurring organism or cell.

[0124] "Capable of producing terpenyl diphosphate" is meant when a particular organism or cell naturally produces a terpenyl diphosphate as defined herein or when it does not naturally produce the diphosphate but is transformed with a nucleic acid as described herein to produce the diphosphate. Organisms or cells that have been transformed to produce higher amounts of terpenyl diphosphate than the naturally occurring organism or cell are also encompassed as "organisms or cells capable of producing terpenyl diphosphate."

[0125] "Capable of producing a terpene alcohol" is meant when a particular organism or cell naturally produces a terpene alcohol as defined herein, or when it does not naturally produce the alcohol but is transformed using a nucleic acid as described herein to produce the alcohol. Also encompassed within the meaning of "organisms or cells capable of producing a terpene alcohol" are organisms or cells that have been transformed to produce a higher amount of a terpene alcohol than the naturally occurring organism or cell.

[0126] For purposes of this specification and the appended claims, the use of "or" means "and / or" unless stated otherwise. Similarly, the various tenses of "including," "comprising," "comprising," and "comprising" are interchangeable and not limiting.

[0127] It should be further understood that while the term "comprising" is used in the description of various embodiments, those skilled in the art will understand that in some specific cases, the language "consisting essentially of" or "consisting of" may be used alternatively to describe the embodiment.

[0128] As used herein, the terms "purified," "substantially purified," and "isolated" refer to a state free from other, different compounds with which the compounds of the invention are normally associated in their natural state, such that "purified," "substantially purified," and "isolated" articles comprise at least 0.5%, 1%, 5%, 10%, or 20%, or at least 50% or 75%, by weight of a given sample. In one embodiment, these terms refer to at least 95%, 96%, 97%, 98%, 99%, or 100% by weight of a compound of the invention. As used herein, when referring to nucleic acids or proteins, the terms "purified," "substantially purified," and "isolated" of nucleic acids or proteins also refer to a purified or concentrated state that is different from the state in which they naturally exist, for example, in a prokaryotic or eukaryotic environment, such as in bacterial or fungal cells, or in mammals, particularly humans. Any degree of purification or concentration greater than that found in nature, including (1) purification from other related structures or compounds, or (2) association with structures or compounds with which they are not normally associated in the prokaryotic or eukaryotic environment, is within the meaning of "isolated." The nucleic acids, proteins, or classes of nucleic acids or proteins described herein can be isolated or otherwise associated with structures or compounds with which they are not normally associated in nature according to various methods and procedures known to those skilled in the art.

[0129] The term "about" indicates a possible variation of ±25%, in particular ±15%, ±10%, more in particular ±5%, ±2% or ±1% of the stated value.

[0130] The term "substantially" describes a value range of about 80 to 100%, such as 85 to 99.9%, particularly 90 to 99.9%, more particularly 95 to 99.9%, or 98 to 99.9%, especially 99 to 99.9%.

[0131] “Predominantly” means a proportion in the range of greater than 50%, for example in the range of 51% to 100%, in particular in the range of 75% to 99.9%; especially 85 to 98.5%, for example 95 to 99%.

[0132] In the context of the present invention, "primary product" means a single compound or a group of at least two compounds, for example two, three, four, five or more, in particular two or three compounds, which is "primarily" produced by the reaction described herein and is contained in the reaction in a major proportion based on the total amount of the components of the products formed by the reaction. The proportion can be a molar ratio, a weight ratio or, preferably, an area ratio calculated from the corresponding chromatogram of the reaction products based on chromatographic analysis.

[0133] In the context of the present invention, "by-product" means a single compound or a group of at least two compounds, such as 2, 3, 4, 5 or more, in particular 2 or 3 compounds, which single compound or group of compounds is not "primarily" prepared by the reaction described herein.

[0134] Due to the reversible nature of enzymatic reactions, unless otherwise stated, the present invention relates to the enzymatic or biocatalytic reactions described herein in both reaction directions.

[0135] "Functional mutants" of the polypeptides described herein include "functional equivalents" of such polypeptides as defined below.

[0136] The term "stereoisomers" includes conformational isomers, in particular configurational isomers.

[0137] According to the present invention, all "stereoisomeric forms" of the compounds described herein, such as "constitutional isomers" and "stereoisomers" are generally included.

[0138] "Stereoisomeric forms" specifically include "stereoisomers" and mixtures thereof, e.g., configurational isomers (optical isomers), e.g., enantiomers, or geometric isomers (diastereomers), e.g., E- and Z-isomers, and combinations thereof. If one or more asymmetric centers are present in a molecule, the present invention includes all combinations of different configurations of these asymmetric centers, e.g., pairs of enantiomers.

[0139] "Stereoselectivity" describes the ability to produce a specific stereoisomer of a compound in stereomerically pure form or the ability to specifically convert a specific stereoisomer from multiple stereoisomers using the enzymatic methods described herein. More specifically, this means that the product of the invention is enriched with respect to a specific stereoisomer, or that the educt is depleted with respect to a specific stereoisomer. This can be quantified by the purity parameter, %ee, calculated according to the following formula:

[0140] %ee=[X A -X B ] / [X A +X B ]*100,

[0141] where X A and X B represents the molar ratio of stereoisomers A and B (Molenbruch).

[0142] The term "selectively convert" or "increase selectivity" generally means that during the entire course of the reaction (i.e., between the start and end of the reaction), at a certain point in time in the reaction, or during a "period" of the reaction, a specific stereoisomeric form, such as the E-form of an unsaturated hydrocarbon, is converted in a higher proportion or amount (compared on a molar basis) than the corresponding other stereoisomeric forms, such as the Z-form. In particular, the selectivity can be observed during a "period" corresponding to a conversion rate of 1 to 99%, 2 to 95%, 3 to 90%, 5 to 85%, 10 to 80%, 15 to 75%, 20 to 70%, 25 to 65%, 30 to 60%, or 40 to 50% of the initial amount of substrate. The higher proportion or amount can be expressed, for example, in the following manner:

[0143] - a higher maximum isomer yield observed during the entire reaction process or during said portion thereof;

[0144] - a higher relative content of an isomer at a determined percentage substrate conversion value; and / or

[0145] - The same relative content of isomers at higher percentage conversion values;

[0146] Each of these is preferably viewed relative to a reference method performed under otherwise identical conditions using a known chemical or biochemical method.

[0147] The present invention generally encompasses all "isomeric forms" of the compounds described herein, such as structural isomers, especially stereoisomers, and mixtures thereof, such as optical isomers or geometric isomers, such as E- and Z-isomers, and combinations thereof. If several asymmetric centers are present in a molecule, the present invention encompasses all combinations of different conformations of these asymmetric centers, such as enantiomeric pairs, or any mixture of stereoisomeric forms.

[0148] The "yield" and / or "conversion" of the reaction according to the invention is determined over a defined period of time, for example 4, 6, 8, 10, 12, 16, 20, 24, 36 or 48 hours, during which the reaction is carried out. In particular, the reaction is carried out under precisely defined conditions, for example "standard conditions" as defined herein.

[0149] The different yield parameters ("yield" or YP / S; "specific productivity yield"; or space-time yield (STY)) are well known in the art and are determined as described in the literature.

[0150] "Yield" and "YP / S" (both expressed as mass of product produced / mass of material consumed) are used as synonyms herein.

[0151] The specific productivity yield describes the amount of product produced per gram of biomass per liter of fermentation broth per hour. The wet cell weight expressed as WCW describes the number of biologically active microorganisms in the biochemical reaction. This value is given as g of product per g WCW per hour (i.e. g / g WCW). -1 h -1 Alternatively, the amount of biomass can also be expressed as the amount of dry cell weight, expressed as DCW. In addition, by measuring the 600nm (OD 600 ) and using experimentally determined correlation factors to estimate the corresponding wet or dry cell weights, respectively, can more easily determine biomass concentration.

[0152] The terms "fermentative production" or "fermentation" refer to the ability of a microorganism (aided by enzyme activities contained in or produced by the microorganism) to produce a compound in a cell culture using at least one carbon source added to the incubation.

[0153] The term "fermentation broth" is understood to mean a liquid, in particular an aqueous solution or an aqueous / organic solution, which is based on a fermentation process and which has been subjected to or has been subjected to a work-up such as described herein.

[0154] "Enzymatic" or "biocatalytic" methods are methods that are performed under the catalytic action of an enzyme (including enzyme mutants as defined herein). Thus, the method can be performed in the presence of the enzyme in isolated (purified, enriched) or crude form, or in the presence of a cell system, in particular a natural or recombinant microbial cell comprising the enzyme in active form and having the ability to catalyze the conversion reaction as disclosed herein.

[0155] If the present disclosure relates to features, parameters and ranges thereof with varying degrees of preference (including generic, non-explicitly preferred features, parameters and ranges thereof), then, unless otherwise stated, any combination of two or more of these features, parameters and ranges is encompassed within the disclosure of the present invention regardless of their respective degrees of preference.

[0156] Detailed description

[0157] a. Specific Embodiments of the Invention

[0158] The present invention specifically relates to the following embodiments:

[0159] 1. The first main embodiment relates to a biocatalytic process for producing a terpene alcohol compound of formula 1,

[0160]

[0161] in

[0162] R represents H or, more particularly, a cyclic or acyclic, linear or branched, saturated or unsaturated, optionally substituted hydrocarbon residue, preferably having a total number of carbon atoms divisible by 5, particularly divisible by 5, 10, 15 or 20, more particularly divisible by 10 or 15,

[0163] The method comprises the following steps:

[0164] (1) contacting the corresponding terpene diphosphate precursor of the terpene compound of formula (1) with a polypeptide having terpene diphosphate phosphatase activity, such as monoterpene-, sesquiterpene- or diterpene-diphosphate phosphatase activity, to form the terpene alcohol; and

[0165] (2) Optionally, the terpene alcohol of step (1) is separated.

[0166] The polypeptide having terpene diphosphate phosphatase activity is selected from diphosphate removal enzyme members of the protein tyrosine phosphatase family.

[0167] The polypeptide of this embodiment having "terpene diphosphate phosphatase activity" is identified as a member of the protein tyrosine phosphatase family, in particular a member of the gamma-phosphatase 3 family having Pfam ID No. PF13350.

[0168] 2. The second main embodiment of the present invention relates to a biocatalytic method for producing bicyclic diterpene alcohol compounds,

[0169] The following steps are involved:

[0170] a) contacting the corresponding bicyclic diterpenyl diphosphate precursor of the bicyclic diterpene compound with a polypeptide having terpene diphosphate phosphatase activity, such as diterpene diphosphate phosphatase activity or more particularly bicyclic diterpene diphosphate phosphatase activity, to form the bicyclic diterpene alcohol; and

[0171] b) Optionally, the bicyclic diterpene alcohol of step (1) is isolated.

[0172] The polypeptide of this embodiment having "terpene diphosphate phosphatase activity" is identified as a member of the protein tyrosine phosphatase family, in particular a member of the gamma-phosphatase 3 family having Pfam ID No. PF13350.

[0173] 3. The method of embodiment 2, wherein the polypeptide having terpene diphosphate phosphatase activity is selected from diphosphate-removing enzyme members of the protein tyrosine phosphatase family.

[0174] 4. The method of embodiment 1 or 3, wherein the polypeptide having terpene diphosphate phosphatase activity is selected from a class of diphosphate removal enzymes characterized by an amino acid sequence having the following active site signature motif:

[0175] HCxxGxxR (SEQ ID NO:57)

[0176] in

[0177] Each x independently represents any natural amino acid residue.

[0178] 5. The method of embodiment 4, wherein the active site signature motif is:

[0179] HC(T / S)xGKDRTG (SEQ ID NO:58)

[0180] in

[0181] x represents any natural amino acid residue and is, for example, selected from the group consisting of L, A, G and V residues.

[0182] In another embodiment, the polypeptide having terpene diphosphate phosphatase activity comprises Figure 16b The amino acid consensus sequence motif is shown.

[0183] 6. The method according to any one of the preceding embodiments, wherein the polypeptide having terpene diphosphate phosphatase activity is selected from the group consisting of:

[0184] a) TalVeTPP comprising the amino acid sequence according to SEQ ID NO: 2

[0185] b) AspWeTPP comprising the amino acid sequence according to SEQ ID NO: 6

[0186] c) HelGriTPP comprising the amino acid sequence according to SEQ ID NO: 10,

[0187] d) UmbPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 13

[0188] e) TalVeTPP2 comprising the amino acid sequence according to SEQ ID NO: 16

[0189] f) HydPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 19,

[0190] g) TalCeTPP1 comprising the amino acid sequence according to SEQ ID NO: 22,

[0191] h) TalMaTPP1 comprising the amino acid sequence according to SEQ ID NO: 25,

[0192] i) TalAstroTPP1 comprising the amino acid sequence according to SEQ ID NO: 28, and

[0193] j) PeSubTPP1 comprising the amino acid sequence according to SEQ ID NO: 31, and

[0194] k) A polypeptide having terpene diphosphate phosphatase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to j).

[0195] 7. The process according to any one of embodiments 1 and 4 to 6, wherein a terpene alcohol compound of the general formula 1 is prepared, wherein R represents H or, more particularly, an acyclic, linear or branched, saturated or unsaturated hydrocarbon residue, preferably having a total number of carbon atoms divisible by 5, in particular divisible by 5, 10, 15 or 20.

[0196] 8. The method of embodiment 7, wherein the terpene alcohol of formula 1 is selected from farnesol and geranylgeraniol.

[0197] 9. The method according to any one of embodiments 2 to 6, wherein step (1) further comprises contacting the acyclic terpene diphosphate precursor with a polypeptide having bicyclic diterpene diphosphate synthase activity to form the bicyclic diterpene diphosphate precursor.

[0198] 10. The method of embodiment 9, wherein the bicyclic diterpene-based diphosphate synthase is selected from the group consisting of:

[0199] a) SmCPS2 comprising the amino acid sequence according to SEQ ID NO: 34,

[0200] b) TaTps1-del59 comprising the amino acid sequence according to SEQ ID NO: 40,

[0201] c) SsLPS comprising the amino acid sequence according to SEQ ID NO: 38, and

[0202] d) a polypeptide having bicyclic diterpene diphosphate synthase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a), b) and c).

[0203] 11. The method according to any one of embodiments 2 to 6, 9 and 10, wherein the biocatalytically produced bicyclic diterpene alcohol is selected from copalol, in particular (+)-copalol and lisdandiol, each of which is in the form of a substantially pure stereoisomer or in the form of a mixture of at least two stereoisomers.

[0204] 12. The method of any one of the preceding embodiments, further comprising processing the terpene alcohol of step (1) or step (2) into an alcohol derivative as step (3) using chemical or biocatalytic synthesis or a combination of both.

[0205] 13. The method of embodiment 12, wherein the derivative is a hydrocarbon, alcohol, diol, triol, acetal, ketal, aldehyde, acid, ether, amide, ketone, lactone, epoxide, acetate, glycoside and / or ester.

[0206] 14. The method according to embodiment 12 or 13, wherein the terpene alcohol is oxidized biocatalytically.

[0207] 15. The method of embodiment 14, wherein the terpene alcohol is converted by contacting with an alcohol dehydrogenase (ADH).

[0208] 16. The method of embodiment 15, wherein the ADH is selected from:

[0209] a) CymB comprising the amino acid sequence according to SEQ ID NO: 42;

[0210] b) AspWeADH1 comprising the amino acid sequence according to SEQ ID NO: 44;

[0211] c) PsAeroADH1 comprising the amino acid sequence according to SEQ ID NO: 46;

[0212] d) AzTolADH1 comprising the amino acid sequence according to SEQ ID NO: 48;

[0213] e) AroAroADH1 comprising the amino acid sequence according to SEQ ID NO: 50;

[0214] f) ThTerpADH1 comprising the amino acid sequence according to SEQ ID NO: 52;

[0215] g) CdGeoA comprising the amino acid sequence according to SEQ ID NO: 54;

[0216] h) VoADH1 comprising the amino acid sequence according to SEQ ID NO: 56; and

[0217] i) A polypeptide having ADH activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to h).

[0218] 17. The method according to any one of embodiments 2 to 6 and 9 to 11 for the biocatalytic production of copalol, comprising the following steps:

[0219] (1) contacting copalyl diphosphate with a polypeptide having copalyl diphosphate (CPP) phosphatase activity to form copalyl alcohol, particularly (+)-copalyl alcohol, in substantially pure stereoisomerically form, or to form copalyl alcohol as a mixture of at least two stereoisomers; and

[0220] (2) Optionally, the copalol from step (1) is separated.

[0221] 18. The method of embodiment 17, wherein the polypeptide having copalyl diphosphate phosphatase activity is selected from the group consisting of:

[0222] a) TalVeTPP comprising the amino acid sequence according to SEQ ID NO: 2

[0223] b) AspWeTPP comprising the amino acid sequence according to SEQ ID NO: 6

[0224] c) HelGriTPP comprising the amino acid sequence according to SEQ ID NO: 10,

[0225] d) UmbPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 13

[0226] e) TalVeTPP2 comprising the amino acid sequence according to SEQ ID NO: 16

[0227] f) HydPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 19,

[0228] g) TalCeTPP1 comprising the amino acid sequence according to SEQ ID NO: 22,

[0229] h) TalMaTPP1 comprising the amino acid sequence according to SEQ ID NO: 25,

[0230] i) TalAstroTPP1 comprising the amino acid sequence according to SEQ ID NO: 28, and

[0231] j) PeSubTPP1 comprising the amino acid sequence according to SEQ ID NO: 31, and

[0232] k) A polypeptide having copalyl diphosphate phosphatase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to j).

[0233] 19. The method of any one of embodiments 17 and 18, wherein step (1) further comprises the biocatalytic conversion of a terpene pyrophosphate (e.g., geranylgeranyl pyrophosphate (GGPP), or a mixture of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP)) into copalyl diisopropyl ester (CPP) by the catalytic action of copalyl pyrophosphate synthase (CPS).

[0234] 20. The method of embodiment 19, wherein the CPS is selected from:

[0235] a) SmCPS2 comprising the amino acid sequence according to SEQ ID NO: 34,

[0236] b) TaTps1-del59 comprising the amino acid sequence according to SEQ ID NO: 40, and

[0237] c) a polypeptide having copalyl pyrophosphate synthase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) and b).

[0238] 21. The method of any one of embodiments 17 to 20, further comprising processing the copalol of step (1) or step (2) into a copalol derivative as step (3) using chemical or biocatalytic synthesis, or a combination of both.

[0239] 22. The method of embodiment 21, wherein the derivative is a hydrocarbon, alcohol, diol, triol, acetal, ketal, aldehyde, acid, ether, amide, ketone, lactone, epoxide, acetate, glycoside and / or ester.

[0240] 23. The method according to embodiment 21 or 22, wherein copalol is oxidized biocatalytically.

[0241] 24. The method of embodiment 23, wherein copalol is oxidized by contacting with an alcohol dehydrogenase (ADH).

[0242] 25. The method of embodiment 24, wherein the ADH is selected from:

[0243] a) CymB comprising the amino acid sequence according to SEQ ID NO: 42;

[0244] b) AspWeADH1 comprising the amino acid sequence according to SEQ ID NO: 44;

[0245] c) PsAeroADH1 comprising the amino acid sequence according to SEQ ID NO: 46;

[0246] d) AzTolADH1 comprising the amino acid sequence according to SEQ ID NO: 48;

[0247] e) AroAroADH1 comprising the amino acid sequence according to SEQ ID NO: 50;

[0248] f) ThTerpADH1 comprising the amino acid sequence according to SEQ ID NO: 52;

[0249] g) CdGeoA comprising the amino acid sequence according to SEQ ID NO: 54;

[0250] h) VoADH1 comprising the amino acid sequence according to SEQ ID NO: 56; and

[0251] i) A polypeptide having ADH activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to h).

[0252] 26. The method of embodiment 1 for biocatalytically producing lisdendiol, comprising the following steps:

[0253] (1) contacting lisdandiol diphosphate (also known as lisdan-13-en-8-ol diphosphate or 8α-hydroxycopalyl diphosphate) with a polypeptide having lisdandiol diphosphate (LPP) phosphatase activity to form lisdandiol in a substantially pure stereoisomeric form or as a mixture of at least two stereoisomers; and

[0254] (2) Optionally, the lisdendiol of step (1) is isolated.

[0255] 27. The method of embodiment 26, wherein the polypeptide having LPP phosphatase activity is selected from the group consisting of:

[0256] a) TalVeTPP comprising the amino acid sequence according to SEQ ID NO: 2

[0257] b) AspWeTPP comprising the amino acid sequence according to SEQ ID NO: 6

[0258] c) HelGriTPP comprising the amino acid sequence according to SEQ ID NO: 10,

[0259] d) UmbPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 13

[0260] e) TalVeTPP2 comprising the amino acid sequence according to SEQ ID NO: 16

[0261] f) HydPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 19,

[0262] g) TalCeTPP1 comprising the amino acid sequence according to SEQ ID NO: 22,

[0263] h) TalMaTPP1 comprising the amino acid sequence according to SEQ ID NO: 25,

[0264] i) TalAstroTPP1 comprising the amino acid sequence according to SEQ ID NO: 28, and

[0265] j) PeSubTPP1 comprising the amino acid sequence according to SEQ ID NO: 31, and

[0266] k) A polypeptide having LPP phosphatase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to j).

[0267] 28. The method of any one of embodiments 26 and 27, wherein step (1) further comprises the biocatalytic conversion of a terpene pyrophosphate (e.g., geranylgeranyl pyrophosphate (GGPP), or a mixture of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP)) into lysenediol diphosphate (LPP) by the catalytic action of lysenediol pyrophosphate synthase (LPS).

[0268] 29. The method of embodiment 28, wherein the LPS is selected from:

[0269] a) SsLPS comprising the amino acid sequence according to SEQ ID NO: 38, and

[0270] b) a polypeptide having lisdendiol pyrophosphate synthase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of said amino acid sequences according to a).

[0271] 30. The method of any one of embodiments 26 to 29, further comprising processing the lisdandiol of step (1) or step (2) into a lisdandiol derivative as step (3) using chemical or biocatalytic synthesis or a combination of both.

[0272] 31. The method of embodiment 30, wherein the derivative is a hydrocarbon, alcohol, diol, triol, acetal, ketal, aldehyde, acid, ether, amide, ketone, lactone, epoxide, acetate, glycoside and / or ester.

[0273] 32. The method of embodiment 30 or 31, wherein lisdandiol is oxidized biocatalytically.

[0274] 33. The method of embodiment 32, wherein lisdandiol is oxidized by contacting with an alcohol dehydrogenase (ADH).

[0275] 34. The method of embodiment 33, wherein the ADH is selected from:

[0276] a) CymB comprising the amino acid sequence according to SEQ ID NO: 42;

[0277] b) AspWeADH1 comprising the amino acid sequence according to SEQ ID NO: 44;

[0278] c) PsAeroADH1 comprising the amino acid sequence according to SEQ ID NO: 46;

[0279] d) AzTolADH1 comprising the amino acid sequence according to SEQ ID NO: 48;

[0280] e) AroAroADH1 comprising the amino acid sequence according to SEQ ID NO: 50;

[0281] f) ThTerpADH1 comprising the amino acid sequence according to SEQ ID NO: 52;

[0282] g) CdGeoA comprising the amino acid sequence according to SEQ ID NO: 54;

[0283] h) VoADH1 comprising the amino acid sequence according to SEQ ID NO: 56;

[0284] i) SCH23-ADH1 comprising the amino acid sequence according to SEQ ID NO: 68

[0285] j) SCH24-ADH1a comprising the amino acid sequence according to SEQ ID NO: 70; and

[0286] k) A polypeptide having ADH activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to j).

[0287] 35. The method of any one of embodiments 19 and 28, wherein the method further comprises biocatalytic formation of GGPP from farnesyl pyrophosphate (FPP) by the catalytic action of geranylgeranyl pyrophosphate synthase (GGPS).

[0288] 36. The method of embodiment 35, wherein the GGPS is selected from:

[0289] a) a polypeptide comprising the amino acid sequence according to SEQ ID NO: 36, and

[0290] b) a polypeptide having geranylgeranyl pyrophosphate synthase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of said amino acid sequences according to a).

[0291] 37. The method according to any one of the preceding embodiments, which is performed in vitro or in vivo.

[0292] 38. The method according to any one of the preceding embodiments, which is performed in vivo and comprises, prior to step (1), introducing one or more nucleic acid molecules into a non-human host organism or cell and optionally stably integrating them into the respective genome; the nucleic acid molecules encoding one or more polypeptides having the enzymatic activity required to perform the corresponding one or more biocatalytic conversion steps.

[0293] 39. The method of embodiment 38, wherein the nucleic acid introduced into the non-human host organism or cell encodes:

[0294] a) at least one polypeptide having terpene diphosphate phosphatase activity, in particular bicyclic diterpene diphosphate phosphatase activity; and optionally

[0295] b) at least one polypeptide having terpene diphosphate synthase activity, in particular bicyclic diterpene diphosphate synthase activity, and / or

[0296] c) at least one polypeptide having ADH activity; and / or

[0297] d) at least one polypeptide having acyclic terpene diphosphate synthase activity, in particular acyclic diterpene diphosphate synthase activity.

[0298] 40. The method of embodiment 39, wherein the nucleic acid introduced into the non-human host organism or cell encodes:

[0299] a) at least one polypeptide having bicyclic diterpene diphosphatase activity selected from the polypeptides defined in embodiment 6; or encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 4, 5, 7, 8, 9, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30 and 32; or a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of said sequences; and optionally at least one of the following:

[0300] b) at least one polypeptide having bicyclic diterpene diphosphate synthase activity selected from the polypeptides defined in embodiment 10; or encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 33, 37, and 39; or a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of said sequences;

[0301] c) at least one polypeptide having ADH activity selected from the polypeptides defined in embodiment 16; or encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 41, 43, 45, 47, 49, 51, 53, and 55; or a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of said sequences;

[0302] d) at least one polypeptide having acyclic diterpene diphosphate synthase activity as defined in embodiment 36; or encoded by a nucleotide sequence selected from SEQ ID NO: 35, or having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.

[0303] 41. The method of any one of embodiments 38 to 40, which is performed by administering a non-human host organism or cell that endogenously produces FPP and / or GGPP, or a mixture of IPP and DMAPP; or by administering a non-human host organism that has been genetically modified to produce increased amounts of FPP and / or GGPP, and / or a mixture of IPP and DMAPP.

[0304] Some of these host cells or organisms do not naturally produce FPP or GGPP or a mixture of IPP and DMAPP, nor do they endogenously produce FPP or GGPP or a mixture of IPP and DMAPP in amounts that are considered too low and should therefore be increased. In order to be suitable for implementing the methods of the embodiments described herein, organisms or cells that do not naturally produce acyclic terpene pyrophosphate precursors (e.g., a mixture of FPP or GGPP or IPP and DMAPP) or produce the compounds in suboptimal amounts are typically genetically modified to produce the precursors. For example, they can be transformed in this manner prior to or simultaneously with modification with the nucleic acids described in any of the above embodiments. Methods for transforming organisms so that they produce acyclic terpene pyrophosphate precursors (e.g., a mixture of FPP or GGPP or IPP and DMAPP) are known in the art. For example, introducing enzyme activities of the mevalonate pathway, the isoprene pathway, or the MEP pathway, particularly the mevalonate pathway, is a suitable strategy for causing an organism to produce a mixture of FPP or GGPP or IPP and DMAPP.

[0305] 42. The method according to any one of embodiments 38 to 41, wherein the non-human host organism or cell is a eukaryote or a prokaryote, in particular a plant, a bacterium or a fungus, in particular a yeast.

[0306] 43. The method according to embodiment 42, wherein the bacteria is of the genus Escherichia, in particular E. coli, and the yeast is of the genus Saccharomyces, in particular S. cerevisiae.

[0307] 44. The method of embodiment 42, wherein the cell is a plant cell.

[0308] 45. A non-human host organism or cell as defined in any one of embodiments 38 to 44.

[0309] 46. ​​A recombinant nucleic acid construct comprising at least one nucleic acid molecule as defined in any one of embodiments 38 to 44.

[0310] 47. An expression vector comprising at least one nucleic acid construct according to embodiment 46.

[0311] 48. The expression vector of embodiment 47, wherein the vector is a prokaryotic vector, a viral vector, a eukaryotic vector, or one or more plasmids.

[0312] 49. The recombinant non-human host organism or cell as defined in embodiment 45, which has been transformed with at least one nucleic acid construct according to embodiment 46 or with at least one vector according to embodiment 47 or 48.

[0313] 50. A polypeptide having terpene diphosphate phosphatase activity, particularly bicyclic diterpene diphosphate phosphatase activity, selected from diphosphate-removing enzyme members of the protein tyrosine phosphatase family and mutants or variants thereof; wherein the polypeptide preferably catalyzes the conversion of terpene diphosphate to the corresponding terpene alcohol with a selectivity of >50%, such as >60%, 70%, 80%, 90%, 95% or 99%. In particular, it preferably catalyzes the conversion of at least one terpene diphosphate selected from CPP and LPP to the corresponding terpene alcohols, copalol and lisdanediol, with a selectivity of >50%, such as >60%, 70%, 80%, 90%, 95% or 99%.

[0314] The polypeptide of this embodiment having "terpene diphosphate phosphatase activity" is identified as a member of the protein tyrosine phosphatase family, in particular a member of the gamma-phosphatase 3 family having Pfam ID No. PF13350.

[0315] In particular, a polypeptide of the invention having "terpene diphosphate phosphatase activity" is identified as a member of the protein tyrosine phosphatase family, particularly a member of the γ-phosphatase 3 family with Pfam ID number PF13350, if the bit score is greater than or equal to the collection threshold for the Pfam domain. Expected values ​​(e-values) can also be used as criteria for including the queried protein in a Pfam family or determining whether the queried protein has a particular Pfam domain. An e-value of less than 1x10 -5 or less than 1x10 -10 , or less than 1x10 -20 , for example in 1x10 -40 to 7.40x10 -80 In the range of 1x10 -45 to 1x10 -70 In the range, for example 3.50x10 -50 to 7.40x10 -66 As a query sequence, the sequence of a polypeptide having "terpene diphosphate phosphatase activity" was used.

[0316] For example, the following websites can be used to search and calculate such e-values: https: / / pfam.xfam.org / search#tabview=tab0 or https: / / www.ebi.ac.uk / Tools / hmmer / .

[0317] In a preferred alternative, such phosphatases also convert FPP and / or GGPP into the corresponding alcohols farnesol and geranylgeraniol.

[0318] In another preferred alternative, such phosphatase does not convert FPP and / or GGPP into the corresponding alcohols farnesol and geranylgeraniol, but retains the ability to convert at least one bicyclic diterpenyl diphosphate selected from CPP and LPP into the corresponding terpenols copal and lisdendiolate.

[0319] In another preferred alternative, such phosphatase produces at least one alcohol selected from copalol and lisdanediol as the primary product. In this case, such enzymes convert FPP and / or GGPP to the corresponding alcohols farnesol and geranylgeraniol at a lower molar yield than their ability to convert at least one bicyclic diterpene diphosphate selected from CPP and LPP to the corresponding terpene alcohols copalol and lisdanediol. The relative molar yield of at least one bicyclic diterpene alcohol selected from copalol and lisdanediol can be as high as 2 times or more, for example, 2 to 1,000 times, or 5 to 100 times, or 10 to 50 times, compared to the yield for at least one acyclic terpene alcohol farnesol and geranylgeraniol.

[0320] 51. The polypeptide of embodiment 50, characterized by an amino acid sequence having the following active site signature motif:

[0321] HCxxGxxR (SEQ ID NO:57)

[0322] in

[0323] Each x independently represents any natural amino acid residue.

[0324] 52. The polypeptide of embodiment 51, wherein the active site signature motif is:

[0325] HC(T / S)xGKDRTG (SEQ ID NO:58)

[0326] in

[0327] x represents any natural amino acid residue.

[0328] 53. The polypeptide of any one of embodiments 50 to 52, wherein the polypeptide having bicyclic diterpene-based diphosphate phosphatase activity is selected from the group consisting of:

[0329] a) TalVeTPP comprising the amino acid sequence according to SEQ ID NO: 2

[0330] b) AspWeTPP comprising the amino acid sequence according to SEQ ID NO: 6

[0331] c) HelGriTPP comprising the amino acid sequence according to SEQ ID NO: 10,

[0332] d) UmbPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 13

[0333] e) TalVeTPP2 comprising the amino acid sequence according to SEQ ID NO: 16

[0334] f) HydPiTPP1 comprising the amino acid sequence according to SEQ ID NO: 19,

[0335] g) TalCeTPP1 comprising the amino acid sequence according to SEQ ID NO: 22,

[0336] h) TalMaTPP1 comprising the amino acid sequence according to SEQ ID NO: 25,

[0337] i) TalAstroTPP1 comprising the amino acid sequence according to SEQ ID NO: 28,

[0338] j) PeSubTPP1 comprising the amino acid sequence according to SEQ ID NO: 31, and

[0339] k) A polypeptide having diterpene diphosphate phosphatase activity and comprising an amino acid sequence that exhibits a degree of sequence identity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to at least one of the amino acid sequences according to a) to j).

[0340] Another specific embodiment relates to polypeptide variants of the novel polypeptides of the present invention having bicyclic diterpene diphosphate phosphatase activity, which are identified above by any of the specific amino acid sequences of SEQ ID NOs: 2, 6, 10, 13, 16, 19, 22, 25, 28 and 31, and wherein the polypeptide variant is selected from amino acid sequences having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any one of SEQ ID NOs: 2, 6, 10, 13, 16, 19, 22, 25, 28 and 31, and contains at least one substitution modification relative to any one of unmodified SEQ ID NOs: 2, 6, 10, 13, 16, 19, 22, 25, 28 and 31.

[0341] 54. A nucleic acid molecule comprising:

[0342] a) a nucleic acid sequence encoding the polypeptide of any one of embodiments 50 to 53;

[0343] b) a complementary nucleic acid sequence of a); or

[0344] c) A nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of a) or b).

[0345] 55. An expression construct comprising at least one nucleic acid molecule according to claim 54.

[0346] 56. A vector comprising at least one nucleic acid molecule according to claim 54.

[0347] 57. The vector of claim 56, wherein the vector is a prokaryotic, viral or eukaryotic vector.

[0348] 58. The vector of embodiment 56 or 57, wherein the vector is an expression vector.

[0349] 59. The vector according to any one of embodiments 56 to 58, which is a plasmid vector.

[0350] 60. A recombinant host cell or a recombinant non-human host organism comprising:

[0351] a) at least one isolated nucleic acid molecule according to embodiment 54, which is optionally stably integrated into the genome; or

[0352] b) at least one expression construct according to embodiment 55, which is optionally stably integrated into the genome; or

[0353] c) at least one vector according to any one of embodiments 56 to 59.

[0354] 61. The host cell or host organism according to embodiment 60, which is selected from a prokaryotic or eukaryotic microorganism, or a cell derived therefrom.

[0355] 62. The host cell or host organism according to embodiment 61, which is selected from bacteria, fungi and plant cells or plants.

[0356] 63. The host cell or host organism according to embodiment 62, wherein the fungal cell is a yeast cell.

[0357] 64. The host cell or host organism of embodiment 63, wherein the bacterial cell is selected from the genus Escherichia, in particular the species E. coli, and the yeast is selected from the genus Saccharomyces or Pichia, in particular from the species Saccharomyces cerevisiae or Pichia pastoris.

[0358] 65. A method for producing at least one catalytically active polypeptide according to any one of embodiments 50 to 53, comprising:

[0359] (1) cultivating a non-human host organism or a host cell according to any one of claims 60 to 64 to express or overexpress at least one polypeptide according to any one of embodiments 50 to 53; and

[0360] (2) Optionally, the polypeptide is isolated from the non-human host cell or organism cultured in step (1).

[0361] 66. The method according to embodiment 65, further comprising, before step a), transforming a non-human host organism or cell with at least one nucleic acid according to embodiment 54, or at least one construct according to embodiment 55, or at least one vector according to any one of embodiments 56 to 59, such that it expresses or overexpresses the polypeptide according to any one of embodiments 50 to 53.

[0362] 67. A method for preparing a mutant polypeptide having terpene synthase activity, particularly terpene diphosphate synthase activity, the method comprising the following steps:

[0363] (1) selecting the nucleic acid molecule of embodiment 54;

[0364] (2) modifying the selected nucleic acid molecule to obtain at least one mutant nucleic acid molecule;

[0365] (3) transforming a host cell or a unicellular host organism with the mutant nucleic acid sequence to express the polypeptide encoded by the mutant nucleic acid sequence.

[0366] (4) screening the expression products for at least one mutant having terpene synthase activity, particularly terpene diphosphate synthase activity;

[0367] (5) Alternatively, if the polypeptide does not have the desired mutant activity, repeating steps (1) to (4) until a polypeptide having the desired mutant activity is obtained; and

[0368] (6) Optionally, if a polypeptide having the desired mutant activity is identified in step (4), the corresponding mutant nucleic acid obtained in step (3) is isolated.

[0369] 68. The method of embodiment 22, wherein the copalol derivative is selected from the group consisting of copalol, myristol, (+)-myristoloxy, Z-11, γ-ambrol and ambrox and structurally related compounds that differ particularly in stereochemistry.

[0370] 69. The method of embodiment 31, wherein the lisdendiol derivative is selected from the group consisting of sclareolide, DOL and ambroxol and structurally related compounds, which compound differs therefrom in particular in stereochemistry.

[0371] 70. A process for the preparation of Ambroxol or an Ambroxol-like compound as defined above, the process comprising:

[0372] a) providing a lisdandiol or copal compound by performing a biocatalytic process as defined in any one of embodiments 1 to 44, and optionally isolating the lisdandiol or copal compound; and

[0373] b) converting the lisdandiol or copal compound of step (1) into ambroxol or an ambroxol-like compound by chemical synthesis and / or biochemical synthesis.

[0374] 71. The present invention further relates to the use of a polypeptide as defined in any one of the above embodiments for the preparation of an odorant, flavoring or fragrance ingredient, in particular Ambrox; and the use of a terpene alcohol prepared according to any one of the above embodiments for the preparation of an odorant, flavoring or fragrance ingredient, in particular Ambrox.

[0375] b. Polypeptides suitable for use according to the present invention

[0376] In the context of this article, the following definitions apply:

[0377] The general terms "polypeptide" or "peptide", which are used interchangeably, refer to a linear chain or sequence of amino acid residues linked in a peptide-like manner, whether natural or synthetic, comprising from about 10 to more than 1000 residues. Short-chain polypeptides of up to 30 residues are also referred to as "oligopeptides".

[0378] The term "protein" refers to a macromolecular structure composed of one or more polypeptides. The amino acid sequence of its polypeptides represents the "primary structure" of the protein. The amino acid sequence also predetermines the "secondary structure" of the protein by forming special structural elements (such as the α-helix and β-pleated structures formed in the polypeptide chain). The arrangement of multiple such secondary structural elements defines the "tertiary structure" or spatial arrangement of the protein. If a protein contains more than one polypeptide chain, the chains are arranged in space to form the "quaternary structure" of the protein. The correct spatial arrangement or "folding" of the protein is a prerequisite for protein function. Denaturation or unfolding will destroy protein function. If this destruction is reversible, protein function can be restored by refolding.

[0379] The typical protein function referred to herein is "enzyme function", i.e. the protein acts as a biocatalyst on a substrate, such as a compound, and catalyzes the conversion of the substrate to a product. Enzymes can exhibit a high or low degree of substrate and / or product specificity.

[0380] Thus, a "polypeptide" referred to herein as having a particular "activity" implicitly refers to a correctly folded protein that exhibits the indicated activity, eg, a particular enzymatic activity.

[0381] Thus, unless otherwise indicated, the term "polypeptide" also encompasses the terms "protein" and "enzyme."

[0382] Similarly, the term "polypeptide fragment" encompasses the terms "protein fragment" and "enzyme fragment."

[0383] The term "isolated polypeptide" refers to an amino acid sequence that has been removed from its natural environment by any method known in the art, or a combination of methods, including recombinant, biochemical, and synthetic methods.

[0384] "Target peptide" refers to an amino acid sequence that targets a protein or polypeptide to an intracellular organelle (i.e., mitochondria or plastids) or the extracellular space (secretion signal peptide). The nucleic acid sequence encoding the target peptide can be fused to the nucleic acid sequence encoding the amino terminus (e.g., N-terminus) of the protein or polypeptide, or can be used to replace the native targeting polypeptide.

[0385] The present invention also relates to "functional equivalents" (also called "analogs" or "functional mutants") of the polypeptides specifically described herein.

[0386] For example, a "functional equivalent" refers to a polypeptide which, in a test for determining the enzymatic terpene diphosphate synthase activity or terpene diphosphate phosphatase activity, exhibits at least 1 to 10% higher or lower activity, or at least 20% higher, or at least 50% lower, or at least 75% lower, or at least 90% higher activity compared to the polypeptide specifically described herein.

[0387] According to the invention, "functional equivalents" also encompass specific mutants which have an amino acid different from the specifically stated amino acid in at least one sequence position of the amino acid sequences described herein, but which nevertheless have one of the above-mentioned biological activities, such as enzymatic activity. Thus, "functional equivalents" include mutants which can be obtained by additions, substitutions, in particular conservative substitutions, deletions and / or inversions of one or more, for example 1 to 20, 1 to 15 or 5 to 10 amino acids, wherein said changes may occur at any sequence position, as long as they result in a mutant having the profile of the properties according to the invention. Functional equivalence is also provided in particular if the activity pattern qualitatively overlaps between the mutant and the unchanged polypeptide, i.e. if, for example, an interaction with the same agonist or antagonist or substrate is observed, but at a different rate (i.e. by EC 50 or IC 50 The following table shows examples of suitable (conservative) amino acid substitutions:

[0388]

[0389] "Functional equivalents" in the above sense are also "precursors" of the polypeptides described herein, as well as "functional derivatives" and "salts" of said polypeptides.

[0390] In this context, a "precursor" is a natural or synthetic precursor of a polypeptide that may or may not possess the desired biological activity.

[0391] The expression "salts" refers to salts of carboxyl groups and acid addition salts of amino groups of the protein molecules according to the present invention. Salts of carboxyl groups can be produced in a known manner and include inorganic salts, such as sodium, calcium, ammonium, iron and zinc salts, and salts formed with organic bases, such as amines, for example triethanolamine, arginine, lysine, piperidine, etc. Acid addition salts, such as salts formed with inorganic acids, such as hydrochloric acid or sulfuric acid, and salts formed with organic acids, such as acetic acid and oxalic acid, are also encompassed by the present invention.

[0392] "Functional derivatives" of the polypeptides according to the present invention can also be produced at the functional amino acid side groups or at their N-termini or C-termini using known techniques. Such derivatives include, for example: aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, which can be obtained by reaction with ammonia or with primary or secondary amines; N-acyl derivatives of free amino groups, which are produced by reaction with acyl groups; or O-acyl derivatives of free hydroxyl groups, which are produced by reaction with acyl groups.

[0393] "Functional equivalents" naturally also include polypeptides obtainable from other organisms and naturally occurring variants. For example, the area of ​​homologous sequence regions can be determined by sequence comparison, and equivalent polypeptides can be determined based on the specific parameters of the present invention.

[0394] "Functional equivalents" also include "fragments" of the polypeptides according to the invention, such as single domains or sequence motifs, or N-terminal and / or C-terminal truncated forms, which may or may not exhibit the desired biological function. Preferably, such "fragments" at least qualitatively retain the desired biological function.

[0395] Furthermore, a "functional equivalent" is a fusion protein comprising one of the polypeptide sequences described herein or a functional equivalent derived therefrom and at least one further functionally different heterologous sequence in functional N-terminal or C-terminal association (i.e., without substantial mutual functional impairment of the fusion protein parts). Non-limiting examples of such heterologous sequences are, for example, signal peptides, histidine anchors or enzymes.

[0396] Also included according to the present invention are "functional equivalents" which are homologs of the specifically disclosed polypeptides. They have at least 60%, preferably at least 75%, in particular at least 80 or 85%, for example 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% homology (or identity) with the specifically disclosed amino acid sequences, as calculated by the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85(8), 1988, 2444-2448. The homology or identity expressed as a percentage of the homologous polypeptides according to the present invention refers in particular to the identity expressed as a percentage of amino acid residues over the total length of one of the amino acid sequences specifically described herein.

[0397] Identity data expressed as a percentage can also be determined with the aid of BLAST alignments, the algorithm blastp (protein-protein BLAST) or by applying the Clustal settings as detailed herein below.

[0398] In case of possible protein glycosylation, "functional equivalents" according to the invention include the polypeptides described herein in deglycosylated or glycosylated form, as well as modified forms which can be obtained by altering the glycosylation pattern.

[0399] Functional equivalents or homologues of the polypeptides according to the invention can be generated by mutagenesis, for example by point mutations, lengthening or shortening the protein or as described in more detail below.

[0400] The functional equivalent of polypeptide according to the present invention or homologue can be identified by screening mutants such as the combined database of shortened mutants.For example, the diversity database of protein variants can be produced by the combined mutagenesis on the nucleic acid level, for example, by the enzymatic connection of synthetic oligonucleotide mixtures.There are many methods that can be used for producing the database of potential homologues from degenerate oligonucleotide sequences.The chemical synthesis of degenerate gene sequences can be carried out in an automatic DNA synthesizer, and then the synthetic gene can be connected in a suitable expression vector.The use of degenerate genome makes it possible to provide all sequences in the mixture, the potential protein sequence set required for its encoding.The synthetic method of degenerate oligonucleotide is well known to those skilled in the art.

[0401] In the prior art, several techniques are known for screening gene products of combinatorial databases produced by point mutation or shortening, as well as cDNA libraries for screening gene products with selected properties. These techniques can be applied to rapidly screen gene libraries produced by combinatorial mutagenesis of homologues according to the present invention. The most commonly used techniques for screening large gene libraries based on high-throughput analysis include cloning the gene library in a reproducible expression vector, transforming suitable cells with the resulting vector database, and expressing the combinatorial genes under specific conditions, under which the detection of the desired activity promotes the isolation of the vector encoding the gene (whose product is detected). Recursive integration mutagenesis (REM) is a technique that increases the frequency of functional mutants in a database and can be used in conjunction with screening tests to identify homologues.

[0402] Embodiments provided herein provide orthologues and paralogues of the polypeptides disclosed herein, as well as methods for identifying and isolating such orthologues and paralogues. The definitions of terms "orthologues" and "paralogues" are given below and are applicable to amino acid and nucleic acid sequences.

[0403] c. Encoding nucleic acid sequences suitable for use according to the present invention

[0404] In the context of this article, the following definitions apply:

[0405] The terms "nucleic acid sequence," "nucleic acid," "nucleic acid molecule," and "polynucleotide" are used interchangeably to refer to a sequence of nucleotides. A nucleic acid sequence can be single-stranded or double-stranded deoxyribonucleotides or ribonucleotides of any length and includes coding and non-coding sequences of genes, exons, introns, sense and antisense complementary sequences, genomic DNA, cDNA, miRNA, siRNA, mRNA, rRNA, tRNA, recombinant nucleic acid sequences, isolated and purified naturally occurring DNA and / or RNA sequences, synthetic DNA and RNA sequences, fragments, primers, and nucleic acid probes. The skilled artisan understands that the nucleic acid sequence of RNA is identical to the sequence of DNA, except that thymine (T) is replaced by uracil (U). The term "nucleotide sequence" should also be understood to include polynucleotide molecules or oligonucleotide molecules, either in the form of individual fragments or as components of a larger nucleic acid.

[0406] "Isolated nucleic acid" or "isolated nucleic acid sequence" refers to a nucleic acid or nucleic acid sequence that is in an environment that is different from that in which the nucleic acid or nucleic acid sequence occurs in nature, and can include those that are substantially free of contaminating endogenous material.

[0407] As used herein, the term "naturally-occurring" as applied to nucleic acids refers to a nucleic acid that is found in the cells of an organism in nature and has not been intentionally modified by man in the laboratory.

[0408] A "fragment" of a polynucleotide or nucleic acid sequence refers to a continuous nucleotide sequence, which is particularly at least 15 bp, at least 30 bp, at least 40 bp, at least 50 bp and / or at least 60 bp of the length of a polynucleotide of one embodiment herein. In particular, a fragment of a polynucleotide comprises at least 25, more particularly at least 50, more particularly at least 75, more particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 700, more particularly at least 800, more particularly at least 900, more particularly at least 1000 continuous nucleotides of a polynucleotide of one embodiment herein. Without limitation, fragments of the polynucleotides herein can be used as PCR primers and / or probes, or for antisense gene silencing or RNAi.

[0409] As used herein, the term "hybridization" or hybridization under certain conditions is intended to describe the conditions of hybridization and washing, under which significantly identical or homologous nucleotide sequences remain bound to each other. The conditions can be such that sequences of at least about 70%, for example, at least about 80%, and for example, at least about 85%, 90% or 95% identity remain bound to each other. The definition of low stringency, medium and high stringency hybridization conditions is provided below. Those skilled in the art can select suitable hybridization conditions with minimal experiments as illustrated by, for example, Ausubel et al. (1995, Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6). In addition, stringent conditions are described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, chapters 7, 9, and 11).

[0410] A "recombinant nucleic acid sequence" is a nucleic acid sequence produced by combining genetic material from more than one source using laboratory methods (e.g., molecular cloning), thereby creating or modifying a nucleic acid sequence that does not occur in nature and is not otherwise found in a biological organism.

[0411] "Recombinant DNA technology" refers to molecular biology methods for preparing recombinant nucleic acid sequences as described, for example, in Laboratory Manuals, ed., Weigel and Glazebrook, 2002, Cold Spring Harbor Lab Press; and Sambrook et al., 1989 Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

[0412] The term "gene" refers to a DNA sequence comprising a region that is transcribed into an RNA molecule (e.g., an mRNA in a cell) operably linked to an appropriate regulatory region (e.g., a promoter). Thus, a gene may comprise several operably linked sequences, such as a promoter, a 5' leader sequence (comprising, for example, sequences involved in translation initiation), a coding region of a cDNA or genomic DNA, introns, exons, and / or a 3' untranslated sequence (comprising, for example, a transcription termination site).

[0413] "Polycistronic" refers to a nucleic acid molecule, particularly mRNA, that can encode more than one polypeptide within the same nucleic acid molecule.

[0414] "Chimeric gene" refers to any gene that can not usually be found in species in nature, particularly a gene in which one or more parts of the nucleic acid sequence are not associated with each other in nature. For example, a promoter is not associated with part or all of a transcription region or with another regulatory region in nature. The term "chimeric gene" should be understood to include expression constructs in which a promoter or transcriptional regulatory sequence is operably linked to one or more coding sequences or antisense (i.e., the reverse complementary strand of the sense strand) or inverted repeats (sense and antisense, whereby RNA transcripts form double-stranded RNA after transcription). The term "chimeric gene" also includes genes obtained by combining parts of one or more coding sequences to produce new genes.

[0415] "3' URT" or "3' untranslated sequence" (also called "3' untranslated region" or "3' end") refers to a nucleic acid sequence found downstream of the coding sequence of a gene that contains, for example, a transcription termination site and (in most but not all eukaryotic mRNAs) a polyadenylation signal, such as AAUAAA or a variant thereof. Following transcription termination, the mRNA transcript may be cleaved downstream of the polyadenylation signal and a poly(A) tail may be added, which participates in the transport of the mRNA to the site of translation, such as the cytoplasm.

[0416] The term "primer" refers to a short nucleic acid sequence that hybridizes to a template nucleic acid sequence and is used to polymerize a nucleic acid sequence complementary to the template.

[0417] The term "selectable marker" refers to any gene that, after expression, can be used to select for one or more cells containing the selectable marker. Examples of selectable markers are described below. Those skilled in the art will appreciate that different antibiotic, fungicide, auxotrophic or herbicide selectable markers may be suitable for use with different target species.

[0418] The present invention also relates to nucleic acid sequences encoding the polypeptides as defined herein.

[0419] In particular, the invention also relates to nucleic acid sequences (single-stranded and double-stranded DNA and RNA sequences, such as cDNA, genomic DNA and mRNA) encoding one of the above polypeptides and functional equivalents thereof, which can be obtained, for example, by using artificial nucleotide analogs.

[0420] The present invention relates both to isolated nucleic acid molecules encoding polypeptides according to the invention or biologically active segments thereof, and to nucleic acid fragments useful as hybridization probes or primers, for example, for identifying or amplifying encoding nucleic acids according to the invention.

[0421] The present invention also relates to nucleic acids having a certain degree of "identity" to the sequences specifically disclosed herein. "Identity" between two nucleic acids refers in each case to the identity of the nucleotides over the entire length of the nucleic acid.

[0422] " Identity " between two nucleotide sequences (applicable also to peptide or amino acid sequences) is the function of the number of nucleotide residues (or amino acid residues) when producing the comparison of these two sequences, or the number of identical residues in the two sequences. Identical residues are defined as the identical residues at a given position of the comparison in the two sequences. The percentage of sequence identity used herein is calculated from the best comparison by dividing the number of identical residues between the two sequences by the total number of residues in the shortest sequence and multiplying by 100. The best comparison is the comparison with the highest probability of identity percentage. Rooms can be introduced into one or more positions of the comparison in one or two sequences to obtain the best comparison. These rooms are then considered as non-identical residues for calculating sequence identity percentage. The comparison for determining amino acid or nucleic acid sequence identity percentage can be implemented in a variety of ways using computer programs and, for example, publicly available computer programs on the Internet.

[0423] In particular, the BLAST program (Tatiana et al., FEMS Microbiol Lett., 1999, 174: 247-250, 1999), available from the National Center for Biotechnology Information (NCBI) at http: / / www.ncbi.nlm.nih.gov / BLAST / bl2seq / wblast2.cgi, set to default parameters, can be used to obtain optimal alignment of protein or nucleic acid sequences and calculate percentages of sequence identity.

[0424] In another example, the identity can be calculated by the Vector NTI Suite 7.1 program of Informax Corporation (USA) using the Clustal method (Higgins DG, Sharp PM. ((1989))) with the following settings:

[0425] Multiple alignment parameters:

[0426]

[0427] Pairwise alignment parameters:

[0428]

[0429] Alternatively, identity can be determined according to the method of Chenna et al. (2003), webpage: http: / / www.ebi.ac.uk / Tools / clustalw / index.html# and the following settings:

[0430]

[0431]

[0432] All nucleic acid sequences mentioned herein (single-stranded and double-stranded DNA and RNA sequences, such as cDNA and mRNA) can be produced from nucleotide building blocks by chemical synthesis in a known manner, for example, by condensation of the fragments of the complementary nucleic acid building blocks of each overlap of a double helix. The chemical synthesis of oligonucleotides can be carried out in a known manner, for example, by the phosphoamidite method (Voet, Voet, 2nd edition, Wiley Press, New York, pages 896-897). The accumulation of synthetic oligonucleotides, and the filling of the vacancies by means of the Klenow fragments of DNA polymerase and ligation, as well as general cloning techniques are described in Sambrook et al. (1989), see below.

[0433] Furthermore, the nucleic acid molecules according to the present invention may additionally comprise untranslated sequences from the 3' and / or 5' end of the coding genetic region.

[0434] The present invention further relates to nucleic acid molecules that are complementary to the specifically described nucleotide sequences or segments thereof.

[0435] The nucleotide sequences according to the invention allow the generation of probes and primers that can be used to identify and / or clone homologous sequences in other cell types and organisms. Such probes or primers typically comprise a region of nucleotide sequence that hybridizes under "stringent" conditions (as defined elsewhere herein) to at least about 12, preferably at least about 25, for example about 40, 50 or 75 consecutive nucleotides of the sense strand or the corresponding antisense strand of a nucleic acid sequence according to the invention.

[0436] "Homologous" sequences include orthologous or paralogous sequences. Methods for identifying orthologs or paralogs include phylogenetic methods, sequence similarity and hybridization methods known in the art and described herein.

[0437] "Paralogs" or paralogous sequences result from gene duplication, which results in two or more genes with similar sequences and similar functions. Paralogs are often clustered together and formed by duplication of genes within related plant species. Paralogs are found in groups of similar genes using Pairwise Blast analysis or using programs such as CLUSTAL during phylogenetic analysis of gene families. Among paralogs, consensus sequences can be identified as sequences that are characteristic of related genes and have similar functions to the genes.

[0438] "Orthologs" or orthologous sequences are sequences that are similar to each other because they are found in species descended from a common ancestor. For example, plant species with a common ancestor are known to contain many enzymes with similar sequences and functions. For example, by constructing a phylogenetic tree of a species' gene family using the CLUSTAL or BLAST programs, technicians can identify orthologous sequences and predict the functions of orthologs. A method for identifying or confirming similar functions between homologous sequences is by comparing transcript profiles in host cells or organisms (such as plants or microorganisms) that overexpress or lack (in gene knockout / knockdown) the relevant polypeptides. It will be understood by the technician that genes with similar transcript profiles (having a common transcript that is greater than 50% regulated, or having a common transcript that is greater than 70% regulated, or a common transcript that is greater than 90% regulated) will have similar functions. By causing a host cell, an organism such as a plant or microorganism to produce a terpene synthase protein, homologs, paralogs, orthologs, and any other variants of the sequences described herein are expected to function in a similar manner.

[0439] The term "selectable marker" refers to any gene that, after expression, can be used to select for one or more cells containing the selectable marker. Examples of selectable markers are described below. Those skilled in the art will appreciate that different antibiotic, fungicide, auxotrophic or herbicide selectable markers may be suitable for use with different target species.

[0440] An "isolated" nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and may be substantially free of other cellular material or culture medium if produced by recombinant techniques, or free of chemical precursors or other chemicals if chemically synthesized.

[0441] Can be separated according to nucleic acid molecules according to the present invention by means of molecular biological standard techniques and the sequence information provided according to the present invention.For example, can use one of concrete disclosed complete sequence or its fragment as hybridization probe and standard hybridization technique (for example, be described in Sambrook, (1989)) from suitable cDNA library, separate cDNA.

[0442] In addition, the nucleic acid molecules that comprises one of disclosed sequence or its segmental can use the oligonucleotide primers that make up based on this sequence, separates by polymerase chain reaction.The nucleic acid that increases in this way can be cloned in the suitable carrier, and can characterize by dna sequencing.Oligonucleotide according to the present invention also can be by the synthetic method of standard, for example use automatic DNA synthesizer to prepare.

[0443] According to nucleotide sequence of the present invention or its derivative, homologue or part of these sequences can for example be separated from other bacteria by conventional hybridization technique or PCR technology, for example by genome or cDNA library.These dna sequences are hybridized with sequence according to the present invention under standard conditions.

[0444] "Hybridization" refers to the ability of a polynucleotide or oligonucleotide to bind to nearly complementary sequences under standard conditions, without nonspecific binding occurring between non-complementary pairs under these conditions. For this purpose, sequences may be 90-100% complementary. The property of complementary sequences to be able to bind specifically to each other is exploited, for example, in Northern or Southern blotting or in primer binding in PCR or RT-PCR.

[0445] Short oligonucleotides of conserved regions are advantageously used for hybridization. However, longer nucleic acid fragments or complete sequences of the invention may also be used for hybridization. These "standard conditions" vary depending on the nucleic acid used (oligonucleotide, longer fragment or complete sequence) or the type of nucleic acid used for hybridization (DNA or RNA). For example, the melting temperature of a DNA:DNA hybrid is approximately 10°C lower than that of a DNA:RNA hybrid of the same length.

[0446] For example, depending on the specific nucleic acid, standard conditions refer to a temperature of 42 to 58° C. in an aqueous buffer solution with a concentration of 0.1 to 5×SSC (1×SSC = 0.15 M NaCl, 15 mM sodium citrate, pH 7.2), or alternatively in the presence of 50% formamide (e.g., 42° C., 5×SSC, 50% formamide). Advantageously, hybridization conditions for DNA:DNA hybrids are 0.1×SSC at a temperature of about 20° C. to 45° C., preferably about 30° C. to 45° C. For DNA:RNA hybrids, hybridization conditions are advantageously 0.1×SSC at a temperature of about 30° C. to 55° C., preferably about 45° C. to 55° C. These stated hybridization temperatures are examples of calculated melting temperature values ​​for a nucleic acid of about 100 nucleotides in length and a G+C content of 50% in the absence of formamide. The experimental conditions for DNA hybridization are described in relevant genetics textbooks (e.g., Sambrook et al., 1989) and can be calculated using formulas known to those skilled in the art, for example depending on the length of the nucleic acids, the type of hybrid or the G+C content. Those skilled in the art can obtain more information on hybridization from the following textbooks: Ausubel et al. (eds), (1985), Brown (ed) (1991).

[0447] Hybridization can be performed under stringent conditions. Such hybridization conditions are described, for example, in Sambrook (1989) or Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6.

[0448] As used herein, the term "hybridizes or hybridizes under conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain bound to each other. The conditions can be such that sequences that are at least about 70%, such as at least about 80%, and for example at least about 85%, 90%, or 95% identical remain bound to each other. Definitions of low stringency, medium stringency, and high stringency hybridization conditions are provided herein.

[0449] Those skilled in the art can select appropriate hybridization conditions with minimal experimentation by, for example, the examples described by Ausubel et al. (1995, Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6). Additionally, stringent conditions are described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, chapters 7, 9, and 11).

[0450] As used herein, the low stringency conditions are defined as follows. The filter containing DNA is pretreated at 40°C for 6 hours in a solution containing 35% formamide, 5xSSC, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA and 500μg / ml denatured salmon sperm DNA. Hybridization is performed in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100μg / ml salmon sperm DNA, 10% (wt / vol) dextran sulfate, and using 5-20x10 6 32P-labeled probe. Incubate the filter in hybridization mixture at 40°C for 18-20 hours, then wash at 55°C for 1.5 hours. Replace the wash solution with fresh solution and incubate at 60°C for an additional 1.5 hours. Blot dry and perform autoradiography.

[0451] As used herein, the medium stringency conditions are defined as follows. The filter containing DNA is pretreated at 50°C for 7 hours in a solution containing 35% formamide, 5x SSC, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA and 500μg / ml denatured salmon sperm DNA. Hybridization is performed in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100μg / ml salmon sperm DNA, 10% (wt / vol) dextran sulfate, and using 5-20x10 6 32P-labeled probe. Incubate the filter in hybridization mixture at 50°C for 30 hours, then wash at 55°C for 1.5 hours. In a solution containing 2x SSC, 25mM Tris-HCl (pH 7.4), 5mM EDTA, and 0.1% SDS. Replace the wash solution with fresh solution and incubate at 60°C for an additional 1.5 hours. Blot dry and perform autoradiography.

[0452] As used herein, the defined high stringency conditions are as follows. The DNA-containing filter is prehybridized at 65°C for 8 hours to overnight in a buffer consisting of 6x SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg / ml denatured salmon sperm DNA. 6 The filters were hybridized at 65°C for 48 hours in a prehybridization mixture containing a cpm 32P-labeled probe. The filters were washed in a solution containing 2x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA at 37°C for 1 hour, followed by a wash in 0.1x SSC at 50°C for 45 minutes.

[0453] If the above conditions are not suitable (eg, as for interspecies hybridization), other low, medium, and high stringency conditions well known in the art (eg, for interspecies hybridization) can be used.

[0454] A detection kit for a nucleic acid sequence encoding a polypeptide of the present invention can include primers and / or probes specific for the nucleic acid sequence encoding the polypeptide, as well as protocols for using the primers and / or probes to detect the nucleic acid sequence encoding the polypeptide in a sample. Such a detection kit can be used to determine whether a plant, organism, microorganism, or cell has been modified, i.e., transformed with a sequence encoding the polypeptide.

[0455] To test the functionality of a variant DNA sequence according to one embodiment herein, the sequence of interest is operably linked to a selectable or screenable marker gene and expression of the reporter gene is tested in transient expression assays using microorganisms or protoplasts or in stably transformed plants.

[0456] The present invention also relates to derivatives of the specifically disclosed or derivable nucleic acid sequences.

[0457] Thus, further nucleic acid sequences according to the invention may be derived from the sequences specifically disclosed herein and may differ therefrom by one or more, for example 1 to 20, in particular 1 to 15 or 5 to 10 additions, substitutions, insertions or deletions of one or several (for example 1 to 10) nucleotides and still encode a polypeptide having the desired properties.

[0458] The invention also encompasses nucleic acid sequences which comprise so-called silent mutations or which have been altered compared to the specifically stated sequence according to the codon usage of the particular origin or host organism.

[0459] According to a specific embodiment of the present invention, variant nucleic acid can be prepared to adapt its nucleotide sequence to a specific expression system. For example, if amino acid is encoded by a specific codon, then known bacterial expression systems can more effectively express polypeptides. Due to the degeneracy of the genetic code, more than one codon can encode the same amino acid sequence, and a plurality of nucleic acid sequences can encode the same protein or polypeptide, and all of these DNA sequences are encompassed in one embodiment of this paper. Where appropriate, the nucleic acid sequence encoding polypeptides described herein can be optimized to increase expression in a host cell. For example, a nucleic acid of one embodiment of this paper can be synthesized using host-specific codons to improve expression.

[0460] The invention also encompasses naturally occurring variants of the sequences described herein, such as splice variants or allelic variants.

[0461] Allelic variants have at least 60% homology, preferably at least 80% homology, and very particularly preferably at least 90% homology over the entire amino acid range at the derived amino acid level (with regard to homology at the amino acid level, reference should be made to the detailed information given above for the polypeptides). Advantageously, the homology may be higher over partial regions of the sequence.

[0462] The invention also relates to sequences obtainable by conservative nucleotide substitutions, ie sequences whereby the amino acid in question is replaced by an amino acid of the same charge, size, polarity and / or solubility.

[0463] The present invention also relates to molecules derived from the specifically disclosed nucleic acids through sequence polymorphisms. Due to natural allelic variation, such genetic polymorphisms may exist in cells from different populations or in cells within a population. Allelic variants may also include functional equivalents. These natural variations typically produce 1-5% variation in the nucleotide sequence of a gene. Such polymorphisms may result in alterations in the amino acid sequence of the polypeptides disclosed herein. Allelic variants may also include functional equivalents.

[0464] Furthermore, derivatives are also to be understood as meaning homologues of the nucleic acid sequences according to the invention, for example animal, plant, fungal or bacterial homologues, shortened sequences, single-stranded DNA or RNA of coding and non-coding DNA sequences. For example, at the DNA level, homologues have a homology of at least 40%, preferably at least 60%, particularly preferably at least 70%, and very particularly preferably at least 80% over a given DNA region in the sequences specifically disclosed herein.

[0465] Furthermore, derivatives are understood to include, for example, fusions with promoters. Promoters added to the nucleotide sequence may be modified by at least one nucleotide exchange, at least one insertion, inversion and / or deletion, without impairing the function or efficacy of the promoter. Furthermore, the efficacy of promoters may be increased by altering their sequence, or they may be completely exchanged for more effective promoters, or even promoters from organisms of different genera.

[0466] d. Generation of functional polypeptide mutants

[0467] In addition, those skilled in the art are familiar with methods for generating functional mutants, that is, a nucleotide sequence encoding a polypeptide having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the SEQ ID NOs disclosed herein with respect to amino acids; and / or encoded by a nucleic acid molecule comprising a nucleotide sequence having at least 70% sequence identity to any of the SEQ ID NOs disclosed herein with respect to nucleotides.

[0468] Depending on the technology used, those skilled in the art can introduce completely random or more targeted mutations into genes or non-coding nucleic acid regions (e.g., important for regulating expression) and subsequently generate genetic libraries. The molecular biology methods required for this purpose are known to the skilled person and are described, for example, in Sambrook and Russell, Molecular Cloning. 3rd Edition, Cold Spring Harbor Laboratory Press 2001.

[0469] Methods for modifying genes and thereby modifying the polypeptides encoded thereby have long been known to those skilled in the art, for example:

[0470] - site-specific mutagenesis, in which single or multiple nucleotides of a gene are replaced in a targeted manner (Trower MK (Ed.) 1996; In vitro mutagenesis protocols. Humana Press, New Jersey),

[0471] - saturation mutagenesis, in which the codon for any amino acid can be exchanged or added at any site in the gene (Kegler-Ebo DM, Docktor CM, DiMaio D (1994) Nucleic Acids Res 22: 1593; Barettino D, Feigenbutz M, Valcarel R, Stunnenberg HG (1994) Nucleic Acids Res 22: 541; Barik S (1995) Mol Biotechnol 3: 1),

[0472] - Error-prone polymerase chain reaction, in which the nucleotide sequence is mutated by an error-prone DNA polymerase (Eckert KA, Kunkel TA (1990) Nucleic Acids Res 18: 3739);

[0473] - SeSaM method (sequence saturation method), in which preferred exchange is prevented by the polymerase. Schenk et al., Biospektrum, Vol. 3, 2006, 277-279,

[0474] - gene propagation in mutant strains in which the mutation rate of the nucleotide sequence is increased, for example due to defects in the DNA repair mechanisms (Greener A, Callahan M, Jerpseth B (1996) An efficient random mutagenesis technique using an E. coli mutator strain. In: Trower MK (Ed.) In vitro mutagenesis protocols. Humana Press, New Jersey), or

[0475] - DNA shuffling, in which a group of closely related genes is created and digested, and these fragments are used as templates for polymerase chain reactions, in which, through repeated strand separation and recombination, the full-length mosaic gene is ultimately generated (Stemmer WPC (1994) Nature 370:389; Stemmer WPC (1994) Proc Natl Acad Sci USA 91:10747).

[0476] Using so-called directed evolution (described, inter alia, in Reetz MT and Jaeger KE (1999), Topics Curr Chem 200: 31; Zhao H, Moore JC, Volkov AA, Arnold FH (1999), Methods for optimizing industrial polypeptides by directed evolution, In: Demain AL, Davies JE (Ed.) Manual of industrial microbiology and biotechnology. American Society for Microbiology), a skilled worker can produce functional mutants in a directed manner on a large scale. To this end, in a first step, a gene library for the respective polypeptide is first generated, for example using the methods given above. The gene library is expressed in a suitable manner, for example by bacterial or phage display systems.

[0477] The relevant gene (its function is corresponding to required characteristic to a great extent) of the host organism expressing functional mutant can be submitted to another mutation cycle.The step of sudden change and selection or screening can be repeated iteratively until functional mutant of the present invention has the required characteristic of enough degree.Use this iterative process, can carry out the sudden change of limited number, for example 1,2,3,4 or 5 sudden changes in stages, and assess and select their influence on the activity studied.Then can be carried out further sudden change step by the selected mutant in the same manner.Like this, can significantly reduce the quantity of single mutant to be studied.

[0478] The results according to the present invention also provide important information about the structure and sequence of related polypeptides, which is necessary for generating other polypeptides with desired modified properties in a targeted manner. In particular, so-called "hot spots" can be defined, i.e., sequence segments that are potentially suitable for modifying properties by introducing targeted mutations.

[0479] Information can also be deduced regarding positions in the amino acid sequence where mutations may occur that may have little effect on activity and can be designated as potential "silent mutations."

[0480] e. Constructs expressing the polypeptides of the present invention

[0481] In the context of this article, the following definitions apply:

[0482] "Gene expression" encompasses "heterologous expression" and "overexpression" and involves the transcription of a gene and the translation of mRNA into protein. Overexpression refers to the production of a gene product in a transgenic cell or organism, as measured by mRNA, polypeptide, and / or enzyme activity levels, that exceeds the level of production in a non-transformed cell or organism of a similar genetic background.

[0483] As used herein, "expression vector" refers to a nucleic acid molecule that is engineered using molecular biology methods and recombinant DNA technology to deliver foreign or exogenous DNA into a host cell. An expression vector typically includes sequences required for the correct transcription of the nucleotide sequence. The coding region usually encodes a protein of interest, but may also encode RNA, such as antisense RNA, siRNA, etc.

[0484] As used herein, "expression vector" includes any linear or circular recombinant vector, including but not limited to viral vectors, phages and plasmids. The skilled person can select a suitable vector according to the expression system. In one embodiment, the expression vector includes a nucleic acid of the embodiments herein, which is operably linked to at least one "regulatory sequence" that controls transcription, translation, initiation and termination, such as a transcriptional promoter, operator or enhancer, or an mRNA ribosome binding site, and optionally includes at least one selection marker. When a regulatory sequence is functionally related to a nucleic acid of the embodiments herein, the nucleotide sequence is "operably linked".

[0485] As used herein, "expression system" encompasses any combination of nucleic acid molecules required to express one, or co-express two or more polypeptides in a given expression host in vivo or in vitro. The respective coding sequences can be located on a single nucleic acid molecule or vector, such as a vector comprising multiple cloning sites, or on a polycistronic nucleic acid, or can be distributed on two or more physically distinct vectors. As a specific example, an operon can be mentioned, which comprises a promoter sequence, one or more operator sequences, and one or more structural genes, each gene encoding an enzyme as described herein.

[0486] As used herein, the terms "amplifying" and "amplification" refer to the use of any suitable amplification method for generating or detecting recombinants of naturally expressed nucleic acids, as described in detail below. For example, the present invention provides methods and reagents (e.g., specific degenerate oligonucleotide primer pairs, oligo dT primers) for amplifying (e.g., by polymerase chain reaction, PCR) naturally expressed (e.g., genomic DNA or mRNA) or recombinant nucleic acids (e.g., cDNA) of the present invention in vivo, ex vivo, or in vitro.

[0487] "Regulatory sequence" refers to a nucleic acid sequence that determines the expression level of the nucleic acid sequence of the embodiments herein and is capable of regulating the transcription rate of the nucleic acid sequence operably linked to the regulatory sequence. Regulatory sequences include promoters, enhancers, transcription factors, promoter elements, etc.

[0488] According to the present invention, "promoter", "nucleic acid with promoter activity" or "promoter sequence" are understood to refer to a nucleic acid that, when functionally linked to a nucleic acid to be transcribed, regulates the transcription of said nucleic acid. "Promoter" refers in particular to a nucleic acid sequence that controls the expression of a coding sequence by providing a binding site for RNA polymerase and other factors suitable for transcription, including but not limited to transcription factor binding sites, repressor and activator protein binding sites. The term promoter also includes the term "promoter regulatory sequence". Promoter regulatory sequences may include upstream and downstream elements that may affect transcription, RNA processing or the stability of the associated coding nucleic acid sequence. Promoters include sequences of natural origin and synthesis. The coding nucleic acid sequence is typically located downstream of the promoter relative to the direction of transcription starting at the transcription start site.

[0489] In this context, "functional" or "operably" connection is understood to refer to, for example, the sequential arrangement of one of the nucleic acids with regulatory sequences. For example, a sequence with promoter activity, and a nucleic acid sequence to be transcribed and optional other regulatory elements (for example, nucleic acid sequences that ensure nucleic acid transcription) and, for example, terminators, are arranged in such a way that each regulatory element can perform its function after the nucleic acid sequence is transcribed. This does not necessarily require a direct connection in a chemical sense. Genetic control sequences, such as enhancer sequences, can even play a role on the target sequence from a more distant position or even from other DNA molecules. A preferred arrangement is such that the nucleic acid sequence to be transcribed is located downstream (i.e., 3' end) of the promoter sequence, so that the two sequences are covalently linked together. The distance between the promoter sequence and the nucleic acid sequence to be recombinantly expressed can be less than 200 base pairs, or less than 100 base pairs or less than 50 base pairs.

[0490] Besides promoters and terminators, the following may be mentioned as examples of further regulatory elements: targeting sequences, enhancers, polyadenylation signals, selectable markers, amplification signals, replication origins, etc. Suitable regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).

[0491] The term "constitutive promoter" refers to an unregulated promoter that allows for continuous transcription of a nucleic acid sequence to which it is operably linked.

[0492] As used herein, the term "operably connected" refers to the connection of a polynucleotide element in a functional relationship. When a nucleic acid is in a functional relationship with another nucleic acid sequence, the nucleic acid is "operably connected". For example, if a promoter or transcriptional regulatory sequence can affect the transcription of a coding sequence, the promoter or transcriptional regulatory sequence is operably connected to the coding sequence. Operably connected means that the DNA sequence being connected is usually adjacent. The nucleotide sequence associated with the promoter sequence can be of homologous or heterologous origin relative to the plant to be transformed. The sequence can also be fully or partially synthesized. Regardless of the source, the nucleic acid sequence associated with the promoter sequence will be expressed or silenced according to the promoter properties connected after being attached to the polypeptide of this paper's embodiment. The relevant nucleic acid can encode a protein that needs to be expressed or suppressed at all times or alternatively at a specific time in the entire organism or in a specific tissue, cell or cell compartment. Such a nucleotide sequence particularly encodes a protein that gives a desired phenotypic trait to a host cell or organism that is changed or transformed by it. More particularly, the relevant nucleotide sequence causes one or more target products as defined herein to be produced in a cell or organism. In particular, the nucleotide sequence encodes a polypeptide having enzymatic activity as defined herein.

[0493] The nucleotide sequence described herein may be part of an "expression cassette". The terms "expression cassette" and "expression construct" are used synonymously. A (preferably recombinant) expression construct comprises a nucleotide sequence encoding a polypeptide according to the invention and under the genetic control of a regulatory nucleic acid sequence.

[0494] In the methods used according to the invention, the expression cassette may be part of an "expression vector", in particular a recombinant expression vector.

[0495] According to the present invention, an "expression unit" is understood to mean a nucleic acid with expression activity, which comprises a promoter as defined herein and which, after functional linkage to a nucleic acid or gene to be expressed, regulates expression, i.e., the transcription and translation of said nucleic acid or gene. Therefore, in this context, it is also referred to as a "regulatory nucleic acid sequence." In addition to the promoter, other regulatory elements, such as enhancers, may also be present.

[0496] According to the present invention, an "expression cassette" or "expression construct" is understood to be an expression unit that is functionally linked to a nucleic acid to be expressed or a gene to be expressed. Thus, in contrast to an expression unit, an expression cassette contains not only nucleic acid sequences that regulate transcription and translation, but also nucleic acid sequences that are expressed as a protein as a result of transcription and translation.

[0497] In the context of the present invention, the terms "expression" or "overexpression" describe the production or increase in the intracellular activity of one or more polypeptides encoded by the corresponding DNA in a microorganism. This can be achieved, for example, by introducing a gene into the organism, replacing an existing gene with another, increasing the copy number of a gene, using a strong promoter, or using a gene encoding a highly active corresponding polypeptide. Alternatively, these measures can be combined.

[0498] Preferably, such constructs according to the invention comprise a promoter 5' upstream and a terminator sequence 3' downstream of the respective coding sequence, and optionally further customary regulatory elements, in each case operably linked to the coding sequence.

[0499] The nucleic acid construct according to the present invention comprises in particular a sequence encoding a polypeptide, which is derived, for example, from an amino acid related SEQ ID NO as described herein or its reverse complement, or derivatives and homologues thereof, and which has been operably or functionally linked to one or more regulatory signals for advantageously controlling, for example increasing, gene expression.

[0500] In addition to these regulatory sequences, the natural regulation of these sequences may still be present before the actual structural gene, and optionally may have been genetically modified so that the natural regulation has been switched off and gene expression has been enhanced. However, the nucleic acid construct may also have a simpler construction, i.e., no additional regulatory signals are inserted before the coding sequence, and the natural promoter with regulatory effects has not been removed. Instead, the natural regulatory sequences are mutated so that regulation no longer occurs and gene expression is increased.

[0501] Preferred nucleic acid constructs advantageously also comprise one or more " enhancer " sequences already mentioned that are functionally connected with the promoter, and this sequence makes the expression of the enhanced nucleic acid sequence become possibility. Other advantageous sequences, for example other regulatory elements or terminators can also be inserted at the 3 ' end of the dna sequence. One or more copies of nucleic acid according to the present invention can be present in the construct. In this construct, other markers can also be present alternatively, for example with genes complementary to auxotrophy or antibiotic resistance, so that this construct can be selected.

[0502] Examples of suitable regulatory sequences are found in promoters such as cos, tac, trp, tet, trp-tet, lpp, lac, lpp-lac, lacIq, T7, T5, T3, gal, trc, ara, rhaP (rhaP BAD )SP6, lambda-P R or lambda-P LAmong the promoters, they are advantageously used in Gram-negative bacteria. Other advantageous regulatory sequences are found, for example, in the Gram-positive promoters amy and SPO2, and in the yeast or fungal promoters ADC1, MFalpha, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH. Artificial promoters can also be used for regulation.

[0503] In order to express in the host organism, the nucleic acid construct is advantageously inserted into a carrier, for example a plasmid or a phage, which makes the optimal expression of the gene in the host possible. Except plasmids and phages, carriers are also understood to be all other carriers well known to those skilled in the art, i.e., for example viruses, for example SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids and linear or circular DNA or artificial chromosomes. These carriers can replicate autonomously or by chromosome replication in the host organism. These carriers are a further development of the present invention. Binary or cpo integrating vectors are also applicable.

[0504] Suitable plasmids are, for example, pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1, pKK223-3, pDHE19.2, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III, 113 -B1, λgt11, or pBdCI, in Streptomyces pIJ101, pIJ364, pIJ702, or pIJ361, in Bacillus pUB110, pC194, or pBD214, in Corynebacterium pSA77 or pAJ667, in fungi pALS1, pIL2, or pBB116, in yeast 2alphaM, pAG-1, YEp6, YEp13, or pEMBLYe23, or in plants pLGV23, pGHlac + , pBIN19, pAK2004 or pDH51. The above plasmids are a small selection of possible plasmids. Other plasmids are well known to the skilled person and can be found, for example, in the book Cloning Vectors (Eds. Pouwels PH et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018).

[0505] In the further development of vectors, vectors comprising the nucleic acid construct of the present invention or the nucleic acid of the present invention can also advantageously be introduced into microorganisms in the form of linear DNA and integrated into the genome of the host organism by heterologous or homologous recombination. This linear DNA can consist of a linearized vector, for example a plasmid, or can consist solely of the nucleic acid construct of the present invention or the nucleic acid.

[0506] For optimal expression of heterologous genes in an organism, it is advantageous to modify the nucleic acid sequence to match the specific "codon usage" used in the organism."Codon usage" can be readily determined by computer evaluation of other known genes of the organism in question.

[0507] The expression cassette according to the present invention is produced by fusing a suitable promoter to a suitable coding nucleotide sequence and terminator or polyadenylation signal. Conventional recombination and cloning techniques are used for this purpose, as for example described in T. Maniatis, E. F. Ritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) and T. J. Silhavy, M. L. Berman and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience (1987).

[0508] For expression in a suitable host organism, the recombinant nucleic acid construct or gene construct is advantageously inserted into a host-specific vector, which enables optimal expression of the gene in the host. Vectors are well known to the skilled person and can be found, for example, in "cloning vectors" (Pouwels PH et al., Ed., Elsevier, Amsterdam-New York-Oxford, 1985).

[0509] An alternative embodiment of the present invention provides a method of "altering gene expression in a host cell." For example, under certain circumstances (e.g., exposure to certain temperature or culture conditions), the polynucleotides of the present invention can be enhanced or overexpressed or induced in a host cell or host organism.

[0510] Alteration of expression of the polynucleotides provided herein can also result in ectopic expression, which is a different expression pattern in the altered and control or wild-type organisms. Alteration of expression occurs due to the interaction of a polypeptide of an embodiment herein with an exogenous or endogenous modulator or due to chemical modification of the polypeptide. The term also refers to an altered expression pattern of a polynucleotide of an embodiment herein, which is altered to below the level of detection or completely inhibited in activity.

[0511] In one embodiment, also provided herein are isolated, recombinant, or synthetic polynucleotides encoding the polypeptides or variant polypeptides provided herein.

[0512] In one embodiment, multiple polypeptide encoding nucleic acid sequences are co-expressed in a single host, particularly under the control of different promoters. In another embodiment, multiple polypeptide encoding nucleic acid sequences can be present on a single transformation vector, or separate vectors can be used and transformants containing two chimeric genes can be selected for simultaneous co-transformation. Similarly, one or more polypeptide encoding genes can be expressed in a single plant, cell, microorganism or organism along with other chimeric genes.

[0513] f. Hosts suitable for the present invention

[0514] Depending on the context, the term "host" may refer to a wild-type host or a genetically altered recombinant host or both.

[0515] In principle, all prokaryotic or eukaryotic organisms can be considered as hosts or recombinant host organisms for the nucleic acids or nucleic acid constructs according to the invention.

[0516] Using the vector according to the present invention, a recombinant host can be produced, which, for example, can be transformed with at least one vector according to the present invention and can be used to produce a polypeptide according to the present invention. Advantageously, the recombinant construct according to the present invention as described above is introduced into a suitable host system and expressed. Preferably, common cloning and transfection methods known to those skilled in the art, such as coprecipitation, protoplast fusion, electroporation, retroviral transfection, etc., are used to express the nucleic acid in their respective expression systems. Suitable systems are described in Current Protocols in Molecular Biology, F. Ausubel et al., Ed., Wiley Interscience, New York 1997, or Sambrook et al. Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

[0517] Advantageously, microorganisms such as bacteria, fungi or yeast are used as host organisms. Advantageously, Gram-positive or Gram-negative bacteria are used, preferably bacteria of the families Enterobacteriaceae, Pseudomonadaceae, Rhizobiaceae, Streptomycetaceae, Streptococcaceae or Nocardiaceae, particularly preferably bacteria of the genus Escherichia, Pseudomonas, Streptomyces, Lactococcus, Nocardia, Burkholderia, Salmonella, Agrobacterium, Clostridium or Rhodococcus. The genus and species of Escherichia coli are very particularly preferred. In addition, other advantageous bacteria are found in the alpha-Proteobacteria, beta-Proteobacteria or gamma-Proteobacteria groups. Advantageously, yeasts such as the Saccharomyces or Pichia families are also suitable hosts.

[0518] Alternatively, whole plants or plant cells can be used as natural or recombinant hosts. As non-limiting examples, the following plants or cells derived therefrom may be mentioned: Nicotiana, in particular Nicotiana benthamiana and Nicotiana tabacum (tobacco); and Arabidopsis, in particular Arabidopsis thaliana.

[0519] Depending on the host organism, the organisms used in the methods of the present invention are grown or cultured in a manner known to those skilled in the art. Cultivation can be carried out in batches, semi-batch, or continuously. Nutrients can be given at the beginning of fermentation or later, semi-continuously or continuously. This is also described in more detail below.

[0520] g. Recombinant production of the polypeptide according to the present invention

[0521] The present invention further relates to a method for the recombinant production of a polypeptide according to the invention or a functional, biologically active fragment thereof, wherein a microorganism producing the polypeptide is cultured, expression of the polypeptide is optionally induced by administering at least one inducer of gene expression, and the polypeptide is isolated from the culture. If desired, the polypeptide can also be produced on an industrial scale in this manner.

[0522] The microorganism that produces according to the present invention can be cultivated continuously or discontinuously by batch process or fed-batch process or repeated fed-batch process.The general introduction of known culture method can be in the textbook (Bioprozesstechnik 1.Einführungin die Bioverfahrenstechnik [Bioprocess technology 1.Introduction tobioprocess technology] (Gustav Fischer Verlag, Stuttgart, 1991)) of Chmiel or in the textbook (Bioreaktoren und periphere Einrichtungen [Bioreactors and peripheralequipment] (Vieweg Verlag, Braunschweig / Wiesbaden, 1994)) of Storhas.

[0523] The culture medium used must be appropriately adapted to the requirements of the respective strain. Descriptions of culture media for various microorganisms are given in the manual "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington DC, USA, 1981).

[0524] The culture media which can be used according to the invention generally comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.

[0525] The preferred carbon source is sugar, for example monosaccharide, disaccharide or polysaccharide. Good carbon source is for example glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose. Sugar also can be added in the substratum by other by-products of complex compound (for example molasses) or sugar refining. It is also favourable to add the mixture of different carbon sources. Other possible carbon sources are oil and fat, for example soybean oil, sunflower seed oil, peanut oil and coconut oil, fatty acid for example palmitic acid, stearic acid or linoleic acid, alcohol for example glycerol, methanol or ethanol, and organic acid, for example acetic acid or lactic acid.

[0526] The nitrogen source is generally an organic or inorganic nitrogen compound or a material containing such a compound. Examples of nitrogen sources include ammonia gas or ammonium salts, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources, such as corn steep liquor, soy flour, soy protein, yeast extract, meat extract, etc. The nitrogen sources can be used alone or in combination.

[0527] Inorganic salt compounds that may be present in the culture medium include chloride, phosphorus or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.

[0528] Inorganic sulfur-containing compounds, such as sulfates, sulfites, dithionites, tetrasulfates, thiosulfates, sulfides, and organic sulfur compounds, such as mercaptans and thiols, can be used as sulfur sources.

[0529] Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as phosphorus sources.

[0530] Chelating agents may be added to the culture medium to keep the metal ions in solution. Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.

[0531] The fermentation medium used according to the present invention generally also includes other growth factors, such as vitamins or growth promoters, which include, for example, biotin, riboflavin, thiamine, folic acid, nicotinic acid, pantothenic acid and pyridoxine. Growth factors and salts are generally derived from the components of complex culture media, such as yeast extract, molasses, corn steep liquor, etc. In addition, suitable precursors can be added to the culture medium. The exact composition of the compound in the culture medium depends to a large extent on the corresponding experiment and is determined respectively for each specific case. Information about culture medium optimization can be found in the textbook " Applied Microbiol. Physiology, A Practical Approach " (Ed. PM Rhodes, PF Stanbury, IRL Press (1997) p.53-73, ISBN 0 19 963577 3). Growth medium can also be obtained from commercial suppliers, such as Standard 1 (Merck) or BHI (brain heart infusion, DIFCO) etc.

[0532] All components of the culture medium are sterilized by heating (1.5 bar and 121°C for 20 minutes) or by sterile filtration. These components can be sterilized together or separately as needed. All components of the culture medium can be given at the beginning of the culture or added continuously or in batches.

[0533] The temperature of the culture is generally between 15°C and 45°C, preferably 25°C to 40°C, and can be changed or kept constant during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0. The pH value during growth can be controlled by adding alkaline compounds (such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water) or acidic compounds (such as phosphoric acid or sulfuric acid). Defoaming agents such as fatty acid polyethylene glycol esters can be used to control foaming. In order to maintain the stability of the plasmid, suitable selective substances such as antibiotics can be added to the culture medium. In order to maintain aerobic conditions, oxygen or an oxygen-containing gas mixture (such as ambient air) is supplied to the culture. The temperature of the culture is generally in the range of 20°C to 45°C. Continue to cultivate until the maximum amount of the desired product is formed. This goal is usually achieved within 10 to 160 hours.

[0534] The fermentation broth is then processed further. Depending on requirements, the biomass can be completely or partially removed from the fermentation broth by separation techniques such as centrifugation, filtration, decantation or a combination of these methods, or can remain completely therein.

[0535] If the polypeptide is not secreted in the culture medium, the cells can also be lysed and the product can be obtained from the lysate by known methods for isolating proteins. The cells can alternatively be disrupted by high-frequency ultrasound, high pressure, for example in a high-pressure cell lyser (French press), by osmosis, by the action of detergents, lytic enzymes or organic solvents, by homogenizers or by a combination of the above methods.

[0536] The polypeptide can be purified by known chromatographic techniques, such as molecular sieve chromatography (gel filtration), e.g., Q-agarose chromatography, ion exchange chromatography and hydrophobic chromatography, and other conventional techniques, such as ultrafiltration, crystallization, salting out, dialysis and native gel electrophoresis. Suitable methods are described, for example, in Cooper, TG, Biochemische Arbeitsmethoden [Biochemical processes], Verlag Walter de Gruyter, Berlin, New York, or Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin.

[0537] In order to separate the recombinant protein, it may be advantageous to use a carrier system or oligonucleotide that extends the cDNA by the nucleotide sequence of limitation, and therefore encodes a changed polypeptide or fusion protein, which is for example used for easier purification. Suitable modifications of this type are, for example, so-called "tags" that serve as anchors, such as modifications of hexa-histidine anchors or epi-positions that can be identified as antibody antigens (e.g., described in Harlow, E. and Lane, D., 1988, Antibodies:A Laboratory Manual. Cold Spring Harbor (NY) Press). These anchors can be used to connect the protein to a solid support, such as a polymer matrix, which can, for example, be used as the filler in a chromatographic column, or can be used in microtiter plates or other carriers.

[0538] At the same time, these anchors can also be used to identify proteins. In order to identify proteins, conventional labels such as fluorescent dyes, enzyme labels (which react with substrates to form detectable reaction products), or radioactive labels can also be used, alone or in combination with anchors to derivatize proteins.

[0539] h. Immobilization of polypeptides

[0540] Enzyme or polypeptide according to the present invention can be used in free form or immobilized in the method described herein.Immobilized enzyme is an enzyme fixed on an inert carrier. Suitable carrier materials and enzymes fixed thereon are known from EP-A-1149849, EP-A-1069183 and DE-OS100193773 and from the references cited therein. In this respect, the full disclosures of these documents are referred to. Suitable carrier materials include, for example, clay, clay minerals, such as kaolinite, diatomaceous earth, perlite, silicon dioxide, aluminum oxide, sodium carbonate, calcium carbonate, cellulose powder, anion exchanger materials, synthetic polymers, such as polystyrene, acrylic resins, phenolic resins, polyurethanes and polyolefins, such as polyethylene and polypropylene. In order to prepare the enzyme of load, carrier materials are usually used in a finely divided granular form, preferably in a porous form. The particle diameter of the carrier material is usually not more than 5 mm, particularly not more than 2 mm (particle size distribution curve). Similarly, when using dehydrogenase as a whole cell catalyst, free form or immobilized form can be selected. Carrier materials are, for example, calcium alginate and carrageenan. Enzymes and cells can also be directly cross-linked with glutaraldehyde (cross-linking with CLEAs). Corresponding and other immobilization techniques are described, for example, in J. Lalonde and A. Margolin "Immobilization of Enzymes" in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic Synthesis 2002, Vol. III, 991-1032, Wiley-VCH, Weinheim. Further information on biotransformations and bioreactors for carrying out the method according to the invention is given in Rehm et al. (Ed.) Biotechnology, 2nd Edn, Vol. 3, Chapter 17, VCH, Weinheim.

[0541] i. Reaction conditions of the biocatalytic production method of the present invention

[0542] The reaction of the present invention can be carried out under in vivo or in vitro conditions.

[0543] The at least one polypeptide / enzyme present in the method of the present invention or in a single step of the multi-step method defined above may be naturally present in living cells, or one or more enzymes may be recombinantly produced in harvested cells (i.e., under in vivo conditions), dead cells, permeabilized cells, crude cell extracts, purified extracts, or in substantially pure or completely pure form (i.e., under in vitro conditions). The at least one enzyme may be present in solution or as an enzyme immobilized on a support. One or more enzymes may be present in both soluble and / or immobilized form.

[0544] The method according to the present invention can be carried out in common reactors known to those skilled in the art, and can be carried out in different scale ranges, for example, from laboratory scale (a few milliliters to tens of liters of reaction volume) to industrial scale (a few liters to thousands of cubic meters of reaction volume). If the polypeptide is used in the form of encapsulation by inanimate, optionally permeabilized cells, in the form of more or less purified cell extracts or in purified form, a chemical reactor can be used. Chemical reactors generally allow the control of the amount of at least one enzyme, the amount of at least one substrate, pH, temperature and the circulation of the reaction medium. When at least one polypeptide / enzyme is present in living cells, the process will be fermentation. In this case, biocatalytic production will be carried out in a bioreactor (fermenter), where the parameters necessary for the suitable living conditions of the living cells (e.g., culture medium with nutrients, temperature, ventilation, aerobic or anaerobic or other gases, antibiotics, etc.) can be controlled. The person skilled in the art is familiar with chemical reactors or bioreactors, for example using procedures for scaling up chemical or biotechnological processes from the laboratory scale to the industrial scale or for optimizing process parameters, which are also widely described in the literature (for biotechnological processes, see, for example, Crueger und Crueger, Biotechnologie—Lehrbuch der angewandten Mikrobiologie, 2. Ed., R. Oldenbourg Verlag, München, Wien, 1984).

[0545] The cells containing at least one enzyme can be permeabilized by physical or mechanical means such as ultrasound or radiofrequency pulses, high pressure cell lysers (French press) or chemical means such as the presence of a hypotonic medium, a lytic enzyme and a detergent in the culture medium or a combination of these methods. Examples of detergents are digitoxin, n-dodecyl maltoside, octyl glucoside, X-100, 20, deoxycholate, CHAPS (3-[(3-chloroamidopropyl)dimethylammonium]-1-propanesulfonate), P40 (ethylphenol poly (ethylene glycol ether)), etc.

[0546] Instead of living cells, non-living cell biomass containing the desired biocatalyst can also be used in the bioconversion reaction of the present invention.

[0547] If at least one enzyme is immobilized, it is attached to an inert support as described above.

[0548] The conversion reaction can be carried out batchwise, semi-batchwise or continuously. The reactants (and optionally nutrients) can be provided at the start of the reaction, or can be provided subsequently semi-continuously or continuously.

[0549] Depending on the particular reaction type, the reactions of the present invention can be carried out in aqueous, aqueous-organic or non-aqueous reaction media.

[0550] The aqueous or aqueous-organic medium may contain a suitable buffer to adjust the pH to 5 to 11, for example 6 to 10.

[0551] In aqueous-organic media, organic solvents that are miscible, partially miscible or immiscible with water can be used. Non-limiting examples of suitable organic solvents are listed below. Further examples are monobasic or polybasic, aromatic or aliphatic alcohols, particularly polybasic aliphatic alcohols, such as glycerol.

[0552] The non-aqueous medium may comprise substantially no water, ie, will comprise less than about 1% or 0.5% by weight water.

[0553] The biocatalytic process can also be carried out in an organic non-aqueous medium. Suitable organic solvents include, for example, aliphatic hydrocarbons having 5 to 8 carbon atoms, such as pentane, cyclopentane, hexane, cyclohexane, heptane, octane or cyclooctane; aromatic hydrocarbons, such as benzene, toluene, xylene, chlorobenzene or dichlorobenzene; aliphatic acyclic hydrocarbons and ethers, such as diethyl ether, methyl tert-butyl ether, ethyl tert-butyl ether, dipropyl ether, diisopropyl ether, dibutyl ether; or mixtures thereof.

[0554] The concentrations of reactants / substrates may be adapted to the optimal reaction conditions, which may depend on the specific enzyme being applied. For example, the initial substrate concentration may be from 0.1 to 0.5 M, such as from 10 to 100 mM.

[0555] The reaction temperature can be adapted to the optimal reaction conditions, which may depend on the specific enzyme being used. For example, the reaction can be carried out at a temperature of 0 to 70° C., such as 20 to 50 or 25 to 40° C. Examples of reaction temperatures are about 30° C., about 35° C., about 37° C., about 40° C., about 45° C., about 50° C., about 55° C., and about 60° C.

[0556] The process can be continued until equilibrium is reached between the substrate and the subsequent product, but can be stopped earlier. Common process times are 1 minute to 25 hours, particularly 10 minutes to 6 hours, for example 1 hour to 4 hours, particularly 1.5 hours to 3.5 hours. These parameters are non-limiting examples of suitable process conditions.

[0557] If the host is a transgenic plant, optimal growing conditions can be provided, such as optimal light, water, and nutrient conditions.

[0558] k. Product separation

[0559] The method of the present invention may further include the step of recovering the final product or intermediate product, which is optionally in the substantially pure form of a stereoisomer or enantiomer. The term "recovery" includes extracting, harvesting, separating or purifying the compound from a culture medium or reaction medium. The recovery of the compound can be carried out according to any conventional separation or purification method known in the art, including but not limited to treatment with conventional resins (e.g., anion or cation exchange resins, nonionic adsorption resins, etc.), treatment with conventional adsorbents (e.g., activated carbon, silicic acid, silica gel, cellulose, aluminum oxide, etc.), changes in pH, solvent extraction (e.g., using conventional solvents such as alcohol, ethyl acetate, hexane, etc.), distillation, dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, freeze-drying, etc.

[0560] The identity and purity of the isolated product can be determined by known techniques, such as high performance liquid chromatography (HPLC), gas chromatography (GC), spectroscopy (e.g. IR, UV, NMR), staining methods, TLC, NIRS, enzyme or microbiological assays (see, for example: Patek et al. (1994) Appl. Environ. Microbiol. 60: 133-140; Malakhova et al. (1996) Biotekhnologiya 11: 27-32; and Schmidt et al. (1998) Bioprocess Engineer. 19: 67-70. Ullmann's Encyclopedia of Industrial Chemistry (1996) Bd. A 27, VCH: Weinheim, S. 89-90, S. 521-540, S. 540-547, S. 559-566, 575-581 and S.581-587; Michal, G (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A. et al. (1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology, Bd. 17.).

[0561] The cyclic terpene compounds produced by any of the methods described herein can be converted into derivatives such as, but not limited to, hydrocarbons, esters, amides, glycosides, ethers, epoxides, aldehydes, ketones, alcohols, diols, acetals, or ketals. Terpene compound derivatives can be obtained by chemical methods such as, but not limited to, oxidation, reduction, alkylation, acylation, and / or rearrangement. Alternatively, terpene compound derivatives can be obtained by biochemical methods by contacting the terpene compound with an enzyme such as, but not limited to, an oxidoreductase, a monooxygenase, a dioxygenase, or a transferase. Biochemical conversions can be performed in vitro using isolated enzymes, enzymes from lysed cells, or in vivo using whole cells.

[0562] 1. Fermentation production of terpene alcohols

[0563] The present invention also relates to a method for the fermentative production of terpene alcohols.

[0564] The fermentation used according to the invention can be carried out, for example, in stirred fermentor tanks, bubble columns and loop reactors. For a comprehensive overview of possible method types, including agitator types and geometric designs, see "Chmiel: Bioprozesstechnik: Einfuhrung in die Bioverfahrenstechnik, Band 1". In the method of the present invention, available typical variations are those known to those skilled in the art or, for example, explained in "Chmiel, Hammes and Bailey: Biochemical Engineering", such as batch, fed-batch, repeated fed-batch or continuous fermentation with or without biomass recovery. Depending on the production strain, injection of air, oxygen, carbon dioxide, hydrogen, nitrogen or a suitable gas mixture can be used to achieve a good yield (YP / S).

[0565] The culture medium to be used must meet the requirements of the specific strain in an appropriate manner. Descriptions of culture media for various microorganisms are given in the manual "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington DC, USA, 1981).

[0566] The culture media which can be used according to the invention generally comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.

[0567] The preferred carbon source is sugar, for example monose, disaccharide or polysaccharide. Very good carbon source is for example glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose. Sugar also can be added in the substratum by other by-products of complex compound (for example molasses) or sugar refining. It is also favourable to add the mixture of various carbon sources. Other possible sources of carbon are oil and fat, for example soybean oil, sunflower seed oil, peanut oil and coconut oil, fatty acid for example palmitic acid, stearic acid or linoleic acid, alcohol for example glycerol, methanol or ethanol, and organic acid, for example acetic acid or lactic acid.

[0568] The nitrogen source is generally an organic or inorganic nitrogen compound or a material containing such a compound. Examples of nitrogen sources include ammonia gas or ammonium salts, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources, such as corn steep liquor, soy flour, soy protein, yeast extract, meat extract, etc. The nitrogen sources can be used alone or in combination.

[0569] Inorganic salt compounds that may be present in the culture medium include chlorides, phosphates or sulfates of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.

[0570] Inorganic sulfur-containing compounds, such as sulfates, sulfites, dithionites, tetrasulfates, thiosulfates, sulfides, and organic sulfur compounds, such as mercaptans and thiols, can be used as sulfur sources.

[0571] Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as phosphorus sources.

[0572] Chelating agents may be added to the culture medium to keep the metal ions in solution. Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.

[0573] The fermentation medium used according to the present invention may also contain other growth factors, such as vitamins or growth promoters, including, for example, biotin, riboflavin, thiamine, folic acid, niacin, pantothenic acid, and pyridoxine. Growth factors and salts are typically derived from complex components of the culture medium, such as yeast extract, molasses, corn steep liquor, etc. In addition, suitable precursors may be added to the culture medium. The precise composition of the compounds in the culture medium depends largely on the specific experiment and must be determined for each specific case. Information on culture medium optimization can be found in the textbook "Applied Microbiol. Physiology, A Practical Approach" (1997). Growth media can also be obtained from commercial suppliers, such as Standard 1 (Merck) or BHI (brain heart infusion, DIFCO).

[0574] All components of the culture medium are sterilized by heating (1.5 bar and 121°C for 20 minutes) or by sterile filtration. These components can be sterilized together or separately as needed. All components of the culture medium can be given at the beginning of growth, or you can choose to add them continuously or in batches.

[0575] The temperature of the culture is generally between 15°C and 45°C, preferably 25°C to 40°C, and can be kept constant or can be varied during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0. The pH during growth can be controlled by adding alkaline compounds (such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water) or acidic compounds (such as phosphoric acid or sulfuric acid). Defoaming agents such as fatty acid polyethylene glycol esters can be used to control foaming. In order to maintain the stability of the plasmid, suitable substances with selective effects such as antibiotics can be added to the culture medium. In order to maintain aerobic conditions, oxygen or an oxygen-containing gas mixture (such as ambient air) is supplied to the culture. The temperature of the culture is generally between 20°C and 45°C. Cultivation is continued until the maximum amount of the desired product is formed. This goal is usually achieved within 1 to 160 hours.

[0576] The method of the present invention may further comprise the step of recovering the terpene alcohol.

[0577] The term "recovery" includes extracting, harvesting, isolating or purifying the compound from the culture medium. The recovery of the compound can be carried out according to any conventional separation or purification method known in the art, including but not limited to treatment with conventional resins (e.g., anion or cation exchange resins, nonionic adsorption resins, etc.), treatment with conventional adsorbents (e.g., activated carbon, silicic acid, silica gel, cellulose, alumina, etc.), pH modification, solvent extraction (e.g., using conventional solvents such as alcohols, ethyl acetate, hexane, etc.), distillation, dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization, etc.

[0578] Before the separation of expectation, the biomass of fermented liquid can be removed.The method of removing biomass is well known to those skilled in the art, for example, filtration, sedimentation and flotation.Therefore, can for example, remove biomass by centrifuge, separator, decanter, filter or in flotation equipment.In order to reclaim valuable product to the greatest extent, it is usually recommended to wash biomass, for example, in the form of diafiltration.The selection of method depends on the content of biomass and the character of biomass in the fermented liquid, and the interaction of biomass and valuable product.

[0579] In one embodiment, the fermentation broth can be sterilized or pasteurized. In another embodiment, the fermentation broth is concentrated. This concentration can be performed in batches or continuously, as desired. The pressure and temperature ranges should be selected to prevent product damage and minimize equipment and energy use. Skilled selection of pressure and temperature levels for multi-stage evaporation can be particularly energy-efficient.

[0580] The following examples are illustrative only and are not meant to limit the scope of the embodiments and embodiments described herein.

[0581] Numerous possible variations that will become immediately apparent to those skilled in the art after considering the disclosure provided herein also fall within the scope of the invention.

[0582] Experimental part

[0583] The present invention will now be described in more detail by way of the following examples.

[0584] Material:

[0585] Unless otherwise stated, all chemical and biochemical materials, and microorganisms or cells used herein are commercially available products.

[0586] Unless otherwise indicated, recombinant proteins were cloned and expressed by standard methods, such as those described in Sambrook, J., Fritsch, EF and Maniatis, T., Molecular cloning: A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

[0587] General method:

[0588] Standard assay for determining copalyl diphosphate phosphatase activity

[0589] The two plasmids were used to transform Escherichia coli cells (strain DP1205).

[0590] - A plasmid carrying a gene encoding an enzyme necessary for the biosynthesis of copalyl diphosphate (CPP), such as the pACYC-CrtE-SmCPS2 plasmid

[0591] a plasmid carrying a gene encoding a protein having terpene phosphate phosphatase activity, for example, the pJ401-TalVeTPP or pJ401-AspWeTPP plasmid.

[0592] Cells were cultured as described below and analyzed for copalol production by GC-MS.

[0593] Standard assay for determining 8-hydroxy-copalyl diphosphate phosphatase activity

[0594] The two plasmids were used to transform Escherichia coli cells (strain DP1205).

[0595] - a plasmid carrying a gene encoding an enzyme necessary for the biosynthesis of 8-hydroxypentyl diphosphate (LPP), such as the pACYC-CrtE-SsLPS plasmid

[0596] a plasmid carrying a gene encoding a protein having terpene phosphate phosphatase activity, for example, the pJ401-TalVeTPP or pJ401-AspWeTPP plasmid.

[0597] Cells were cultured as described below and analyzed for lisdendiol production by GC-MS.

[0598] Standard assay for determining copalol dehydrogenase activity

[0599] The two plasmids were used to transform Escherichia coli cells (strain DP1205).

[0600] - a plasmid carrying genes encoding enzymes necessary for copalol biosynthesis, such as the pJ401-CPOL-2 plasmid,

[0601] - A plasmid carrying a gene encoding alcohol dehydrogenase, for example using pJ423 as a background plasmid.

[0602] Cells were cultured as described below and analyzed for copalaldehyde production by GC-MS.

[0603] Standard assay for determining lisdendiol dehydrogenase activity

[0604] The two plasmids were used to transform Escherichia coli cells (strain DP1205).

[0605] - a plasmid carrying genes encoding enzymes necessary for the biosynthesis of lisdendiol, such as the pJ401-LOH-2 plasmid,

[0606] - A plasmid carrying a gene encoding alcohol dehydrogenase, for example using pJ423 as a background plasmid.

[0607] Cells were cultured as described below and product production was analyzed by GC-MS.

[0608] Gas chromatography-mass spectrometry (GC-MS)

[0609] Terpene content was analyzed by GC-MS using an Agilent 6890 Series GC system connected to an Agilent 5975 mass detector. The GC was equipped with a 0.25 mm ID, 30 m long HP-5MS capillary column (Agilent). The carrier gas was helium at a flow rate of 1 mL / min. The inlet temperature was set to 250°C. The oven temperature was initially set at 100°C for 1 minute and then increased to 300°C at a gradient of 10°C / min. Product identification was based on comparison of mass spectra and retention indices with authentic standards and a proprietary mass spectral database. Concentrations were estimated based on internal standards.

[0610] Preparation of recombinant bacterial strains with chromosomal integration of genes encoding mevalonate pathway enzymes

[0611] An E. coli strain was engineered to produce the terpene precursor farnesyl pyrophosphate (FPP) by chromosomal integration of recombinant genes encoding mevalonate pathway enzymes. Figure 15 The construction scheme and recombination events are shown in .

[0612] An upper pathway operon (acetyl-CoA to mevalonate operon 1) was designed, consisting of the atoB gene encoding acetoacetyl-CoA thiolase from Escherichia coli, and the mvaA and mvaS genes encoding HMG-CoA synthase and HMG-CoA reductase, respectively, from Staphylococcus aureus.

[0613] As the lower mevalonate pathway operon (operon 2 from mevalonate to farnesyl pyrophosphate), a native operon from the Gram-negative bacterium Streptococcus pneumoniae was selected, which encodes mevalonate kinase (mvaK1), phosphomevalonate kinase (mvaK2), phosphomevalonate decarboxylase (mvaD) and isopentenyl diphosphate isomerase (fni).

[0614] A codon-optimized Saccharomyces cerevisiae FPP synthase encoding gene (ERG20) was introduced into the 3' end of the upstream pathway operon to convert isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) to FPP.

[0615] The above operon was synthesized by DNA2.0 and integrated into the araA gene of the Escherichia coli BL21 (DE3) strain. Using the CRISPR / Cas9 genome engineering system, the heterologous pathway was introduced in two separate recombination steps. The first operon to be integrated (downstream pathway; operon 2) was marked with spectinomycin (Spec), which was used to screen for candidate integrants resistant to Spec. The second operon was designed to replace the Spec marker of the previously integrated operon, and Spec candidate integrants were screened accordingly after the second recombination event (see Figure 15 A guide RNA expression vector targeting the araA gene was designed and synthesized by DNA 2.0. PCR was used to verify operon integration by designing PCR primers to amplify the trans-araA gene integration target and the trans-integron recombination junction. One clone that produced the correct PCR result was then fully sequenced and archived as strain DP1205.

[0616] Cultivation of bacterial cells and analysis of terpene production

[0617] E. coli cells were transformed with one or two expression plasmids carrying terpene biosynthesis genes and cultured on LB-agarose plates with appropriate antibiotics (kanamycin (50 μg / ml) and / or chloramphenicol (34 μg / ml)). A single colony was used to inoculate 5 mL of liquid LB medium supplemented with the same antibiotics, 4 g / l glucose, and 10% (v / v) dodecane. The next day, 0.2 mL of overnight culture was used to inoculate 2 mL of TB medium supplemented with the same antibiotics and 10% (v / v) dodecane. The culture was incubated at 37°C until the optical density reached 3. Expression of the recombinant protein was induced by adding 1 mM IPTG and the culture was incubated at 20°C for 72 hours.

[0618] The culture was then extracted with tert-butyl methyl ether (MTBE) and an internal standard (α-longifolia pinene (Aldrich)) was added to the organic phase. The terpene content of the organic phase was analyzed by GC-MS as described above.

[0619] Example 1 : Identification and characterization of the copalyl diphosphate phosphatase activity of TalVeTPP and AspVeTPP.

[0620] TalVeTPP and AspWeTPP albumen are respectively coded by two predicted genes in Talaromyces verruculosus and Aspergillus wentii genome.TalVeTPP coding gene is located in 150095..151030 zone of the Talaromyces verruculosus genome scaffold sequence with NCBI accession number LHCL01000010.1.It is reported that the protein encoded is the protein of hypothesis, does not have functional characteristics (NCBI accession number KUL89334.1).AspWeTPP coding gene is located in 2487776..2483627 zone of the unplaced genome scaffold ASPWEscaffold_5 (NCBI accession number KV878213.1) of Aspergillus wentii (Aspergillus wentii) DTO 134E9. The encoded protein has NCBI accession number OJJ34585.1 and is also reported as a putative protein with no functional characterization.

[0621] The genes encoding TalVeTPP and AspWeTPP are located in the genome, possibly adjacent to genes related to secondary metabolite biosynthesis, such as genes encoding oxidases, hydroxylases, and dehydrogenases, particularly genes with high homology to monofunctional copalyl diphosphate synthase or difunctional copalyl diphosphate synthase, the latter reported in Mitsuhashi et al, Chembiochem. 2017 Nov 2; 18(21): 2104-2109. Functional analysis of the amino acid sequences of TalVeTPP and AspWeTPP by searching for the presence of protein family domain signatures (e.g., using the Interpro sequence analysis tool at www.ebi.ac.uk / interpro / or the Pfam database search tool http: / / pfam.xfam.org / search#tabview=tab0 or https: / / www.ebi.ac.uk / Tools / pfa / pfamscan / ) showed that these two proteins are expected to contain protein tyrosine phosphatase signatures. Enzymes from the tyrosine phosphatase family are described for removing phosphate groups from various phosphorylated molecules, particularly proteins. However, it has never been demonstrated that enzymes from this protein family can act on compounds such as copalyl diphosphate. However, considering the genomic localization of the genes encoding TalVeTPP and AspWeTPP, we hypothesized that TalVeTPP and AspWeTPP could catalyze the cleavage of the diphosphate group of copalyl diphosphate or other isoprenoid diphosphate compounds ( Figure 1 .).

[0622] TalVeTPP and AspWeTPP encoding cDNAs (SEQ ID NOs: 3 and 7, respectively) were codon optimized (SEQ ID NOs: 1 and 5, respectively) and cloned into expression plasmid pJ401 (ATUM, Newark, California) to provide plasmids pJ401-TalVeTPP and pJ401-AspWeTPP, respectively.

[0623] Another expression plasmid was constructed that carries the gene encoding geranylgeranyl pyrophosphate synthase (GGPS) and the gene encoding copalyl pyrophosphate synthase (CPS). For the CPS gene, the cDNA encoding the CPS from Salvia miltiorrhiza (NCBI accession number ABV57835.1) was codon-optimized for optimal expression in E. coli. In addition, the first 58 codons were removed and the ATG start codon was added. The optimized cDNA encoding the truncated Salvia miltiorrhiza CPS (SmCPS2) (SEQ ID NO: 33) was synthesized in vitro and first cloned into the pJ208 plasmid flanked by NdeI and KpnI restriction enzyme recognition sites (ATUM, Newark, California). For GGPS, the GGPP synthase (NCBI accession number AAA24819.1) encoded by the CrtE gene from Pantoea agglomerans (NCBI accession number M38424.1) was used. The GGPP synthase was codon-optimized (SEQ ID NO: 35) and NcoI and BamHI restriction enzyme recognition sites were added at the 3' and 5' ends (ATUM, Newark, California) and cloned into pACYCDuet TM The CrtE gene was synthesized by ligation between the NcoI and BamHI sites of the Agilent ® -1 plasmid (Merck) to obtain the pACYC-CrtE plasmid. The modified SmCPS2 encoding cDNA was digested with NdeI and KpnI and ligated into the pACYC-CrtE plasmid to provide the pACYC-CrtE-SmCPS2 construct.

[0624] E. coli cells (strain DP1205, prepared above) were transformed with the two plasmids pACYC-CrtE-SmCPS2 and either pJ401-TalVeTPP or pJ401-AspWeTPP. The cells were cultured and analyzed for terpene production as described in the Methods section. Figure 2 shows a representative GC-MS profile of copalol produced by recombinant E. coli cells. Cells expressing only mevalonate pathway enzymes and SmCPS2 produced a small amount of copalol (6.7 mg / L, 0.79%) due to hydrolysis of CPP by endogenous alkaline phosphatase. Figure 3E. coli cells transformed to additionally express TalVeTPP or AspWeTPP produced significantly higher amounts of copalol: 462 mg / l and 298 mg / l for TalVeTPP and AspWeTPP, respectively (Fig. Figure 3 This experiment demonstrated that TalVeTPP and AspWeTPP can effectively hydrolyze (+)-CPP to produce (+)-copalol. Copalol was produced in high purity (>95%). The relatively low amount of copalyl acetate observed in GC-MS analysis (Figure 2) was attributed to endogenous cellular acetyltransferase activity.

[0625] Example 2 : Identification and characterization of TalVeTPP and AspVeTPP variants with copalyl pyrophosphate phosphatase activity.

[0626] The TalVeTPP and AspVeTPP sequences were used to search for homologous sequences in public databases. Eight new sequences with the Pfam protein tyrosine phosphatase protein family PF13350 signature were selected: HelGriTPP1, a hypothetical protein from Helicocarpus griseus (SEQ ID NO: 10) (GenBank: PGG95910.1); UmbPiTPP1, a tyrosine phosphatase from Umbilicaria pustulata (SEQ ID NO: 13) (GenBank: SLM34787.1); TAlVeTPP2, a hypothetical protein from Talaromyces verruculosus (SEQ ID NO: 16) (GenBank: KUL92314.1); HydPiTPP1, a hypothetical protein from Hydnomerulius pinastri (SEQ ID NO: 17) (GenBank: KUL92314.1); NO:19)(GenBank: KIJ69780.1); TalCeTPP1, a hypothetical protein from Talaromyces cellulolyticus (SEQ ID NO:22) (GenBank: GAM42000.1); TalMaTPP1, a hypothetical protein from Talaromyces marneffei (SEQ ID NO:25) (NCBI XP_002152917.1); TalAstroTPP1, a hypothetical protein from Talaromyces atroroseus (SEQ ID NO:28) (NCBI XP_020117849.1); and PeSubTPP1, PeSubTPP1, a hypothetical protein from Penicillium subrubescens (SEQ ID NO:31) (GenBank: OKP14340.1). A search for protein family features revealed that the eighth amino acid sequence was a member of the Pfam protein tyrosine phosphatase protein family PF13350.

[0627] Sequence comparison of the ten amino acid sequences showed sequence identities ranging from 24% to 93% (Table 1).

[0628] Table 1. Pairwise sequence comparisons of selected putative terpene phosphatases. The percent sequence identity for each pairwise comparison is listed.

[0629]

[0630] The cDNA sequences encoding HelGriTPP1 (SEQ ID NO: 11), UmbPiTPP1 (SEQ ID NO: 14), TalVeTPP2 (SEQ ID NO: 17), HydPiTPP1 (SEQ ID NO: 20), TalCeTPP1 (SEQ ID NO: 23), TalMaTPP1 (SEQ ID NO: 26), TalAstroTPP1 (SEQ ID NO: 29) and PeSubTPP1 (SEQ ID NO: 32) were codon-optimized for E. coli expression and cloned into the pJ401 expression plasmid (ATUM, Newark, California), respectively.

[0631] DP1205 E. coli cells were transformed with the pACYC-CrtE-SmCPS2 plasmid and a pJ401 plasmid carrying optimized cDNAs encoding HelGriTPP1 (SEQ ID NO: 9), UmbPiTPP1 (SEQ ID NO: 12), TalVeTPP2 (SEQ ID NO: 15), HydPiTPP1 (SEQ ID NO: 18), TalCeTPP1 (SEQ ID NO: 21), TalMaTPP1 (SEQ ID NO: 24), TalAstroTPP1 (SEQ ID NO: 27), and PeSubTPP1 (SEQ ID NO: 30). The cells were cultured and analyzed for copalol production under the conditions described in the Methods section. Cells transformed with the pACYC-CrtE-SaLPS plasmid and an empty pJ401 plasmid served as control strains. All strains expressing recombinant TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1 proteins accumulated copalol in amounts ranging from 32 to 240 mg / l, confirming that all of these recombinant enzymes enabled enzymatic conversion of CPP to copalol. Figure 4 ).

[0632] This example shows that TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, and PeSubTPP1 can be used to enzymatically convert CPPs to copalol and can be used to produce copalol in engineered cells.

[0633] Example 3: Production of lisdendiol in Escherichia coli cells.

[0634] An expression plasmid was constructed that carries genes encoding geranylgeranyl pyrophosphate synthase (GGPS) and lisdendiol pyrophosphate synthase (LPS). For GGPS, the CrtE gene from Pantoea agglomerans described in Example 1 was used. For the LPS gene, a cDNA encoding SsLPS from Salvia sclarea (WO2009095366, GenBank: AET21246.1) was used. The SsLPS encoding cDNA sequence (SEQ ID NO: 37) was optimized as described in WO2009095366 and cloned between the NdeI and KpnI sites of the pACYC-CrtE plasmid, providing the plasmid pACYC-CrtE-SaLPS, which carries the GGP synthase and LPP synthase genes. E. coli cells transformed with pACYC-CrtE-SsLPS (e.g., strain DP1205) accumulate LPP as a diterpene precursor compound ( Figure 5 ).

[0635] DP1205 E. coli cells (prepared above) were transformed with the pACYC-CrtE-SsLPS plasmid and a pJ401 plasmid carrying an optimized cDNA encoding TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1 (see Examples 1 and 2 above). The cells were cultured and analyzed for lisdendiolide production under the conditions described in the Methods section. All cells transformed to produce recombinant TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1 protein produced significantly increased amounts of lisdendiol (5- to 25-fold increases) compared to control cells transformed with the empty pJ401 plasmid and pACYC-CrtE-SsLPS ( Figure 6 At the end of the culture period, the lisdendiol concentration in the cell culture ranged from 50 to 272 g / l.

[0636] A GC-MS analysis of a typical E. coli cell line producing lisdendiol is shown in Figure 7. The total ion chromatogram indicates that lisdendiol produced under these conditions has a purity of at least 98%.

[0637] Example 4 : Production of farnesol and geranylgeraniol in Escherichia coli cells.

[0638] The enzyme activities of the recombinant proteins TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, and PeSubTPP1 on linear substrates such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) were also evaluated. The assays were performed under conditions similar to those in Examples 1 and 2 and in the Methods section, except that pACYCDuet TM -1 plasmid is suitable for the production of FPP and GGPP in vivo. For the accumulation of FPP in E. coli cells, empty pACYCDuet TM -1 plasmid. Use empty plasmid pACYCDuet TM -1 (Merck) transformed E. coli cells (e.g., strain DP1205) will accumulate FPP as a terpene precursor compound ( Figure 8 For E. coli cells that accumulate GGPP, plasmid pACYC-CrtE (Example 1) is used. E. coli cells transformed with pACYC-CrtE plasmid (e.g., strain DP1205) accumulate GGPP as a terpene precursor compound ( Figure 5 and Figure 8 ).

[0639] Use pACYC-CrtE or pACYCDuet TM DP1205 E. coli cells were transformed with the pJ401 plasmid and a pJ401 plasmid carrying an optimized cDNA encoding TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1 (see Examples 1 and 2). The cells were cultured and analyzed for farnesol and geranylgeraniol production under the conditions described in the Methods section. Some cells transformed to produce recombinant TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1, or PeSubTPP1 protein produced significantly increased amounts of farnesol and geranylgeraniol compared to control cells transformed with empty pJ401 ( Figure 9For example, cells expressing TalVeTPP2, TalCeTPP1, and TalVeTPP produced large amounts (763 to 976 mg / ml) of farnesol. Similarly, cells expressing PeSubTPP1 and TalVeTPP produced large amounts (196 to 198 mg / ml) of geranylgeraniol. In contrast, HelGriTPP1, UmbPiTPP1, HydPiTPP1, or TalMaTPP1 showed low FPP and GGPP phosphatase activity.

[0640] Example 5 : Substrate selectivity of phosphatases.

[0641] Comparison of the enzyme activities observed in the previous examples with four different substrates showed that TalVeTPP, AspWeTPP, HelGriTPP1, UmbPiTPP1, TalVeTPP2, HydPiTPP1, TalCeTPP1, TalMaTPP1, TalAstroTPP1 or PeSubTPP1 had different substrate selectivities ( Figure 10 ). Thus, this method allows for the selection of enzymes with phosphatase activity based on their substrate selectivity. For example, compared to the other listed enzymes, HelGriTPP1, HydPiTPP1, or AspWeTPP exhibited higher activity on CPP and LPP, but lower activity on FPP and GGP. Therefore, these enzymes can be used to most efficiently produce copalactone or lisdendiolide with limited side activity on pathway intermediates. UmbPiTPP1, TalMaTPP1, and TalAstroTPP1 also exhibited limited side activity on FPP and GGPP, however, they produced lower amounts of lisdendiolide and copalactone.

[0642] Example 6 : Copal and lisdendiol are produced using an operon containing GGPP synthase, diterpene synthase, and phosphatase.

[0643] An operon was constructed containing three cDNAs encoding TalVeTPP: TaTps1-del59 and GGPP synthase. TaTps1-del59 is an N-terminally truncated CPP synthase from wheat (Triticum aestivum) (NCBI accession number BAH56559.1). The cDNA encoding TaTps1-del59 was codon-optimized (SEQ ID NO: 39). For GGPP synthase, a codon-optimized version of the CrtE gene from Pantoea agglomerans (NCBI accession number M38424.1) (SEQ ID NO: 35) was used. The operon was cloned into the pJ401 expression plasmid (ATUM, Newark, California) to provide the construct pJ401-CPOL-2.

[0644] Another operon was constructed using a similar structure to CPOL-2 above, except that the gene encoding TaTps1-del59 was replaced by an optimized gene encoding SaLPS (SEQ ID NO: 37). This operon was cloned into plasmid pJ401 (ATUM, Newark, California) to provide construct pJ401-LOH-2.

[0645] DP1205 E. coli cells prepared as described above were transformed with plasmids pJ401-CPOL-2 or pJ401-LOH-2. Cells were cultured as described above and analyzed for diterpene production as described in the Methods section. In parallel, cells transformed with an empty pJ401 plasmid and with either pACYC-CrtE-SsLPS or pACYC-CrtE-SmCPS plasmids were used as controls.

[0646] The average concentrations of copalol and farnesol produced by cells transformed with plasmid CPOL-2 were 200 mg / l and 300 mg / l for copalol and farnesol, respectively. The average concentrations of lisdendiol and farnesol produced by cells transformed with plasmid LOH-2 were 1260 mg / l and 830 mg / l for copalol and farnesol, respectively. Figure 11 The large amounts of farnesol produced using these two constructs were due to the incomplete conversion of the FPP pool to GGPP and the enzymatic activity of TalVeTPP towards FPP in addition to CPP (see Figure 10 For example, using HelGriTPP1 (and Figure 10 Corresponding experiments with other, higher specificities (shown in ) would yield even less farnesol.

[0647] Example 7: Enzymatic oxidation of terpene compounds produced by recombinant phosphatase to generate the corresponding α,β-unsaturated aldehydes.

[0648] The following alcohol dehydrogenases (ADHs) can be used to oxidize the terpene compounds produced by the phosphatases described in the previous examples:

[0649] - CymB from Pseudomonas sp. 19-rlim strain (SEQ ID NO: 42) (GenBank Accession No. AEO27362.1);

[0650] AspWeADH1 (SEQ ID NO: 44) encoded by a gene located in the 2487333..2488627 region of the unplaced genomic scaffold ASPWEscaffold_5 (NCBI Accession No. KV878213.1) of Aspergillus wentii DTO 134E9 (GenBank Accession No. OJJ34588.1);

[0651] - PsAeroADH1 from Pseudomonas aeruginosa (SEQ ID NO: 46) (GenBank Accession No. WP_079868259.1);

[0652] - AzTolADH1 from Azoarcus toluclasticus (SEQ ID NO: 48) (GenBank Accession No. WP_018990713.1);

[0653] - AroAroADH1 from Aromatoleum aromaticum (SEQ ID NO: 50) (GenBank Accession No. KM105875.2).

[0654] - ThTerpADH1 from Thauera terpenica (SEQ ID NO: 52) (Genbank Accession No. WP_021250577.1).

[0655] - CdGeoA from Castellaniella defragrans (SEQ ID NO: 54) (NCBI Accession No. WP_043683915.1).

[0656] - VoADH1 from Valeriana officinalis (SEQ ID NO: 56) (GenBan Accession No. AVX32614.1).

[0657] Codon-optimized cDNAs encoding each of the above ADHs (see SEQ ID NOs: 41, 43, 45, 47, 49, 51, 53, and 55, respectively) were synthesized and cloned into the pJ423 expression plasmid (ATUM, Newark, California).

[0658] DP1205 E. coli cells prepared as above were transformed with plasmid pJ401-CPOL-2 and one of these pJ423-ADH plasmids. Cells were cultured as described above and analyzed for diterpene production as described in the methods section. In parallel, cells transformed with pJ401-CPOL-2 and empty pJ423 plasmids were used as controls ( FIG. 12 ). Copalol formation was observed in all cells, suggesting that a combination of enzymes from the copalol biosynthetic pathway, including protein tyrosine phosphatases and ADHs selected from the ADHs listed above, can be used to efficiently produce copalaldehyde. It is expected that for AspWeADH1 and VoADH1, the conversion of copalol to copalaldehyde in the cells will be at least 90%. Due to the non-enzymatic isomerization of trans-copalaldehyde produced by the ADHs, a mixture of cis- and trans-isomers of copalaldehyde was observed. Using the same ADHs, the conversion of farnesol to farnesaldehyde was also observed ( FIG. 13 ).

[0659] In E. coli cells co-transformed with either pJ401-LOH-2 or pJ423-ADH plasmids, the formation of two oxidation products of lisdendiol was observed ( Figure 14 ). NMR analysis confirmed that the two compounds were two isomers of 8,13-epoxy-lisdane-15-aldehyde ((13R) and (13S)). Figure 17 The two compounds are due to the instability of the α,β-unsaturated aldehyde 8-hydroxy-lisdendiol, prepared by oxidation of lisdendiol. The proposed mechanism for the dehydration and rearrangement of the aldehyde into the isomers is shown in the scheme below.

[0660] Example 8 : Engineering of recombinant bacterial cells for copalol production using a multifunctional CPP synthase

[0661] An operon was constructed containing two cDNAs encoding:

[0662] - AspWeTPP from Aspergillus wentii (SEQ ID NO: 6),

[0663] - PvCPS, a protein having prenyltransferase and copalyl diphosphate synthase activities from Talaromyces verruculosus (SED ID NO: 59) (GenBank Accession No. BBF88128.1). PvCPS catalyzes the production of copalyl PP from IPP and DMAPP.

[0664] The cDNAs encoding AspWeTPP and PvCPS were codon optimized (SEQ ID NOs: 8 and 60). An operon containing the two cDNAs and an RBS sequence (AAGGAGGTAAAAAA) (SEQ ID NO: 61) located upstream of each cDNA was designed. The operon was synthesized and cloned into the pJ401 expression plasmid (ATUM, Newark, California) to provide plasmid pJ401-CPOL-4.

[0665] DP1205 E. coli cells were transformed with plasmid pJ401-CPOL-4. The transformed cells were cultured as described above and analyzed for diterpene production as described in the Methods section. Under these conditions, cells transformed with plasmid pJ401-CPOL-4 produced copalidol as the major product at concentrations significantly higher (up to 1 mg / L) than cells transformed with plasmid pJ401-CPOL-2. This experiment demonstrates that using a multifunctional protein with both prenyltransferase and CPP synthase activity can yield higher concentrations of copalidol than various monofunctional proteins.

[0666] Example 9 : In vivo production of copalol and copalaldehyde in Saccharomyces cerevisiae cells using copalyl pyrophosphate phosphatase and different alcohol dehydrogenases.

[0667] To produce copalol and copalaldehyde, genes encoding the GGPP synthase CrtE (SEQ ID NO:61) (from Pantoea agglomerans, NCBI Accession No. M38424.1), the copalyl pyrophosphate synthase SmCPS2 (SEQ ID NO:63) (from Salvia miltiorrhiza, NCBI Accession No. ABV57835.1), the copalyl pyrophosphate phosphatase TalVeTPP (SEQ ID NO:65), and various alcohol dehydrogenases (cDNA optimized for expression in yeast) were expressed in engineered Saccharomyces cerevisiae cells with elevated levels of endogenous farnesyl diphosphate (FPP).

[0668] Four alcohol dehydrogenases were evaluated.

[0669] -AzTolADH1 (SEQ ID NO:48) (yeast optimized cDNA SEQ ID NO:66)

[0670] - PsAeroADH1 (SEQ ID NO: 46), (yeast optimized cDNA SEQ ID NO: 67)

[0671] - SCH23-ADH1 from Hyphozyma roseonigra (SEQ ID NO: 69) (yeast optimized cDNA SEQ ID NO: 68)

[0672] - SCH24-ADH1a from Cryptococcus albidus (SEQ ID NO: 71) (yeast optimized cDNA SEQ ID NO: 70)

[0673] To increase the level of endogenous farnesyl diphosphate (FPP) pools in Saccharomyces cerevisiae cells, additional copies of all yeast endogenous genes involved in the mevalonate pathway, from ERG10 encoding acetyl-CoA C-acetyltransferase to ERG20 encoding FPP synthase, were integrated into the genome of Saccharomyces cerevisiae strain CEN.PK2-1C (Euroscarf, Frankfurt, Germany) under the control of a galactose-inducible promoter, similar to that described in Paddon et al., Nature, 2013, 496:528-532. Briefly, three cassettes were integrated into the LEU2, TRP1, and URA3 loci, respectively. The first cassette contains the ERG20 gene and a truncated HMG1 (tHMG1, as described by Donald et al., Proc Natl Acad Sci USA, 1997, 109: E111-8) under the control of the GAL10 / GAL1 bidirectional promoter, and the ERG19 and ERG13 genes also under the control of the GAL10 / GAL1 promoter, flanked by two 100 nucleotide regions corresponding to the upstream and downstream portions of LEU2, respectively. In the second cassette, the genes IDI1 and tHMG1 are under the control of the GAL10 / GAL1 promoter, while the gene ERG13 is under the control of the GAL7 promoter region, flanked by two 100 nucleotide regions corresponding to the upstream and downstream portions of TRP1, respectively. The third cassette contains the ERG10, ERG12, tHMG1, and ERG8 genes, all under the control of the GAL10 / GAL1 promoter, flanked by two 100-nucleotide regions corresponding to the upstream and downstream portions of URA3. All genes in the three cassettes contain 200 nucleotides of their own terminator regions. Furthermore, upstream of the ERG9 promoter region, an additional copy of GAL4 under the control of a mutant form of its own promoter, as described in Griggs and Johnston, Proc Natl Acad Sci USA, 1991, 88:8597-8601, was integrated. In addition, ERG9 expression was modified by promoter swapping. A cassette containing the HIS3 gene with its own promoter and terminator was used to delete the GAL7, GAL10, and GAL1 genes. The resulting strain was mated with strain CEN.PK2-1D (Euroscarf, Frankfurt, Germany) to obtain a diploid strain designated YST045, which was induced to form spores according to Solis-Escalante et al., FEMS Yeast Res, 2015, 15: 2. Spores were isolated by resuspending the asci in 200 μL of 0.5 M sorbitol and 2 μL of zymolyase (1000 U mL -1, Zymoresearch, Irvine, CA) and incubated for 20 minutes at 37° C. The mixture was then plated on a medium containing 20 g / L protein, 10 g / L yeast extract, and 20 g / L agar, and one germinated spore was isolated and designated YST075.

[0674] To express different genes encoding alcohol dehydrogenases, genomic integration was performed in strain YST075. Each integration cassette consisted of four fragments.

[0675] 1) a fragment containing 261 bp corresponding to the upstream portion of the BUD9 gene and the sequence 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 72), which was obtained by PCR using genomic DNA from strain YST075 as a template;

[0676] 2) a fragment containing the sequence 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 72), the promoter region of the GAL1 gene, one of the genes encoding alcohol dehydrogenases codon-optimized for expression in Saccharomyces cerevisiae, the terminator region of the PGK1 gene, and the sequence 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 73), which was obtained by DNA synthesis (ATUM, Menlo Park, CA 94025),

[0677] 3) a fragment containing the sequence 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 73), the TRP1 gene with its own promoter and terminator regions and the sequence 5'-TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTTGACCACGA-3' (SEQ ID NO: 74), which was obtained by PCR using pESC-TRP1 (Agilent Technologies, California, USA) as a template; and

[0678] 4) A fragment containing the sequence 5'-TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTTGACCACGA-3' (SEQ ID NO: 74) and a 344 bp fragment corresponding to the BUD9 gene, which was obtained by PCR using genomic DNA from strain YST075 as a template.

[0679] YST075 was transformed with the four fragments required for the genomic integration of each alcohol dehydrogenase evaluated. Yeast transformation was performed using a lithium acetate protocol as described in Gietz and Woods, Methods Enzymol., 2002, 350: 87–96. The transformation mixture was plated on a SmLeu medium containing 6.7 g / L yeast nitrogen base (BD Difco, New Jersey, USA) without amino acids, 1.6 g / L leucine-free drip supplement (Sigma Aldrich, Missouri, USA), 20 g / L glucose, and 20 g / L agar. The plate was incubated at 30°C for 3 to 4 days. Single colonies containing the correct integration were isolated and named as YST149 (with SCH23-ADH1), YST150 (with SCH24-ADH1a), YST151 (with AzTolADH1), and YST152 (with PsAeroADH1).

[0680] To express CrtE, SmCPS2, and TalVeTPP in YST149, YST150, YST151, and YST152, a plasmid was constructed using homologous recombination in yeast, as described in Kuijpers et al., Microb Cell Fact., 2013, 12:47. This plasmid consists of six DNA fragments for co-transformation of Saccharomyces cerevisiae. These fragments are:

[0681] a) LEU2 yeast marker, constructed by PCR using primers 5′AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCATTCGACTACGTCGTAAGGCC-3′ (SEQ ID NO: 75) and 5′TCGTGGTCAAGGCGTGCAATTCTCAACACGAGAGTGATTCTTCGGCGTTGTTGCTGACCATCGACGGTCGAGGAGAACTT-3′ (SEQ ID NO: 76) with plasmid pESC-LEU (Agilent Technologies, California, USA) as template;

[0682] b) AmpR E. coli marker, constructed by PCR using primers 5′-TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTTGACCACGACACGTGTAGAGGGTTTTGGTCATGAG-3′ (SEQ ID NO: 77) and 5′-AACGCGTACCCTAAGTACGGCACCACAGTGACTATGCAGTCCGCACTTTGCCAATGCCAAAAATGTGCGCGGAACCCCTA-3′ (SEQ ID NO: 78) with plasmid pESC-URA as template;

[0683] c) Yeast origin of replication, obtained by PCR with primers 5′-TTGGCATTGGCAAAGTGCGGACTGCATAGTCACTGTGGTGCCGTACTTAGGGTACGCGTTCCTGAACGAAGCATCTGTGCTTCA-3′ (SEQ ID NO: 79) and 5′-CCGAGATGCCAAAGGATAGGTGCTATGTTGATGACTACGACACAGAACTGCGGGTGACATAATGATAGCATTGAAGGATGAGACT-3′ (SEQ ID NO: 80) using pESC-URA as template;

[0684] d) E. coli origin of replication, obtained by PCR using primers 5′-ATGTCACCCGCAGTTCTGTGTGTCGTAGTCATCAACATAGCACCTATCCTTTGGCATCTCGGTGAGCAAAAGGCCAGCAAAAGG-3′ (SEQ ID NO: 81) and 5′-CTCAGATGTACGGTGATCGCCACCATGTGACGGAAGCTATCCTGACAGTGTAGCAAGTGCTGAGCGTCAGACCCCGTAGAA-3′ (SEQ ID NO: 82) with plasmid pESC-URA as template;

[0685] e) a fragment consisting of the last 60 nucleotides of fragment "d", 200 nucleotides downstream of the stop codon of the yeast gene PGK1, the GGPP synthase coding sequence CrtE (SEQ ID NO:62) codon-optimized for expression in Saccharomyces cerevisiae, the bidirectional yeast promoter of GAL10 / GAL1, the coding sequence of TalVeTPP (SEQ ID NO:65) codon-optimized for expression in Saccharomyces cerevisiae, 200 nucleotides downstream of the stop codon of the yeast gene CYC1, and the sequence 5'-ATTCCTAGTGACGGCCTTGGGAACTCGATACACGATGTTCAGTAGACCGCTCACACATGG-3' (SEQ ID NO:83), which was obtained by DNA synthesis (ATUM, Menlo Park, CA 94025),

[0686] f) A fragment consisting of the last 60 nucleotides of fragment "e", 200 nucleotides downstream of the stop codon of the yeast gene CYC1, the SmCPS2 synthase coding sequence codon-optimized for expression in Saccharomyces cerevisiae (SEQ ID NO:63), the bidirectional yeast promoter of GAL10 / GAL1, and the 60 nucleotides corresponding to the beginning of fragment "a", which was obtained by DNA synthesis (ATUM, Menlo Park, CA 94025).

[0687] All strains were transformed with the fragments required for in vivo plasmid assembly. Yeast transformation was performed using a lithium acetate protocol as described in Gietz and Woods, Methods Enzymol., 2002, 350: 87–96. The transformation mixture was plated on SmLeu medium containing 6.7 g / L yeast nitrogen base without amino acids (BD Difco, New Jersey, USA), 1.6 g / L leucine-free drip supplement (Sigma Aldrich, Missouri, USA), 20 g / L glucose, and 20 g / L agar. The plates were incubated at 30°C for 3 to 4 days. As described in Westfall et al., Proc Natl Acad Sci USA, 2012, 109: E111-118, single colonies were used to produce copal and copalaldehyde in glass tubes containing 2 mL of culture medium, and dodecane was used as an organic overlay.

[0688] Under these culture conditions, the highest average concentration of copalol produced by strain YST152, which contains a copalol biosynthesis plasmid, was 153.51 mg / L. The highest average concentration of copalol produced by strain YST149, which contains a copalol biosynthesis plasmid, was 98.47 mg / L. The average percentages of copalol conversion to copalaldehyde in strains YST149, YST150, YST151, and YST152, which contain a copalol biosynthesis plasmid, were 61.6%, 39.9%, 30.1%, and 22.1%, respectively. GC-MS analysis using an internal standard ( Figure 18 ) identified and quantified the production of copalol and copalaldehyde.

[0689] Sequences used in the present invention:

[0690]

[0691]

[0692] NA = Nucleic Acid

[0693] AA = amino acid.

[0694] TalVeTPP optimized cDNA ORF only – SEQ ID NO: 1

[0695] ATGAGCAATGACACGACGACCACCGCGAGCGCCGGTACTGCAACTTCTAGCCGTTTTCTGAGCGTCGGCGGCGTTGTGAATTTTCGCGAGCTGGGTGGCTATCCATGCGACAGCGTGCCGCCGGCTCCGGCAAGCAACGGTTCGCCTGATAATGCGTCCGAGGCAACGCTGTGGGTTGGTCACTCCAGCATTCGTCCGGGTTTCCTGTTCCGCAGCGCGCAGCCGAGCCAGATTACGCCGGCGGGTATCGAAACGCTGATCCGCCAACTGGGCATCCAGACCATTTTTGATTTCCGTAGCCGTACCGAGATCGAACTGGTGGCGACCCGTTACCCGGACTCTCTGTTGGAAATTCCGGGCACCACGCGCTATTCCGTCCCGGTTTTCTCCGAGGGTGACTATTCTCCGGCGAGCCTGGTGAAGCGCTATGGTGTTAGCAGCGATACCGCCACGGACAGCACCTCTAGCAAGAGCGCGAAGCCGACCGGCTTCGTTCATGCATACGAAGCCATTGCGCGCAGCGCCGCTGAGAACGGTAGCTTCCGTAAAATTACCGACCACATCATCCAGCATCCTGATCGTCCAATTTTGTTCCACTGTACCCTGGGTAAAGACCGTACGGGTGTCTTTGCGGCGCTGTTGCTGAGCCTGTGTGGTGTGCCGGACGAAACCATCGTCGAAGATTACGCGATGACCACCGAAGGCTTTGGTGCATGGCGTGAGCACCTGATCCAACGTCTGCTGCAACGTAAAGACGCTGCAACCCGTGAAGATGCCGAGAGCATCATTGCGTCGCCGCCGGAGACTATGAAAGCATTTCTGGAAGATGTTGTGGCAGCGAAATTTGGTGGCGCGCGTAACTACTTCATTCAACATTGCGGCTTCACTGAAGCTGAAGTCGATAAGCTGAGCCACACCCTGGCGATCACGAACTAA

[0696] TalVeTPP Amino Acid Sequence - SEQ ID NO:2

[0697] MSNDTTTTASAGTATSSRFLSVGGVVNFRELGGYPCDSVPPAPASNGSPDNASEATLWVGHSSIRPGFLFRSAQPSQITPAGIETLIRQLGIQTIFDFRSRTEIELVATRYPDSLLEIPGTTRYSVPVFSEGDYSPASLVKRYGVSSDTATDSTSSKSAKPTGFVHAYEAIARSAAENGSFRKITDHIIQHPDRPILFHCTLGKDRTGVFAALLLSLCGVPDETIVEDYAMTTEGFGAWREHLIQRLLQRKDAATREDAESIIASPPETMKAFLEDVVAAKFGGARNYFIQHCGFTEAEVDKLSHTLAITN

[0698] TalVeTPP wild type cDNA–SEQ ID NO:3

[0699] ATGTCTAATGACACCACTACCACGGCTTCTGCCGGAACAGCAACTTCTTCGCGGTTTCTTTCCGTGGGGGGAGTTGTGAACTTCCGTGAACTGGGCGGTTACCCATGTGATTCTGTCCCTCCTGCTCCTGCCTCAAACGGCTCACCGGACAATGCATCTGAAGCGACCCTTTGGGTTGGCCACTCGTCCATTCGGCCTGGATTTCTGTTTCGATCGGCACAGCCGTCTCAGATTACCCCGGCCGGTATTGAGACATTGATCCGCCAGCTTGGCATCCAGACAATTTTTGACTTTCGTTCAAGGACGGAAATTGAGCTTGTTGCCACTCGCTATCCTGATTCGCTACTTGAGATACCTGGCACGACTCGCTATTCCGTGCCCGTCTTCTCGGAAGGCGACTATTCCCCAGCGTCATTAGTCAAGAGGTACGGAGTGTCCTCCGATACTGCAACCGATTCCACTTCCTCCAAAAGTGCTAAGCCTACAGGATTCGTCCACGCATATGAGGCTATCGCACGCAGTGCAGCAGAAAACGGCAGTTTTCGTAAGATAACGGACCACATAATACAACATCCGGACCGGCCTATTCTGTTTCACTGTACACTGGGGAAAGACCGAACCGGTGTGTTTGCAGCATTGTTATTGAGTCTTTGCGGGGTACCAGACGAGACGATAGTTGAAGACTATGCTATGACTACCGAGGGATTTGGAGCCTGGCGGGAACATCTAATTCAACGCTTGCTACAAAGGAAGGATGCAGCTACGCGCGAGGATGCAGAATCCATTATTGCCAGCCCCCCGGAGACTATGAAGGCTTTTCTAGAAGATGTGGTAGCAGCCAAGTTCGGGGGTGCTCGAAATTACTTTATCCAGCACTGTGGATTTACGGAAGCTGAGGTTGATAAGTTAAGCCATACACTGGCCATTACGAATTGA

[0700] The TalVeTPP-optimized cDNA includes non-coding sequences – SEQ ID NO:4

[0701] GGTACCAAGGAGGTAAAAAATGAGCAATGACACGACGACCACCGCGAGCGCCGGTACTGCAACTTCTAGCCGTTTTCTGAGCGTCGGCGGCGTTGTGAATTTTCGCGAGCTGGGTGGCTATCCATGCGACAGCGTGCCGCCGGCTCCGGCAAGCAACGGTTCGCCTGATAATGCGTCCGAGGCAACGCTGTGGGTTGGTCACTCCAGCATTCGTCCGGGTTTCCTGTTCCGCAGCGCGCAGCCGAGCCAGATTACGCCGGCGGGTATCGAAACGCTGATCCGCCAACTGGGCATCCAGACCATTTTTGATTTCCGTAGCCGTACCGAGATCGAACTGGTGGCGACCCGTTACCCGGACTCTCTGTTGGAAATTCCGGGCACCACGCGCTATTCCGTCCCGGTTTTCTCCGAGGGTGACTATTCTCCGGCGAGCCTGGTGAAGCGCTATGGTGTTAGCAGCGATACCGCCACGGACAGCACCTCTAGCAAGAGCGCGAAGCCGACCGGCTTCGTTCATGCATACGAAGCCATTGCGCGCAGCGCCGCTGAGAACGGTAGCTTCCGTAAAATTACCGACCACATCATCCAGCATCCTGATCGTCCAATTTTGTTCCACTGTACCCTGGGTAAAGACCGTACGGGTGTCTTTGCGGCGCTGTTGCTGAGCCTGTGTGGTGTGCCGGACGAAACCATCGTCGAAGATTACGCGATGACCACCGAAGGCTTTGGTGCATGGCGTGAGCACCTGATCCAACGTCTGCTGCAACGTAAAGACGCTGCAACCCGTGAAGATGCCGAGAGCATCATTGCGTCGCCGCCGGAGACTATGAAAGCATTTCTGGAAGATGTTGTGGCAGCGAAATTTGGTGGCGCGCGTAACTACTTCATTCAACATTGCGGCTTCACTGAAGCTGAAGTCGATAAGCTGAGCCACACCCTGGCGATCACGAACTAACTCGAG

[0702] cDNA optimized by AspWeTPP – SEQ ID NO:5

[0703] ATGGCGTCTGTCCCTGCTCCACCGTTTGTTCATGTTGAAGGTATGTCTAATTTTCGTAGCATCGGTGGCTACCCGCTGGAGACTGCCTCCACGAATAACCATCGCTCGACCCGTCAAGGCTTCGCGTTTCGTAGCGCGGACCCGACGTATGTGACGCAGAAAGGCCTGGAAACCATTCTGTCCCTGGATATTACCCGCGCATTTGACTTGCGTAGCTTGGAAGAAGCAAAGGCACAACGTGCGAAGTTGCAGGCCGCGAGCGGTTGTCTGGATTGCAGCATTAGCCAACACATGATCCACCAACCGACCCCGCTGTTCCCGGATGGTGACTGGTCCCCGGAAGCGGCGGGTGAGCGCTACTTGCAGTACGCACAAGCTGAGGGTGATGGTATCAGCGGTTATGTCGAAGTTTATGGTAATATGCTGGAAGAGGGCTGGATGGCGATCCGTGAGATTCTGCTGCACGTCCGTGACCGCCCGACCGAAGCATTCCTGTGCCACTGTTCCGCCGGTAAAGATCGTACGGGTATCGTGATTGCTGTTCTGCTCAAAGTCGCGGGTTGCAGCGACGACCTGGTGTGTCGTGAGTACGAACTGACCGAGATTGGCCTGGCGCGCCGTAGAGAGTTCATCGTTCAGCATCTGCTGAAGAAACCGGAAATGAACGGCAGCCGTGAGCTGGCGGAGCGCGTCGCAGGCGCCCGTTACGAGAACATGAAAGAAACCCTGGAAATGGTGCAGACCCGTTACCGCGGCATGCGCGGCTATTGCAAAGAAATCTGCGGTCTGACCGACGAAGATCTGAGCATTATCCAGGGTAACCTGACGAGCCCGGAGAGCCCGATTTTCTAA

[0704] Amino acid sequence of AspWeTPP – SEQ ID NO:6

[0705] MASVPAPPFVHVEGMSNFRSIGGYPLETASTNNHRSTRQGFAFRSADPTYVTQKGLETILSLDITRAFDLRSLEEAKAQRAKLQAASGCLDCSISQHMIHQPTPLFPDGDWSPEAAGERYLQYAQAEGDGISGYVEVYGNMLEEGWMAIREILLHVRDRPTEAFLCHCSAGKDRTGIVIAVLLKVAGCSDDLVCREYELTEIGLARRREFIVQHLLKKPEMNGSRELAERVAGARYENMKETLEMVQTRYRGMRGYCKEICGLTDEDLSIIQGNLTSPESPIF

[0706] AspWeTPP wild-type cDNA–SEQ ID NO:7

[0707] ATGGCATCTGTACCAGCTCCCCCATTTGTCCACGTCGAAGGAATGAGCAATTTCCGATCGATAGGAGGATATCCCCTTGAGACAGCATCGACAAACAATCACCGCTCCACGAGGCAAGGATTCGCATTTCGCAGTGCCGATCCAACCTACGTCACCCAGAAAGGCCTGGAAACCATCCTTTCGCTCGACATCACTCGAGCCTTTGACCTCCGCTCACTGGAAGAAGCAAAGGCACAGCGCGCAAAACTCCAGGCCGCCTCAGGATGTCTCGACTGCAGCATCAGCCAGCACATGATCCACCAGCCCACACCCCTATTTCCAGATGGGGACTGGAGTCCAGAGGCCGCAGGGGAGCGGTATCTGCAGTACGCCCAGGCTGAGGGAGATGGGATATCGGGCTACGTGGAGGTCTACGGAAACATGCTCGAGGAAGGTTGGATGGCGATTCGCGAGATTCTGCTTCATGTCCGGGACCGGCCTACAGAGGCGTTTCTATGCCATTGTAGTGCAGGGAAAGATCGTACGGGGATTGTCATTGCGGTTTTGTTGAAGGTTGCAGGGTGCTCGGATGATCTTGTGTGCAGAGAGTATGAGTTGACCGAGATCGGGTTGGCTCGACGGAGGGAGTTTATCGTGCAGCATCTGCTTAAGAAGCCGGAAATGAATGGATCGAGGGAACTGGCCGAAAGAGTGGCGGGGGCCAGGTATGAGAATATGAAGGAAACGCTGGAGATGGTGCAAACTAGATATAGAGGGATGAGGGGCTATTGCAAGGAGATTTGCGGCTTGACCGACGAAGATCTATCTATTATCCAGGGGAACTTGACTAGTCCGGAGAGTCCTATCTTCTAA

[0708] The AspWeTPP-optimized cDNA includes the non-coding end – SEQ ID NO:8

[0709] GGTACCAAGGAGGTAAAAAATGGCGTCTGTCCCTGCTCCACCGTTTGTTCATGTTGAAGGTATGTCTAATTTTCGTAGCATCGGTGGCTACCCGCTGGAGACTGCCTCCACGAATAACCATCGCTCGACCCGTCAAGGCTTCGCGTTTCGTAGCGCGGACCCGACGTATGTGACGCAGAAAGGCCTGGAAACCATTCTGTCCCTGGATATTACCCGCGCATTTGACTTGCGTAGCTTGGAAGAAGCAAAGGCACAACGTGCGAAGTTGCAGGCCGCGAGCGGTTGTCTGGATTGCAGCATTAGCCAACACATGATCCACCAACCGACCCCGCTGTTCCCGGATGGTGACTGGTCCCCGGAAGCGGCGGGTGAGCGCTACTTGCAGTACGCACAAGCTGAGGGTGATGGTATCAGCGGTTATGTCGAAGTTTATGGTAATATGCTGGAAGAGGGCTGGATGGCGATCCGTGAGATTCTGCTGCACGTCCGTGACCGCCCGACCGAAGCATTCCTGTGCCACTGTTCCGCCGGTAAAGATCGTACGGGTATCGTGATTGCTGTTCTGCTCAAAGTCGCGGGTTGCAGCGACGACCTGGTGTGTCGTGAGTACGAACTGACCGAGATTGGCCTGGCGCGCCGTAGAGAGTTCATCGTTCAGCATCTGCTGAAGAAACCGGAAATGAACGGCAGCCGTGAGCTGGCGGAGCGCGTCGCAGGCGCCCGTTACGAGAACATGAAAGAAACCCTGGAAATGGTGCAGACCCGTTACCGCGGCATGCGCGGCTATTGCAAAGAAATCTGCGGTCTGACCGACGAAGATCTGAGCATTATCCAGGGTAACCTGACGAGCCCGGAGAGCCCGATTTTCTAACTCGAG

[0710] HelGriTPP1-optimized cDNA–SEQ ID NO:9

[0711] ATGGCATCCCCACCAGGTCATCCGTTCGTTCAAGTTGAAGGCGTTAATAATTTTCGCTCTGTGGGTGGCTATCCGATTACGCCTAGCAGCGATGCGCGCTTCACGCGTGACAACTTTATCTACCGTAGCGCTGATCCGTGTTACATTACTCCGGAAGGCCGTAGCAAGATTCGCAGCCTGGGTATCACCACCGTGTTCGATCTGCGTAGCCAGCCGGAGGTTGACAAGCAACTGGCGAAAGACCCGAGCAGCGGTGTGCCGATTGCGGATGGTGTCATTCGTCGCTTCACCCCGGTTTTTAGCCGCGAGGATTGGGGTCCGGAAGCATCCGCGGTTCGTCACAACCTGTATGCAGACGCGTCCGGTGCTAGCGGTTACGTCGATGTGTACGCGGATATCCTGGAAAACGGTGGCGTACGCGTTCCGTGAGATCCTGCTGCACGTGCGTGACCGTCCGGGTGACGCTCTGTTGTGCCACTGCTCCGCAGGCAAAGACCGTACCGGCGTTGCGATTGCGATCCTGCTCAAACTGGCCGGTTGCGAAGATGAGTGCATTTCGAAAGAGTATGAACTGACCGAGGTCGGTCTGGCCAGCCGTAAAGAATTTATTATCGAGTACCTGATTAAGCAACCTGAGCTGGAAGGCGACCGTGCGAAAGCCGAGAAAATTGCTGGCGCGAAATACGAAAACATGTTGGGTACGCTGCAGATGATGGAACAGAAATATGGTGGCGTTGAGGGCTACGTGAAGGCCTACTGTAAGTTGACGGATAAAGACATCGCAACCATCCGTCGCAATCTGGTCAGCGGTGACAAGATGATTGCGTAA

[0712] HelGriTPP1 Amino Acid Sequence – SEQ ID NO:10

[0713] MASPPGHPFVQVEGVNNFRSVGGYPTPSSDARFTRDNFYRSADPCYITPEGRSKIRSLGITTVFDLRSQPEVDKQLAKDPSSGVPIADGVIRRFTPVFSREDWGPEASAVRHNLYADASGASGYVDVYADILENG GAAFREILHLVRDRPGDALLCHCSAGKDRTGVAAIILLKLAGCEDECISKEYELTEVGLASRKEFIIEYLIKQPELEGDRAKAEKIAGAKYENMLGTLQMMEQKYGGVEGYVKAYCKLTDKDIATIRRNLVSGDKMIA

[0714] HelGriTPP1 wild type cDNA–SEQ ID NO:11

[0715] ATGGCATCACCCCCAGGGCACCCTTTCGTGCAAGTTGAAGGCGTCAACAACTTCCGCTCTGTAGGAGGATATCCCATCACCCCATCCTCCGACGCACGCTTCACACGAGATAACTTCATCTATCGCAGCGCCGACCCGTGTTACATCACGCCCGAAGGACGCTCCAAAATCCGCTCACTCGGAATCACGACTGTTTTTGATCTGCGCTCCCAGCCAGAGGTTGACAAGCAGCTTGCCAAAGACCCTTCCTCAGGGGTTCCAATCGCCGACGGCGTCATTAGACGTTTTACGCCGGTATTTTCCCGAGAGGATTGGGGTCCGGAAGCTTCCGCCGTCCGCCATAATCTGTATGCTGATGCCTCTGGGGCTTCTGGGTACGTCGATGTGTATGCCGACATTCTGGAGAATGGAGGGGCGGCATTCCGCGAGATCTTGTTGCACGTAAGAGACCGGCCTGGTGATGCGCTGCTATGTCATTGTAGTGCCGGAAAAGATCGTACCGGCGTGGCGATAGCGATACTGCTCAAGCTTGCGGGGTGCGAGGATGAATGTATCTCAAAGGAGTACGAGCTGACCGAGGTTGGTCTAGCCTCAAGAAAGGAGTTCATTATAGAGTACCTCATCAAGCAGCCGGAACTAGAGGGGGATAGAGCAAAAGCTGAAAAAATTGCGGGAGCCAAATATGAGAACATGTTAGGGACCTTGCAAATGATGGAACAGAAATACGGGGGTGTTGAGGGGTACGTGAAAGCGTATTGCAAGTTGACGGATAAAGATATTGCTACGATACGCAGGAATCTCGTCTCAGGTGACAAAATGATTGCCTAG

[0716] UmbPiTPP1-optimized cDNA – SEQ ID NO:12

[0717] ATGTCCCTGCTGCCTAGCCCACCGTTTGTTCCAGTTGAAGGTATTCACAATTTTCGCGATCTGGGCGGCTATCCGGTTAGCACCAGCCCGAGCAAGACCATTCGTCGCAATATCATCTTTCGTTGTGCCGAACCGTCGAAAATCACCCCGAACGGCATTCAAACGCTGCAGAGCCTGGGTGTGGCGACGTTCTTTGACCTCCGTAGCGGTCCGGAAATCGAGAAAATGAAAGCGCATGCACCGGTCGTTGAGATCAAGGGTATTGAGCGTGTTTTCGTGCCGGTGTTCGCGGATGGTGATTATAGCCCGGAACAAATTGCGCTGCGTTACAAAGACTATGCGTCCTCTGGCACTGGTGGCTTCACCCGTGCGTACCACGACATTCTGCGTTCTGCCCCTCCGAGCTATCGTCGTATCCTGCTGCACCTGGCAGAGAAGCCGAACCAGCCGTGCGTGATCCACTGTACCGCTGGCAAAGACCGCACGGGTGTTCTGGCAGCGCTGATTCTGGAACTGGCGGGTGTCGATCAAGACACCATCGCGCATGAGTACGCCCTGACCGAGCTGGGCCTGAAGGCATGGCGTCCGACGGTTGTCGAGCACTTACTGCAGAATCCGGCGCTGGAAGGCAATCGCGAGGGTGCATTGAATATGGTCAGCGCTCGTGCGGAGAACATGCTGGCCGCCTTGGAAATGATTCGCGAGATCTACGGTGGTGCTGAGGCGTACGTGAAAGAAAAGTGCGGTCTGAGCGACGAAGATATTGCACGCATTCGCCAGAACATTTTGCATACGCCGAGCCCGTAA

[0718] UmbPiTPP1 Amino Acid Sequence – SEQ ID NO:13

[0719] MSLLPSPPFVPVEGIHNFRDLGGYPVSTSPSKTIRRNIIFRCAEPSKITPNGIQTLQSLGVATFFDLRSGPEIEKMKAHAPVVEIKGIERVFVPVFADGDYSPEQIALRYKDYASSGTGGFTRAYHDILRSAPPSYRRILLHLAEKPNQPCVIHCTAGKDRTGVLAALILELAGVDQDTIAHEYALTELGLKAWRPTVVEHLLQNPALEGNREGALNMVSARAENMLAALEMIREIYGGAEAYVKEKCGLSDEDIARIRQNILHTPSP

[0720] UmbPiTPP1 wild-type cDNA – SEQ ID NO:14

[0721] ATGTCTCTGCTACCGTCACCTCCCTTCGTACCCGTTGAGGGTATCCACAACTTCCGGGACCTAGGCGGCTACCCCGTCTCGACTTCCCCTTCCAAGACCATACGTCGCAACATCATCTTTCGCTGCGCCGAACCCTCGAAAATCACTCCCAATGGCATCCAGACGCTCCAATCTTTGGGCGTCGCTACGTTCTTCGACCTCCGCTCCGGCCCGGAAATCGAGAAGATGAAAGCACATGCACCTGTCGTCGAGATTAAGGGCATCGAGCGTGTGTTCGTTCCCGTCTTCGCCGACGGGGATTACTCGCCCGAACAAATCGCTCTGCGATACAAAGACTACGCTTCCAGCGGAACGGGGGGTTTTACCAGGGCGTACCATGATATCCTCCGAAGTGCCCCTCCGAGCTATCGGCGCATACTATTACATCTGGCGGAGAAGCCCAACCAGCCATGCGTCATTCATTGCACGGCCGGGAAAGATAGGACGGGCGTATTGGCGGCGTTGATACTCGAGTTGGCCGGGGTTGATCAGGATACAATTGCGCACGAGTACGCATTGACGGAACTGGGGTTGAAGGCCTGGCGTCCCACTGTGGTGGAGCACCTCTTGCAGAATCCAGCGTTGGAGGGAAATCGGGAAGGGGCATTGAACATGGTCAGCGCGAGGGCAGAGAACATGCTGGCAGCCTTGGAGATGATCCGGGAGATCTATGGCGGCGCCGAAGCATATGTGAAGGAGAAGTGTGGCCTCAGCGACGAAGACATTGCGCGGATACGGCAGAATATTCTACACACGCCATCTCCGTGA

[0722] TalVeTPP2-optimized cDNA–SEQ ID NO:15

[0723] ATGTCTGTCACCGAACATGTTGTCGAAGCTAGCACCCCGTCCACTCTGCCGCCACCGTTCATTCACGTGGACGGTGTTCCGAACTTCCGTGACATTGGTGGCTATCCGATTACCGATCTGCTGAGCACCCGTCGCAATTTCGTTTATCGCTCCGCAGTTCCTACCCGCATCACCCCAACGGGCCTGCAGACGCTGACCCAAGATCTGCAGATTACGACGGTCTACGACTTACGTTCGAATGCTGAGCTGCGTAAAGATCCTATCGCGAGCAGCCCGTTGGACACCCACGACAGCGTGACTGTCCTGCATACCCCGGTTTTCCCGGAGCGCGATTCTAGCCCGGAACAGCTGGCAAAGCGTTTTGCCAACTATATGAGCGCGAACGGTTCCGAGGGTTTCGTTGCGGCGTACGCAGAGATTCTGCGTGATGGTGTGGATGCCTACCGCAAGGTTTTTGAACACGTGCGTGACCGTCCGCGTGATGCGTTTCTGGTGCACTGCACCGGTGGCAAAGACCGTACGGGTGTGTTGGTTGCGCTGATGCTGTTGGTGGCAGGCGTCAAAGACCGTGACGTTATTGCCGATGAGTACAGCCTGACGGAAAAGGGTTTTGCGGCTGTCATCAAAGCCGATGCTGCGGAAAAGATCATCAAAGACATGGGTGTTGACGGTGCCAATCGTGCGGGCATCGAGCGTCTGTTGAGCGCACGCAAAGAAAACATGAGCGCGACCCTGGAGTACATTGAGAAGCAATTTGGTGGCGCAGAGGGCTATCTGCGCGACCAACTGGGTTTCGGCGACGAAGATGTGGAACAGATCCGTAAGAGCCTGGTCGTTGAGGATAAAGGCCTGTTCTAA

[0724] TalVeTPP2 Amino Acid Sequence – SEQ ID NO:16

[0725] MSVTEHVVEASTPSTLPPFIHVDGVPNFRDIGGYPITDLLSTRRNFVYRSAVPTRITPTGLQTLTQDLQITTVYDLRSNAELRKDPIASSPLDTHDSVTVLHTPVFPERDSSPEQLAKRFANYMSANGSEGFVAAYAEILRDGVDAYRKVFEHVRDRPRDAFLVHCTGGKDRTGVLVALMLLVAGVKDRDVIADEYSLTEKGFAAVIKADAAEKIIKDMGVDGANRAGIERLLSARKENMASTLEYIEKQFGGAEGYLRDQLGFGDEDVEQIRKSLVVEDKGLF

[0726] TalVeTPP2 wild type cDNA–SEQ ID NO:17

[0727] ATGAGCGTCACAGAACATGTAGTCGAAGCCTCGACACCATCAACCCTTCCACCACCCTTCATCCATGTCGACGGCGTCCCCAACTTCCGCGACATCGGCGGCTACCCCATCACAGACTTACTGTCAACACGACGAAACTTCGTGTATCGCTCCGCAGTCCCAACACGCATCACTCCCACAGGTCTACAGACACTCACCCAAGACCTCCAAATCACAACAGTCTACGACCTACGCTCCAACGCTGAACTGCGCAAGGATCCCATTGCCTCCAGCCCTCTAGACACCCATGACTCTGTAACGGTGCTACACACCCCCGTCTTTCCCGAACGGGACTCAAGTCCCGAACAACTCGCAAAGAGGTTTGCGAATTACATGTCCGCCAACGGCTCGGAAGGGTTTGTAGCCGCCTACGCCGAGATTTTGCGTGATGGCGTTGATGCATACCGCAAGGTGTTTGAGCATGTCCGTGATCGGCCCCGGGATGCGTTTTTGGTGCATTGTACTGGTGGGAAGGATAGAACGGGTGTCCTTGTAGCGCTCATGTTACTTGTTGCGGGTGTCAAGGATAGAGATGTGATTGCCGACGAGTACTCGTTGACGGAGAAGGGGTTTGCTGCTGTTATTAAGGCGGATGCGGCGGAGAAGATTATAAAGGATATGGGAGTGGATGGGGCGAATAGGGCGGGCATTGAGAGATTGCTGTCGGCGAGGAAGGAGAATATGAGTGCTACGTTGGAGTATATCGAGAAACAGTTTGGTGGGGCGGAGGGTTATTTGAGGGATCAGTTAGGGTTTGGTGATGAGGATGTTGAGCAGATTAGGAAGAGTCTTGTCGTGGAGGATAAGGGTTTATTTTAG

[0728] Optimized cDNA of HydPiTPP1 – SEQ ID NO:18

[0729] ATGACTGCAACCGACAATGGCTTAGAACCGCTGGACCCTGCATACGTTGCTGATGTGTTGAGCCGTCCGCCGTTTGTCCAGATCTCCGGCGTGTGTAACGTCAGAGATCTGGGCAGCTATCCGACCGCTACCCCGAATGTGATTACCAAGCCTGGTTATGCATACCGTGGTGCCGAAGTTTCCAATATCACCGAAGAGGGCAGCCAACAAATGAAAGCACTGGGTATTACCACGATCTTTGATCTGCGTTCTGACCCAGAGATGCAGAAGTACAGCACGCCGATTCCGCATATCGAGGGTGTCCTGATTCTGCGTACCCCGGTGTTCGCCACCGAGGACTATAGCCCGGAGTCGATGGCGAAGCGTTTTGAGCTGTACGCGTCTGGTACGACCGAAGCATTCATGAAGCTGTATAGCCAGATTCTGGACCACGGCGGCAAAGCGTTCGGTACTATTCTGCGTCATGTTCGTGACCGCCCGAACAGCGTTTTTCTGTTTCACTGCACGGCCGGTAAAGATCGCACGGGCATTATTGCGGCCATCCTGTTCAAATTGGCGGGTGTGGATGATCACTTGATCTGTCAGGACTACAGCCTGACGCGCATCGGTCGTGAGCCAGACCGTGAAAAAGTTCTGCGCCGTCTGCTGAATGAACCGCTGTTCGCGGCGAATACCGAGCTTGCGCTGCGCATGTTGACGAGCCGCTACGAAACCATGCAAGCGACCCTGGGTCTGTTGAGCGACAAATATGGCGGTGTGGAAGCATACGTCAAGAACTTCTGCGGTCTGACCGATAACGACATCAGCGTTATCCGTACCAACCTGGTTGTGCCGACGAAAGCGCGTATGTAA

[0730] HydPiTPP1 Amino Acid Sequence – SEQ ID NO:19

[0731] MTATDNGLEPLDPAYVADVLSRPPFVQISGVCNVRDLGSYPTATPNVITKPGYAYRGAEVSNITEEGSQQMKALGITTIFDLRSDPEMQKYSTPIPHIEGVLILRTPVFATEDYSPESMAKRFELYASGTTEAFMKLYSQILDHGGKAFGTILRHVRDRPNSVFLFHCTAGKDRTGIIAAILFKLAGVDDHLICQDYSLTRIGREPDREKVLRRLLNEPLFAANTELALRMLTSRYETMQATLGLLSDKYGGVEAYVKNFCGLTDNDISVIRTNLVVPTKARM

[0732] HydPiTPP1 wild-type cDNA–SEQ ID NO:20

[0733] ATGACCGCAACAGACAACGGACTAGAACCCTTAGACCCTGCATATGTCGCAGATGTGCTCTCAAGACCACCATTCGTACAAATATCTGGTGTTTGCAACGTCCGTGATCTAGGATCCTACCCTACCGCCACTCCCAATGTCATAACAAAGCCGGGATATGCATACCGGGGCGCAGAGGTCTCTAACATTACCGAAGAAGGTAGCCAGCAAATGAAGGCGCTAGGCATAACGACTATATTTGATCTTAGATCGGATCCAGAGATGCAGAAATACAGCACTCCAATACCCCACATTGAAGGCGTACTGATATTGCGCACGCCTGTCTTCGCGACCGAGGATTATAGTCCGGAAAGTATGGCCAAGAGATTTGAGCTATACGCAAGTGGTACTACTGAAGCATTTATGAAACTATACTCTCAAATACTAGACCATGGAGGCAAAGCCTTCGGAACAATTCTCCGGCACGTTCGGGACAGGCCAAATTCTGTCTTTCTTTTCCATTGCACTGCGGGGAAAGACCGGACCGGCATCATTGCTGCAATTCTGTTCAAGCTCGCCGGCGTAGACGACCATCTCATATGTCAAGATTACTCCCTCACACGAATAGGTCGCGAGCCTGATCGTGAAAAGGTCCTCCGGCGACTCTTGAATGAACCTCTATTTGCCGCCAACACGGAACTTGCACTACGAATGCTCACGTCTCGATATGAAACTATGCAAGCAACGTTGGGGCTTCTTAGCGATAAGTATGGCGGGGTGGAGGCGTATGTGAAGAATTTCTGTGGGCTCACGGATAATGATATATCGGTCATACGAACAAATCTCGTTGTACCTACAAAGGCGCGGATGTAG

[0734] Optimized cDNA of TalCeTPP1 – SEQ ID NO:21

[0735] ATGAGCAACGACACGACCAGCACCGCATCCGCAGGCACCGCAACTTCTTCGCGCTTTCTGAGCGTCGGTGGCGTGGTTAACTTCCGTGAGTTGGGTGGCTACCCGTGCGACAGCGTTCCTCCTGCACCAGCAAGCAATGGTAGCCCGGACAATGCGAGCGAAGCGATTCTGTGGGTTGGTCACAGCAGCATTCGTCCGCGCTTCTTGTTTCGTAGCGCACAGCCGTCCCAGATCACCCCGGCCGGTATTGAAACGCTGATTCGCCAACTCGGTATTCAAGCGATCTTTGACTTTCGTTCCCGTACCGAGATCCAACTGGTGGCAACCCGCTACCCAGATAGCCTGCTGGAAATTCCGGGCACGACTCGTTACTCTGTTCCGGTCTTTACCGAGGGCGACTACAGCCCGGCTTCTCTGGTTAAGCGTTATGGTGTCTCTAGCGACACGGCAACGGATAGCACCAGCTCAAAGTGCGCGAAACCGACCGGCTTTGTGCATGCTTATGAAGCGATTGCTCGTTCTGCCGCGGAGAACGGTAGCTTCCGCAAGATCACCGACCACATTATCCAACATCCGGATCGCCCGATCCTGTTTCACTGCACGCTGGGCAAAGACCGTACCGGTGTTTTCGCAGCGCTGCTGCTGAGCTTGTGTGGTGTCCCGAATGACACCATCGTGGAAGATTATGCGATGACGACCGAAGGCTTCGGTGTGTGGCGTGAGCACTTGATTCAGCGTCTGCTGCAGCGCAAAGATGCGGCTACGCGTGAAGATGCCGAGTTCATTATCGCGAGCCATCCGGAGAGCATGAAAGCGTTCCTGGAAGATGTCGTTGCGACCAAATTCGGTGACGCCCGCAACTACTTTATCCAGCACTGTGGTCTGACCGAAGCCGAAGTGGATAAGCTGATCCGTACGCTGGTGATCGCGAATTAA

[0736] TalCeTPP1 Amino Acid Sequence - SEQ ID NO:22

[0737] MSNDTTSTASAGTATSSRFLSVGGVVNFRELGGYPCDSVPPAPASNGSPDNASEAILWVGHSSIRPRFLFRSAQPSQITPAGIETLIRQLGIQAIFDFRSRTEIQLVATRYPDLLEIPGTTRYSVPVFTEGDYSPASLVKRYGVSSDTATDSTSSKCAKPTGFVHAYEAIARSAAENGSFRKITDHIIQHPDRPILFHCTLGKDRTGVFAALLLSLCGVPNDTIVEDYAMTTEGFGVWREHLIQRLLQRKDAATREDAEFIIASHPESMKAFLEDVVATKFGDARNYFIQHCGLTEAEVDKLIRTLVIAN

[0738] TalCeTPP1 wild type cDNA–SEQ ID NO:23

[0739] ATGTCTAATGACACCACTAGCACGGCTTCTGCCGGAACAGCAACTTCTTCGCGGTTTCTTTCTGTGGGCGGAGTTGTGAATTTCCGTGAACTGGGCGGTTATCCATGTGATTCTGTCCCTCCTGCTCCTGCCTCAAACGGCTCACCGGACAACGCATCTGAAGCGATCCTTTGGGTTGGCCACTCGTCCATTCGGCCTAGGTTTCTCTTTCGATCGGCACAGCCGTCTCAGATTACCCCGGCCGGTATTGAGACATTGATCCGCCAGCTTGGCATCCAGGCAATTTTTGACTTTCGTTCACGGACGGAAATTCAGCTTGTCGCCACTCGCTATCCTGATTCGCTACTCGAGATACCTGGTACGACTCGCTATTCCGTGCCCGTCTTCACGGAGGGCGACTATTCCCCGGCGTCATTAGTCAAGAGGTACGGAGTGTCCTCCGATACTGCAACTGATTCCACTTCCTCCAAATGTGCCAAGCCTACAGGATTCGTCCACGCATATGAGGCTATCGCACGCAGCGCAGCAGAAAACGGCAGTTTTCGTAAAATAACGGACCACATAATACAACATCCGGACCGGCCTATCCTGTTTCACTGTACATTGGGAAAAGACCGAACCGGTGTATTTGCAGCATTGTTATTGAGTCTTTGCGGGGTACCAAACGACACGATAGTTGAAGACTATGCTATGACTACCGAGGGATTTGGGGTCTGGCGAGAACATCTAATTCAACGCCTGTTACAAAGAAAGGATGCAGCTACGCGTGAGGATGCAGAATTCATTATTGCCAGCCACCCGGAGAGTATGAAGGCTTTTCTAGAAGATGTGGTAGCAACCAAGTTCGGGGATGCTCGAAATTACTTTATCCAGCACTGTGGATTGACGGAAGCGGAGGTTGATAAGCTAATTCGGACACTGGTCATTGCGAATTGA

[0740] Optimized cDNA of TalMaTPP1 – SEQ ID NO:24

[0741] ATGTGGAATTTGCACTATTATATTCCGGGCTCTGCACCAGTTAATTTGAACGACATGCCGAACGATACGGCGACGACGGCTTCCGCAGGCACTAGCGCCACGAGCCGCTTCCTCTGTGTCAGCGGTGTTGCGAACTTCCGTGAACTGGGTGGCTATCCGTGCGACACCGTTCCTCCAGCACCGGCGAGCAATGGTAGCCCGCATAATGCATCCGAGGCCACGCTGCAAGGTTCCCACTCTAGCATTCGTCCGGGCTTCATCTTCCGTAGCGCGCAACCGAGCCAGATCAATCCGGCAGGCATCGCGACGCTGGCGCATGAACTGTCTATTCAAGTCATCTTCGACTTCCGTTCGCAGACCGAGATCCAGCTGGTCACCACCCACTACCCGGATAGCCTGTTGGAGATCCCGTGTACCACCCGTTACAGCGTGCCGGTGTTTAACGAGGGTGACTATAGCCCGGCTTCGCTGGTCAAGAAATACGGTGTGAGCCCGGACCCAGTGACGCATTCCGCTAGCAGCACCAGCGCGAATCCTGCCGGCTTTGTGCCGGCCTACGAAGCAATCGCTCGTAGCGCAGCCGAAAACGGTAGCTTTCGCAAAATCACCGAGCACATTATTCAGCACCCGGATCAGCCGATTTTGTTTCATTGCACCCTGGGTAAAGATCGCACGGGTGTGTTTGCGGCCCTGCTGCTGAGCCTGTGCGGTGTTTCCACCGAAAAGATCGTGGAAGATTACGCGATGACCACCGAGGGTTTCGGTGCTTGGCGTGAGCACCTGATTAAGCGCCTGCTGCAGCGTAAAGATGCGGCAACCCGCCAAGACGCTGAGTTCATCATTGCCAGCCACCCGGAAACCATGAAATCTTTTCTGGACGACGTTGTTCGTGCGAAGTTTGGCTCCGCGCGTAACTATTTCGTGCAACAGTGCGGTCTGACTGAGTACGAAGTTGATAAGCTGATTCATACGCTGGTCATTATCAAGTAA

[0742] TalMaTPP1 Amino Acid Sequence – SEQ ID NO:25

[0743] MWNLHYYIPGSAPVNLNDMPNDTATTASAGTSATSRFLCVSGVANFRELGGYPCDTVPPAPASNGSPHNASEATLQGSHSSIRPGFIFRSAQPSQINPAGIATLAHELSIQVIFDFRSQTEIQLVTTHYPDSLLEIPCTTRYSVPVFNEGDYSPASLVKKYGVSPDPVTHSASSTSANPAGFVPAYEAIARSAAENGSFRKITEHIIQHPDQPILFHCTLGKDRTGVFAALLLSLCGVSTEKIVEDYAMTTEGFGAWREHLIKRLLQRKDAATRQDAEFIIASHPETMKSFLDDVVRAKFGSARNYFVQQCGLTEYEVDKLIHTLVIIK

[0744] TalMaTPP1 Wild-Type cDNA – SEQ ID NO:26

[0745] ATGTGGAACCTACACTACTATATTCCTGGATCAGCACCAGTCAACTTGAACGACATGCCTAATGACACCGCTACCACGGCTTCTGCCGGAACATCAGCAACTTCACGGTTTCTTTGCGTGAGCGGAGTGGCGAATTTCCGTGAACTGGGCGGTTACCCATGCGATACTGTCCCTCCTGCTCCTGCGTCAAACGGTTCACCGCACAATGCATCTGAAGCGACCCTCCAGGGTAGTCATTCGTCTATTCGGCCTGGATTTATCTTTCGATCGGCTCAGCCGTCGCAGATTAACCCGGCTGGTATTGCCACATTAGCACACGAGCTTAGCATCCAGGTGATTTTTGACTTTCGTTCGCAAACCGAAATTCAGCTTGTCACTACTCATTATCCTGATTCGCTACTTGAGATACCTTGCACGACTCGCTATTCCGTGCCGGTCTTCAATGAGGGCGACTATTCCCCAGCGTCGTTAGTCAAGAAGTACGGGGTATCCCCCGATCCTGTAACACATTCCGCTTCCTCCACGAGTGCCAATCCTGCAGGATTTGTCCCCGCGTATGAAGCCATCGCACGAAGCGCAGCAGAAAACGGCAGTTTCCGTAAAATAACAGAGCACATAATACAGCATCCGGACCAGCCGATCCTGTTTCATTGTACTCTGGGAAAGGACCGGACCGGAGTTTTTGCAGCATTGCTATTGAGCCTTTGCGGTGTTTCGACTGAGAAGATAGTTGAAGACTATGCTATGACTACCGAGGGTTTCGGAGCCTGGCGGGAACATCTAATTAAACGCCTGCTGCAAAGGAAAGATGCAGCAACACGCCAGGATGCGGAATTCATTATCGCCAGCCACCCGGAGACTATGAAGTCTTTCCTAGACGATGTCGTGCGAGCTAAGTTCGGAAGTGCTCGAAATTACTTTGTCCAGCAGTGTGGATTGACAGAATATGAGGTTGATAAGTTAATCCATACACTCGTGATTATAAAATGA

[0746] TalAstroTPP1 optimized cDNA – SEQ ID NO:27

[0747] ATGTCCACCAATGCAGATCCGACCACGTTTTCCGATAAGTCCCCGTTCATCAATGTCAGCGGCGTGGTGAATTTTCGTGACCTGGGCGGCTACAGCTGCTTGACCCCGTTGACGCCAGTCAGCAACGGCAGCCCGGTAATTGCGTCGAAGGGTAGCCCTTCTAGCTATATCCGTCCAGGTTTCCTGTTTCGCTCTGCTCAGCCGAGCCAGATTACCGAAACCGGTATCGAGGTCCTGACCCACAAGCTGAATATCGGTGCGATTTTTGACTTCCGTTCCCAAACCGAGATCCAACTGGTTGCGACGCGTTACCCGGACAGCCTGCTGGAAATTCCGTTTACCTCTCGTTATGCAGTCCCGGTTTTCGAGCATTGTGATTTCAGCCCGGTTAGCTTGAGCAAGAAATATGGTGCGCCGAGCAACGCACCGCCTACCGAAGCGGAGCACGGTAGCTTTGTGCAGGCGTACGAAGATATTGCCCGTAGCGCAGCAGAGAACGGCAGCTTCCGCAGCATCACGGACCACATTTTGCGCTACCCGGATATGCCGATCCTGTTCCACTGCACCGTGGGCAAAGACCGCACCGGCGTTTTTGCGGCGCTGCTGCTGAAACTGTGTGGTGTGAGCGACGAAGTTGTGATTCAGGACTATGCCCTGACTACGCAAGGTCTGGGTGCCTGGAGAGAGCATCTGATCCAACGCCTGCTGCAGCGTAATGACGTCGCGACGCGTGAAGATGCAGAGTTTATCCTGGCTAGCCGTCCGGAGACTATGAAATCGTTCCTGGCCGATGTTGTGGAAACCAAGTTCGGTGGCGCTCGCAACTACTTCACGCTGCTGTGCGGTCTGACCGAAGATGATGTTAACAACCTGATTAGCCTGGTTGTCATTCATAACACGAATTAA

[0748] TalAstroTPP1 Amino Acid Sequence – SEQ ID NO:28

[0749] MSTNADPTTFSDKSPFINVSGVVNFRDLGGYSCLTPLTPVSNGSPVIASKGSPSSYIRPGFLFRSAQPSQITETGIEVLTHKLNIGAIFDFRSQTEIQLVATRYPDSLLEIPFTSRYAVPVFEHCDFSPVSLSKKYGAPSNAPPTEAEHGSFVQAYEDIARSAAENGSFRSITDHILRYPDMPILFHCTVGKDRTGVFAALLLKLCGVSDEVVIQDYALTTQGLGAWREHLIQRLLQRNDVATREDAEFILASRPETMKSFLADVVETKFGGARNYFTLLCGLTEDDVNNLISLVVIHNTN

[0750] TalAstroTPP1 Wild-Type cDNA – SEQ ID NO:29

[0751] ATGTCTACCAACGCTGACCCTACTACTTTTTCCGATAAATCACCGTTTATTAACGTAAGCGGCGTTGTCAATTTTCGTGATCTGGGCGGTTACTCATGTCTCACTCCTCTCACCCCTGTCTCAAATGGTTCACCGGTGATAGCGTCAAAGGGATCCCCCTCATCATACATTCGCCCCGGCTTCTTGTTCCGTTCAGCACAGCCTTCACAAATTACCGAGACTGGTATCGAAGTTCTGACGCACAAGCTTAATATCGGAGCTATATTTGACTTTCGGTCACAGACAGAAATCCAGCTTGTTGCGACTCGATATCCAGATTCCCTGCTCGAAATACCATTTACTAGCCGATACGCTGTTCCAGTGTTCGAACATTGCGACTTTTCTCCGGTCTCGCTGTCTAAGAAGTATGGGGCTCCGTCAAACGCTCCTCCTACAGAAGCCGAGCACGGTAGCTTCGTCCAGGCTTATGAAGATATCGCCCGCAGTGCAGCGGAAAATGGAAGTTTTCGCAGCATAACAGATCATATTCTGCGATATCCCGACATGCCAATTCTTTTTCATTGTACGGTTGGCAAAGACAGAACTGGTGTGTTTGCAGCATTGTTGTTGAAGCTGTGTGGAGTGTCTGATGAAGTAGTTATTCAAGACTACGCACTCACTACTCAAGGCCTAGGTGCATGGCGCGAACACCTGATTCAGCGCCTGCTGCAAAGGAATGATGTTGCTACCCGTGAGGATGCCGAGTTCATACTCGCTAGCCGACCAGAGACTATGAAGTCATTCTTGGCAGATGTGGTGGAAACCAAATTTGGAGGAGCTCGCAACTATTTTACTCTGCTGTGCGGATTGACCGAGGACGATGTCAATAACTTGATCTCCCTTGTAGTTATTCATAATACAAATTAG

[0752] Optimized cDNA of PeSubTPP1 – SEQ ID NO:30

[0753] ATGCAACCTTTTATTAGCGTCGATGGTGTGGTGAATTTTCGTGATATTGGTGGTTATGTTTGCCGTAATCCGGCCGGTTTGTCGAGCCTGCCGAGCAACGTTGACGAAACCCCGGAAAAGCAATGGTGTATCCGCCCAGGCTTCGTTTTCCGTGCAGCGCAACCGTCCCAAATTACGCCGGCTGGTATCGAGATTCTTAAGAAAACGCTGGCGATCCAAGCGATTTTCGATTTTCGTAGCGAGTCCGAGATCCAACTGGTGAGCAAGCGTTACCCGGACAGCCTGCTGGACATCCCGGGCACTACGCGTCATGCTGTTCCGGTGTTTCAGGAGGGTGATTACAGCCCGATCTCGTTGGCCAAACGTTACGGTGTGACCGCGGACGAGAGCACCAACGATCAGTCCTTCCGTCCGGGTTTTGTCAAAGCGTATGAAGCCATCGCACGCAACGCAGCACAGGCTGGTAGCTTCCGCGCCATTATCCAGCATATCCTGCAGGACTCCGCTGGCCCAGTTTTGTTTCACTGCACCGTAGGCAAAGATCGCACGGGTGTTTTCTCTGCACTGATTCTGAAGCTGTGCGGTGTGGCCGACGAAGATATTGTGGCAGACTATGCGCTGACCACTCAGGGCCTGGGTGTCTGGCGTGAGCACCTGATCCAGCGCCTGTTGCAGCGTGGTGAAGCGACCACCAAAGAACAAGCGGAAGCGATCATCTCTAGCGACCCGCGCGACATGAAAGCGTTCCTGAGCAACGTCGTTGAGGGCGAGTTTGGTGGCGCACGCAACTACTTCGTGAATCTGTGTGGCCTGCCTGAAGGCGAGGTTGACCGTGTCATTACCAAACTGGTCGTCCCGAAAACCACCAAGTAA

[0754] PeSubTPP1 Amino Acid Sequence - SEQ ID NO:31

[0755] MQPFISVDGVVNFRDIGGYVCRNPAGLSSLPSNVDETPEKQWCIRPGFVFRAAQPSQITPAGIEILKKTLAIQAIFDFRSESEIQLVSKRYPDSLLDIPGTTRHAVPVFQEGDYSPISLAKRYGVTADESTNDQSFRPGFVKAYEAIARNAAQAGSFRAIIQHILQDSAGPVLFHCTVGKDRTGVFSALILKLCGVADEDIVADYALTTQGLGVWREHLIQRLLQRGEATTKEQAEAIISSDPRDMKAFLSNVVEGEFGGARNYFVNLCGLPEGEVDRVITKLVVPKTTK

[0756] PeSubTPP1 wild-type cDNA–SEQ ID NO:32

[0757] ATGCAGCCATTCATCTCGGTGGATGGAGTCGTCAACTTCCGCGATATCGGAGGCTATGTATGCCGGAATCCCGCTGGTTTATCCTCCTTGCCCTCGAATGTCGACGAAACCCCAGAGAAACAGTGGTGCATTCGGCCAGGATTCGTCTTCCGCGCGGCACAGCCATCCCAAATCACCCCTGCAGGGATTGAGATCCTGAAAAAGACCCTTGCTATCCAAGCCATCTTTGACTTTCGGTCAGAGAGTGAGATTCAGCTTGTGTCTAAGCGCTATCCAGACTCCCTCCTCGATATTCCCGGGACAACTCGCCATGCAGTACCGGTCTTCCAAGAAGGTGATTACTCTCCCATCTCACTGGCAAAACGGTATGGAGTCACCGCGGACGAATCCACGAATGATCAGTCCTTTAGACCGGGATTCGTCAAGGCCTACGAGGCCATTGCGCGCAACGCGGCTCAAGCGGGCAGCTTCCGTGCAATCATACAGCACATTCTGCAGGATTCGGCCGGCCCGGTACTTTTCCACTGCACGGTGGGCAAGGACCGGACAGGGGTCTTTTCGGCTTTGATCCTCAAGCTGTGCGGGGTGGCCGATGAGGACATTGTCGCTGATTATGCACTCACCACGCAAGGCTTAGGTGTGTGGCGGGAGCATTTGATTCAACGGCTCTTGCAGAGAGGGGAGGCCACAACCAAGGAACAAGCCGAAGCCATAATCAGCAGTGACCCGAGAGACATGAAGGCGTTTTTGAGCAATGTAGTGGAAGGGGAATTTGGAGGTGCTCGGAACTACTTCGTCAACCTCTGCGGACTACCGGAAGGCGAAGTCGATCGGGTTATCACCAAGCTTGTGGTACCAAAGACTACTAAATAG

[0758] Codon-optimized cDNA sequence encoding SmCPS–SEQ ID NO:33

[0759]

[0760] SmCPS, a CPP synthase from Salvia miltiorrhiza, amino acid sequence – SEQ ID NO:34

[0761] MATVDAPQVHDHDGTTVHQGHDAVKNIEDPIEYIRTLLRTTGDGRISVSPYDTAWVAMIKDVEGRDGPQFPSSLEWIVQNQLEDGSWGDQKLFCVYDRLVNTIACVVALRSWNVHAHKVKRGVTYIKENVDKLMEGNEEHMTCGFEVVFPALLQKAKSLGIEDLPYDSPAVQEVYHVREQKLKRIPLEIMHKIPTSLLFSLEGLENLDWDKLLKLQSADGSFLTSPSSTAFAFMQTKDEKCYQFIKNTIDTFNGGAPHTYPVDVFGRLWAIDRLQRLGISRFFEPEIADCLSHIHKFWTDKGVFSGRESEFCDIDDTSMGMRLMRMHGYDVDPNVLRNFKQKDGKFSCYGGQMIESPSPIYNLYRASQLRFPGEEILEDAKRFAYDFLKEKLANNQILDKWVISKHLPDEIKLGLEMPWLATLPRVEAKYYIQYYAGSGDVWIGKTLYRMPEISNDTYHDLAKTDFKRCQAKHQFEWLYMQEWYESCGIEEFGISRKDLLLSYFLATASIFELERTNERIAWAKSQIIAKMITSFFNKETTSEEDKRALLNELGNINGLNDTNGAGREGGAGSIALATLTQFLEGFDRYTRHQLKNAWSVWLTQLQHGEADDAELLTNTLNICAGHIAFREEILAHNEYKALSNLTSKICRQLSFIQSEKEMGVEGEIAAKSSIKNKELEEDMQMLVKLVLEKYGGIDRNIKKAFLAVAKTYYYRAYHAADTIDTHMFKVLFEPVA

[0762] Codon-optimized cDNA encoding a GGPP synthase from Pantoea agglomerans – SEQ ID NO:35

[0763] ATGGTTTCTGGTTCGAAAGCAGGAGTATCACCTCATAGGGAAATCGAAGTCATGAGACAGTCCATTGATGACCACTTAGCAGGATTGTTGCCAGAAACAGATTCCCAGGATATCGTTAGCCTTGCTATGAGAGAAGGTGTTATGGCACCTGGTAAACGTATCAGACCTTTGCTGATGTTACTTGCTGCAAGAGACCTGAGATATCAGGGTTCTATGCCTACACTACTGGATCTAGCTTGTGCTGTTGAACTGACACATACTGCTTCCTTGATGCTGGATGACATGCCTTGTATGGACAATGCGGAACTTAGAAGAGGTCAACCAACAACCCACAAGAAATTCGGAGAATCTGTTGCCATTTTGGCTTCTGTAGGTCTGTTGTCGAAAGCATTTGGCTTGATTGCTGCAACTGGTGATCTTCCAGGTGAAAGGAGAGCACAAGCTGTAAACGAGCTATCTACTGCAGTTGGTGTTCAAGGTCTAGTCTTAGGACAGTTCAGAGATTTGAATGACGCAGCTTTGGACAGAACTCCTGATGCTATCCTGTCTACGAACCATCTGAAGACTGGCATCTTGTTCTCAGCTATGTTGCAAATCGTAGCCATTGCTTCTGCTTCTTCACCATCTACTAGGGAAACGTTACACGCATTCGCATTGGACTTTGGTCAAGCCTTTCAACTGCTAGACGATTTGAGGGATGATCATCCAGAGACAGGTAAAGACCGTAACAAAGACGCTGGTAAAAGCACTCTAGTCAACAGATTGGGTGCTGATGCAGCTAGACAGAAACTGAGAGAGCACATTGACTCTGCTGACAAACACCTGACATTTGCATGTCCACAAGGAGGTGCTATAAGGCAGTTTATGCACCTATGGTTTGGACACCATCTTGCTGATTGGTCTCCAGTGATGAAGATCGCCTAA

[0764] GGPP synthase from Pantoea agglomerans, amino acid sequence – SEQ ID NO: 36

[0765] MVSGSKAGVSPHREIEVMRQSIDDHLAGLLPETDSQDIVSLAMREGVMAPGKRIRPLLMLLAARDLRYQGSMPTLLDLACAVELTHTASLMLDDMPCMDNAELRRGQPTTHKKFGESVAILASVGLLSKAFGLIAATGDLPGERRAQAVNELS TAVGVQGLVLGQFRDLNDAALDRTPDAILSTNHLKTGILFSAMLQIVAIASASSPSTRETLHAFALDFGQAFQLLDDLRDDHPETGKDRNKDAGKSTLVNRLGADAARQKLREHIDSADKHLTFACPQGGAIRQFMHLWFGHHLADWSPVMKIA

[0766] Optimized cDNA encoding SsLPS – SEQ ID NO: 37

[0767]

[0768] SsLPS amino acid sequence – SEQ ID NO:38

[0769] MASQASEKDISLVQTPHKVEVNEKIEESIEYVQNLLMTSGDGRISVSPYDTAVIALIKDLKGRDAPQFPSCLEWIAHHQLADGSWGDEFFCIYDRILNTLACVVALKSWNLHSDIIEKGVTYIKENVHKLKGANVEHRTAGFELVVPTFMQMATDLGIQDLPYDHPLIKEIADTKQQRLKEIPKDLVYQMPTNLLYSLEGLGDLEWERLLKLQSGNGSFLTSPSSTAAVLMHTKDEKCLKYIENALKNCDGGAPHTYPVDIFSRLWAIDRLQRLGISRFFQHEIKYFLDHIESVWEETGVFSGRYTKFSDIDDTSMGVRLLKMHGYDVDPNVLKHFKQQDGKFSCYIGQSVESASPMYNLYRAAQLRFPGEEVLEEATKFAFNFLQEMLVKDRLQERWVISDHLFDEIKLGLKMPWYATLPRVEAAYYLDHYAGSGDVWIGKSFYRMPEISNDTYKELAILDFNRCQTQHQLEWIHMQEWYDRCSLSEFGISKRELLRSYFLAAATIFEPERTQERLLWAKTRILSKMITSFVNISGTTLSLDYNFNGLDEIISSANEDQGLAGTLLATFHQLLDGFDIYTLHQLKHVWSQWFMKVQQGEGSGGEDAVLLANTLNICAGLNEDVLSNNEYTALSTLTNKICNRLAQIQDNKILQVVDGSIKDKELEQDMQALVKLVLQENGGAVDRNIRHTFLSVSKTFYYDAYHDDETTDLHIFKVLFRPVV

[0770] Optimized cDNA encoding TaTps1 - del59 – SEQ ID NO:39

[0771]

[0772] Triticum aestivum truncated copalyl diphosphate synthase, TaTPS1-del59–SEQ ID NO:40

[0773] MYRQRTDEPSETRQMIDDIRTALASLGDDETSMSVSAYDTALVALVKNLDGGDGPQFPSCIDWIVQNQLPDGSWGDPAFFMVQDRMISTLACVVAVKSWNIDRDNLCDRGVLFIKENMSRLVEEEQDWMPCGFEINFPALLEKAKDLDLDIPYDHPVLEEIYAKRNLKLLKIPLDVLHAIPTTLLFSVEGMVDLPLDWEKLLRLRCPDGSFHSSPAATAAALSHTGDKECHAFLDRLIQKFEGGVPCSHSMDTFEQLWVVDRLMRLGISRHFTSEIQQCLEFIYRRWTQKGLAHNMHCPIPDIDDTAMGFRLLRQHGYDVTPSVFKHFEKDGKFVCFPMETNHASVTPMHNTYRASQFMFPGDDDVLARAGRYCRAFLQERQSSNKLYDKWIITKDLPGEVGYTLNFPWKSSLPRIETRMYLDQYGGNNDVWIAKVLYRMNLVSNDLYLKMAKADFTEYQRLSRIEWNGLRKWYFRNHLQRYGATPKSALKAYFLASANIFEPGRAAERLAWARMAVLAEAVTTHFRHIGGPCYSTENLEELIDLVSFDDVSGGLREAWKQWLMAWTAKESHGSVDGDTALLFVRTIEICSGRIVSSEQKLNLWDYSQLEQLTSSICHKLATIGLSQNEASMENTEDLHQQVDLEMQELSWRVHQGCHGINRETRQTFLNVVKSFYYSAHCSPETVDSHIAKVIFQDVI

[0774] Optimized cDNA, CymB–SEQ ID NO:41

[0775]

[0776] CymB, Amino acid sequence – SEQ ID NO:42

[0777] MTINSIQPIQAKAAVLRAVGSPFNIEPIRISPPKGDEVLVRIVGVGVCHTDVVCRDSFPVPLPIILGHEGSGVIEAIGDQVTSLKPGDHVVLSFNSCGHCYNCGHAEPASCLQMLPLNFGGAERAADGTIQDDKGEAVRGMFFGQSSFGTYAIARAVNAVKVDDDLPLPLLGPLGCGIQTGAGAAMNSLSLQSGQSFIVFGGGAVGLSAVMAAKALGVSPLIVVEPNESRRALALELGASHVFDPFNTEDLVASIREVVPAGANHALDTTGLPKVIASAIDCIMSGGKLGLLGMASPEANVPATLLDLLSKNVTLKPITEGDANPQEFIPRMLALYREGKFPFEKLITTFPFEHINEAMEATESGKAIKPVLTL

[0778] AspWeADH1, Optimized cDNA – SEQ ID NO:43

[0779]

[0780] AspWeADH1, Amino Acid Sequence - SEQ ID NO:44

[0781] MGSITEDIPTMRAATVVEYNKPLQILNIPIPTPSQDQILVKVTACSLCNSDLAGWLGVVGAVAPYCPGHEPVGVIESVGSAVRGFKKGDRAGFMPSSFTCKDCNECQTGNHRFCNKKTSVGFQGPYGGFSQYAVADPLSTVKIPDALSDEVTAPLLCAGVTAYGALRKVPPGVQSVNVIGCGGVGHLVIQYAKALGYYVRGFDVNDKKLGLAARSGADETFYSTDATHADQASATIVATGAVAAYKAAFAVTANHGRIIAIGVPKGEIPVSLLDMVKRDLSLVATNQGSKEELEEALEIAVQHQIAPEYEIRQLDQLNDGFQEMMKGESHGRLVYRLW

[0782] PsAerADH, Optimized cDNA - SEQ ID NO:45

[0783]

[0784] PsAerADH1, Amino Acid Sequence – SEQ ID NO:46

[0785] MNSIQPTQAKAAVLRAVGGPFSIEPIRISPPKGDEVLVRIVGVGVCHTDVVCRDSFPVPLPIILGHEGSGVIEAVGDQVTGLKPGDHVVLSFNSCGHCYNCGHDEPASCLQMLPLNFGGAERAADGTIEDDQGAAVRGLFFGQSSFGSYAIARAVNTVKVDDDLPLALLGPLGCGIQTGAGAAMNSLGLQGGQSFIVFGGGAVGLSAVMAAKALGVSPLIVVEPNEARRALALELGASHAFDPFNTEDLVASIREVVPAGANHALDTTGLPKVIANAIDCIMSGGKLGLLGMANPEANVPATLLDLLSKNVTLKPITEGDANPQEFIPRMLALYREGKFPFDKLITTFPFEHINEAMEATESGKAIKPVLTL

[0786] AzTolADH1, Optimized cDNA – SEQ ID NO:47

[0787]

[0788] AzTolADH1, Amino Acid Sequence – SEQ ID NO:48

[0789] MGSIQDSLFIRARAAVLRTVGGPLEIENVRISPPKGDEVLVRMVGVGVCHTDVVCRDGFPVPLPIVLGHEGSGIVEAVGERVTKVKPGQRVVLSFNSCGHCASCCEDHPATCHQMLPLNFGAAQRVDGGTVIDASGEAVQSLFFGQSSFGTYALAREVNTVPVPDAVPLEILGPLGCGIQTGAGAAINSLALKPGQSLAIFGGGSVGLSALLGALAVGAGPVVVIEPNERRRALALDLGASHAFDPFNTEDLVASIKAATGGGVTHSLDSTGLPPVIANAINCTLPGGTVGLLGVPSPEAAVPVTLLDLLVKSVTLRPITEGDANPQEFIPRMVQLYRDGKFPFDKLITTYRFDDINQAFKATETGEAIKPVLVF

[0790] AroAroADH1, Optimized cDNA – SEQ ID NO:49

[0791]

[0792] AroAroADH1, Amino Acid Sequence – SEQ ID NO:50

[0793] MGSIQDSLFIPARAAVLRAVGGPLEIEDVRISPPKGDEVLVRMVGVGVCHTDVVCRDGFPVPLPIVLGHEGAGIVEAVGERVTKVKPGQRVVLSFNSCGHCSSCGEDHPATCHQMLPLNFGAAQRVDGGCVTDASGEAVHSLFFGQSSFCTFALAREVNTVPVGDGVPLEILGPLGCGIQTGAGAAINSLAIKPGQSLAIFGGGSVGLSALLGALAVGAGPVVVVEPNDRRRALALDLGASHVFDPFNTEDLVASIKAATGGGVTHSLDSTGLPPVIAKAIDCTLPGGTVGLLGVPAPDAAVPVTLLDLLVKSVTLRPITEGDANPQEFIPRMVQLYRDGKFPFDKLITTYRFENINDAFKATETGEAIKPVLVF

[0794] ThTerpADH1, Optimized cDNA – SEQ ID NO:51

[0795]

[0796] ThTerpADH1, Amino Acid Sequence - SEQ ID NO:52

[0797] MCSNHDFTAARAAVLRKVGGPLEIEDVRISAPKGDEVLVRMVGVGVCHTDLVCRDAFPVPLPIVLGHEGAGIVEAVGEGVRSLEPGDRVVLSFNSCGRCGNCGSGHPSNCLQMLPLNFGGAQRVDGGRMLDAAGNAVQGLFFGQSSFGTYAIAREINAVKVAEDLPLEILGPLGCGIQTGAGAAINSLGIGPGQSLAVFGGGGVGLSALLGARAVGAAQVVVVEPNAARRALALELGASHAFDPFAGDDLVAAIRAATGGGATHALDTTGLPSVIGNAIDCTLPGGTVGMVGMPAPDAAVPATLLDLLTKSVTLRPITEGDADPQAFIPQMLRFYREGKFPFDRLITRYRFDQINEALHATEKGGAIKPVLVF

[0798] CdGeoA Optimized cDNA - SEQ ID NO:53

[0799]

[0800] CdGeoA, Amino acid sequence – SEQ ID NO:54

[0801] MNDTQDFISAQAAVLRQVGGPLAVEPVRISMPKGDEVLIRIAGVGVCHTDLVCRDGFPVPLPIVLGHEGSGTVEAVGEQVRTLKPGDRVVLSFNSCGHCGNCHDGHPSNCLQMLPLNFGGAQRVDGGQVLDGAGHPVQSMFFGQSSFGTHAVAREINAVKVGDDLPLELLGPLGCGIQTGAGAAINSLGIGPGQSLAIFGGGGVGLSALLGARAVGADRVVVIEPNAARRALALELGASHALDPHAEGDLVAAIKAATGGGATHSLDTTGLPPVIGSAIACTLPGGTVGMVGLPAPDAPVPATLLDLLSKSVTLRPITEGDADPQRFIPRMLDFHRAGKFPFDRLITRYRFDQINEALHATEKGEAIKPVLVF

[0802] VoADH1, Optimized cDNA – SEQ ID NO:55

[0803]

[0804] VoADH1, amino acid sequence – SEQ ID NO:56

[0805] MTKSSGEVISCKAAVIYKSGEPAKVEEIRVDPPKSSEVRIKMLYASLCHTDILCCNGLPVPLFPRIPGHEGVGVVESAGEDVKDVKEGDIVMPLYLGECGECLNCSSGKTNLCHKYPLDFSGVLPSDGTSRMSVAKSGEKIFHHFSCSTWSEYVVIESSYVVKVDSRLPLPHASFLACGFTTGYGAAWKE ADIPKGSTVAVLGLGAVGLGVVAGARSQGASRIIGVDINDKKKAKAEIFGVTEFLNPKQLGKSASESIKDVTGGLGVDYCFECTGVPALLNEAVDASKIGLGTIVMIGAGMETSGVINYIPLLCGRKLIGSIYGGVRIRSDLPLIIEKCINKEIPLNELQTHEVSLEGINDAFGMLKQPDCVKIVIKFEQK

[0806] Active site signature motif - SEQ ID NO: 57

[0807] HCxxGxxR

[0808] in

[0809] Each x independently represents any natural amino acid residue.

[0810] Active site signature motif - SEQ ID NO: 58

[0811] HC(T / S)xGKDRTG

[0812] in

[0813] x represents any natural amino acid residue.

[0814] PvCPS, a multifunctional protein with both prenyltransferase and copalyl diphosphate synthase functions, codon-optimized cDNA - SEQ ID NO: 59

[0815]

[0816] PvCPS, a multifunctional protein with both prenyltransferase and copalyl diphosphate synthase properties, amino acid sequence - SEQ ID NO: 60

[0817] MSPMDLQESAAALVRQLGERVEDRRGFGFMSPAIYDTAWVSMISKTIDDQKTWLFAECFQYILSHQLEDGGWAMYASEIDAILNTSASLLSLKRHLSNPYQITSITQEDLSARINRAQNALQKLLNEWNVDSTLHVGFEILVPALLRYLEDEGIAFAFSGRERLLEIEKQKLSKFKAQYLYLPIKVTALHSLEAFIGAIEFDKVSHHKVSGAFMASPSSTAAYMMHATQWDDECEDYLRHVIAHASGKGSGGVPSAFPSTIFESVWPLSTLLKVGYDLNSAPFIEKIRSYLHDAYIAEKGILGFTPFVGADADDTATTILVLNLLNQPVSVDAMLKEFEEEHHFKTYSQERNPSFSANCNVLLALLYSQEPSLYSAQIEKAIRFLYKQFTDSEMDVRDKWNLSPYYSWMLMTQAITRLTTLQKTSKLSTLRDDSISKGLISLLFRIASTVVKDQKPGGSWGTRASKEETAYAVLILTYAFYLDEVTESLRHDIKIAIENGCSFLSERTMQSDSEWLWVEKVTYKSEVLSEAYILAALKRAADLPDENAEAAPVINGISTNGFEHTDRINGKLKVNGTNGTNGSHETNGINGTHEIEQINGVNGTNGHSDVPHDTNGWVEEPTAINETNGHYVNGTNHETPLTNGISNGDSVSVHTDHSDSYYQRSDWTADEEQILLGPFDYLESLPGKNMRSQLIQSFNTWLKVPTESLDVIIKVISMLHTASLLIDDIQDQSILRRGQPVAHSIFGTAQAMNSGNYVYFLALREVQKLQNPKAISIYVDSLIDLHRGQGMELFWRDSLMCPTEEQYLDMVANKTGGLFCLAIQLMQAEATIQVDFIPLVRLLGIIFQICDDYLNLKSTAYTDNKGLCEDLTEGKFSFPIIHSIRSNPGNRQLINILKQKPREDDIKRYALSYMESTNSFEYTRGVVRKLKTEAIDTIQGLEKHGLEENIGIRKILARMSLEL

[0818] Ribosome binding site – SEQ ID NO:61

[0819] AAGGAGGTAAAAAA

[0820] CrtE, GGPP synthase from Pantoea agglomerans, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 62

[0821] ATGGTTTCTGGTTCTAAGGCTGGTGTTTCTCCACACAGAGAAATCGAAGTTATGAGACAATCTATCGACGACCACTTGGCTGGTTTGTTGCCAGAAACTGACTCTCAAGACATCGTTTCTTTGGCTATGAGAGAAGGTGTTATGGCTCCAGGTAAGAGAATCAGACCATTGTTGATGTTGTTGGCTGCTAGAGACTTGAGATACCAAGGTTCTATGCCAACTTTGTTGGACTTGGCTTGTGCTGTTGAATTGACTCACACTGCTTCTTTGATGTTGGACGACATGCCATGTATGGACAACGCTGAATTGAGAAGAGGTCAACCAACTACTCACAAGAAGTTCGGTGAATCTGTTGCTATCTTGGCTTCTGTTGGTTTGTTGTCTAAGGCTTTCGGTTTGATCGCTGCTACTGGTGACTTGCCAGGTGAAAGAAGAGCTCAAGCTGTTAACGAATTGTCTACTGCTGTTGGTGTTCAAGGTTTGGTTTTGGGTCAATTCAGAGACTTGAACGACGCTGCTTTGGACAGAACTCCAGACGCTATCTTGTCTACTAACCACTTGAAGACTGGTATCTTGTTCTCTGCTATGTTGCAAATCGTTGCTATCGCTTCTGCTTCTTCTCCATCTACTAGAGAAACTTTGCACGCTTTCGCTTTGGACTTCGGTCAAGCTTTCCAATTGTTGGACGACTTGAGAGACGACCACCCAGAAACTGGTAAGGACAGAAACAAGGACGCTGGTAAGTCTACTTTGGTTAACAGATTGGGTGCTGACGCTGCTAGACAAAAGTTGAGAGAACACATCGACTCTGCTGACAAGCACTTGACTTTCGCTTGTCCACAAGGTGGTGCTATCAGACAATTCATGCACTTGTGGTTCGGTCACCACTTGGCTGACTGGTCTCCAGTTATGAAGATCGCTTAA

[0822] SmCPS2, copalyl pyrophosphate synthase from Salvia miltiorrhiza, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 63

[0823]

[0824] SmCPS2, copalyl pyrophosphate synthase from Salvia miltiorrhiza, amino acid sequence - SEQ ID NO: 64

[0825] *

[0826] TalVeTPP, copalyl pyrophosphate phosphatase, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 65

[0827] ATGTCTAACGACACTACTACTACTGCTTCTGCTGGTACTGCTACTTCTTCTAGATTCTTGTCTGTTGGTGGTGTTGTTAACTTCAGAGAATTGGGTGGTTACCCATGTGACTCTGTTCCACCAGCTCCAGCTTCTAACGGTTCTCCAGACAACGCTTCTGAAGCTACTTTGTGGGTTGGTCACTCTTCTATCAGACCAGGTTTCTTGTTCAGATCTGCTCAACCATCTCAAATCACTCCAGCTGGTATCGAAACTTTGATCAGACAATTGGGTATCCAAACTATCTTCGACTTCAGATCTAGAACTGAAATCGAATTGGTTGCTACTAGATACCCAGACTCTTTGTTGGAAATCCCAGGTACTACTAGATACTCTGTTCCAGTTTTCTCTGAAGGTGACTACTCTCCAGCTTCTTTGGTTAAGAGATACGGTGTTTCTTCTGACACTGCTACTGACTCTACTTCTTCTAAGTCTGCTAAGCCAACTGGTTTCGTTCACGCTTACGAAGCTATCGCTAGATCTGCTGCTGAAAACGGTTCTTTCAGAAAGATCACTGACCACATCATCCAACACCCAGACAGACCAATCTTGTTCCACTGTACTTTGGGTAAGGACAGAACTGGTGTTTTCGCTGCTTTGTTGTTGTCTTTGTGTGGTGTTCCAGACGAAACTATCGTTGAAGACTACGCTATGACTACTGAAGGTTTCGGTGCTTGGAGAGAACACTTGATCCAAAGATTGTTGCAAAGAAAGGACGCTGCTACTAGAGAAGACGCTGAATCTATCATCGCTTCTCCACCAGAAACTATGAAGGCTTTCTTGGAAGACGTTGTTGCTGCTAAGTTCGGTGGTGCTAGAAACTACTTCATCCAACACTGTGGTTTCACTGAAGCTGAAGTTGACAAGTTGTCTCACACTTTGGCTATCACTAACTAA

[0828] AzTolADH1, alcohol dehydrogenase from Azoarcus toluclasticus, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 66

[0829]

[0830] PsAeroADH1, alcohol dehydrogenase from Pseudomonas aeruginosa, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 67

[0831]

[0832] SCH23-ADH1, alcohol dehydrogenase from Hyphozyma roseonigra, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 68

[0833]

[0834] SCH23-ADH1, alcohol dehydrogenase from Hyphozyma roseonigra, amino acid sequence - SEQ ID NO: 69

[0835] MQFSIGDVLAIVDKTILNPLVVSAGLLSLHFLTNDKYAITANDGLFPYQISTPDSHRKALFALGFGLLLRANRYMSRKALNNNTAAQFDWNREIIVVTGGSGGIGAQAAQKLAERGSKVIVIDVLPLTFDKPKNLYHYKCDLTNYKELQEVAAKIEREVGTPTCVVANAGICRGK NIFDATERDVQLTFGVNNLGLLWTAKTFLPSMAKANHGHFLIIASQTGHLATAGVVDYAATKAAAIAIYEGLQTEMKHFYKAPAVRVSCISPSAVKTKMFAGIKTGGNFFMPMLTPDDLGDLIAKTLWDGVAVNILSPAAAYISPPTRALPDWMRVGMQDAGAEIMTELTPHKPLE

[0836] SCH24-ADH1a, alcohol dehydrogenase from Cryptococcus albidus, codon-optimized for expression in Saccharomyces cerevisiae - SEQ ID NO: 70

[0837]

[0838] SCH24-ADH1a, alcohol dehydrogenase from Cryptococcus albidus, amino acid sequence - SEQ ID NO: 71

[0839] MPTPIFGAREGFTIDSVLSILDATVLNPWFTGVCLIAVCARDRTITYPDWPAALDQVLPFLSQMWRETVRPTFGDRNVLHLLTTVCVGLAIRTNRRMSRGARNNWVWDTSYDWKKEIVVVTGGAAGFGADIVQQLDTRGIQVVVLDVGSLTYRPSSRVHYYKCDVSNPQDVASVAKAIVSNVGHPT ILVNNAGVFRGATILSTPRDLDMTYDINVKAHYHLTKAFLPNMISKNHGHIVTVSSATAYAQACSGVSYCSSKAAILSFHEGLSEEILWIYKAPKVRTSVICPGHVNTAMFTGIGAAAPSFMAPALHPSTVAETIVDVLLSCESQHVLMPAAMHMSVAGRALPTWFFRGLLASGKDTMGSVVRR*

[0840] Sequence 1 for homologous recombination—SEQ ID NO: 72

[0841] GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG

[0842] Sequence 2 for homologous recombination - SEQ ID NO: 73

[0843] AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT

[0844] Sequence 3 for homologous recombination - SEQ ID NO: 74

[0845] TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTTGACCACGA

[0846] Primer 1 for LEU2 yeast marker - SEQ ID NO: 75

[0847] AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCATTCGACTACGTCGTAAGGCC

[0848] Primer 2 for LEU2 yeast marker - SEQ ID NO: 76

[0849] TCGTGGTCAAGGCGTGCAATTCTCAACACGAGAGTGATTCTTCGGCGTTGTTGCTGACATCGACGGTCGAGGAGAACTT

[0850] Primer 1 for AmpR bacterial marker—SEQ ID NO: 77

[0851] TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTTGACCACGACACGTTAAGGGATTTTGGTCATGAG

[0852] Primer 2 for AmpR bacterial marker - SEQ ID NO: 78

[0853] AACGCGTACCCTAAGTACGGCACCACAGTGACTATGCAGTCCGCACTTTGCCAATGCCAAAAATGTGCGCGGAACCCCTA

[0854] Primer 1 for yeast replication origin - SEQ ID NO: 79

[0855] TTGGCATTGGCAAAGTGCGGACTGCATAGTCACTGTGGTGCCGTACTTAGGGTACGCGTTCCTGAACGAAGCATCTGTGCTTCA

[0856] Primer 2 for yeast replication origin - SEQ ID NO: 80

[0857] CCGAGATGCCAAAGGATAGGTGCTATGTTGATGACTACGACACAGAACTGCGGGTGACATAATGATAGCATTGAAGGATGAGACT

[0858] Primer 1 for E. coli origin of replication - SEQ ID NO: 81

[0859] ATGTCACCCGCAGTTCTGTGTCGTAGTCATCAACATAGCACCTATCCTTTGGCATCTCGGTGAGCAAAAGGCCAGCAAAAGG

[0860] Primer 2 for E. coli origin of replication - SEQ ID NO: 82

[0861] CTCAGATGTACGGTGATCGCCACCATGTGACGGAAGCTATCCTGACAGTGTAGCAAGTGCTGAGCGTCAGACCCCGTAGAA

[0862] Sequence 4 for homologous recombination - SEQ ID NO: 83

[0863] ATTCCTAGTGACGGCCTTGGGAACTCGATACACGATGTTCAGTAGACCGCTCACACATGG. Sequence Listing <110> Vermenischer GmbH <120> Method for producing terpene compounds by biocatalysis <130> 10940 / WO <160> 83 <170> PatentIn version 3.5 <210> 1 <211> 936 <212> DNA <213> Talaromyces verruculosus <220> <221> CDS <222> (1)..(936) <400> 1 atg agc aat gac acg acg acc acc gcg agc gcc ggt act gca act tct 48 Met Ser Asn Asp Thr Thr Thr Thr Ala Ser Ala Gly Thr Ala Thr Ser 1 5 10 15 agc cgt ttt ctg agc gtc ggc ggc gtt gtg aat ttt cgc gag ctg ggt 96 Ser Arg Phe Leu Ser Val Gly Gly Val Val Asn Phe Arg Glu Leu Gly 20 25 30 ggc tat cca tgc gac agc gtg ccg ccg gct ccg gca agc aac ggt tcg 144 Gly Tyr Pro Cys Asp Ser Val Pro Pro Ala Pro Ala Ser Asn Gly Ser 35 40 45 cct gat aat gcg tcc gag gca acg ctg tgg gtt ggt cac tcc agc att 192 Pro Asp Asn Ala Ser Glu Ala Thr Leu Trp Val Gly His Ser Ser Ile 50 55 60 cgt ccg ggt ttc ctg ttc cgc agc gcg cag ccg agc cag att acg ccg 240 Arg Pro Gly Phe Leu Phe Arg Ser Ala Gln Pro Ser Gln Ile Thr Pro 65 70 75 80 gcg ggt atc gaa acg ctg atc cgc caa ctg ggc atc cag acc att ttt 288 Ala Gly Ile Glu Thr Leu Ile Arg Gln Leu Gly Ile Gln Thr Ile Phe 85 90 95 gat ttc cgt agc cgt acc gag atc gaa ctg gtg gcg acc cgt tac ccg 336 Asp Phe Arg Ser Arg Thr Glu Ile Glu Leu Val Ala Thr Arg Tyr Pro 100 105 110 gac tct ctg ttg gaa att ccg ggc acc acg cgc tat tcc gtc ccg gtt 384 Asp Ser Leu Leu Glu Ile Pro Gly Thr Thr Arg Tyr Ser Val Pro Val 115 120 125 ttc tcc gag ggt gac tat tct ccg gcg agc ctg gtg aag cgc tat ggt 432 Phe Ser Glu Gly Asp Tyr Ser Pro Ala Ser Leu Val Lys Arg Tyr Gly 130 135 140 gtt agc agc gat acc gcc acg gac agc acc tct agc aag agc gcg aag 480 Val Ser Ser Asp Thr Ala Thr Asp Ser Thr Ser Ser Lys Ser Ala Lys 145 150 155 160 ccg acc ggc ttc gtt cat gca tac gaa gcc that gcg cgc agc gcc gct 528 Pro Thr Gly Phe Val His Ala Tyr Glu Ala Ile Ala Arg Ser Ala Ala 165 170 175 gag aac ggt agc ttc cgt aaa att acc gac cac atc atc cag cat cct 576 Glu Asn Gly Ser Phe Arg Lys Ile Thr Asp His Ile Ile Gln His Pro 180 185 190 gat cgt cca att ttg ttc cac tgt acc ctg ggt aaa gac cgt acg ggt 624 Asp Arg Pro Ile Leu Phe His Cys Thr Leu Gly Lys Asp Arg Thr Gly 195 200 205 gtc ttt gcg gcg ctg ttg ctg agc ctg tgt ggt gtg ccg gac gaa acc 672 Val Phe Ala Ala Leu Leu Leu Ser Leu Cys Gly Val Pro Asp Glu Thr 210 215 220 atc gtc gaa gat tac gcg atg acc acc gaa ggc ttt ggt gca tgg cgt 720 Ile Val Glu Asp Tyr Ala Met Thr Thr Glu Gly Phe Gly Ala Trp Arg 225 230 235 240 gag cac ctg atc caa cgt ctg ctg caa cgt aaa gac gct gca acc cgt 768 Glu His Leu Ile Gln Arg Leu Leu Gln Arg Lys Asp Ala Ala Thr Arg 245 250 255 gaa gat gcc gag agc atc att gcg tcg ccg ccg gag act atg aaa gca 816 Glu Asp Ala Glu Ser Ile Ile Ala Ser Pro Pro Glu Thr Met Lys Ala 260 265 270 ttt ctg gaa gat gtt gtg gca gcg aaa ttt ggt ggc gcg cgt aac tac 864 Phe Leu Glu Asp Val Val Ala Ala Lys Phe Gly Gly Ala Arg Asn Tyr 275 280 285 ttc att caa cat tgc ggc ttc act gaa gct gaa gtc gat aag ctg agc 912 Phe Ile Gln His Cys Gly Phe Thr Glu Ala Glu Val Asp Lys Leu Ser 290 295 300 cac acc ctg gcg atc acg aac taa 936 His Thr Leu Ala Ile Thr Asn 305 310 <210> 2 <211> 311 <212> PRT <213> Talaromyces verruculosus <400> 2 Met Ser Asn Asp Thr Thr Thr Thr Ala Ser Ala Gly Thr Ala Thr Ser 1 5 10 15 Ser Arg Phe Leu Ser Val Gly Gly Val Val Asn Phe Arg Glu Leu Gly 20 25 30 Gly Tyr Pro Cys Asp Ser Val Pro Pro Ala Pro Ala Ser Asn Gly Ser 35 40 45 Pro Asp Asn Ala Ser Glu Ala Thr Leu Trp Val Gly His Ser Ser Ile 50 55 60 Arg Pro Gly Phe Leu Phe Arg Ser Ala Gln Pro Ser Gln Ile Thr Pro 65 70 75 80 Ala Gly Ile Glu Thr Leu Ile Arg Gln Leu Gly Ile Gln Thr Ile Phe 85 90 95 Asp Phe Arg Ser Arg Thr Glu Ile Glu Leu Val Ala Thr Arg Tyr Pro 100 105 110 Asp Ser Leu Leu Glu Ile Pro Gly Thr Thr Arg Tyr Ser Val Pro Val 115 120 125 Phe Ser Glu Gly Asp Tyr Ser Pro Ala Ser Leu Val Lys Arg Tyr Gly 130 135 140 Val Ser Ser Asp Thr Ala Thr Asp Ser Thr Ser Ser Lys Ser Ala Lys 145 150 155 160 Pro Thr Gly Phe Val His Ala Tyr Glu Ala Ile Ala Arg Ser Ala Ala 165 170 175 Glu Asn Gly Ser Phe Arg Lys Ile Thr Asp His Ile Ile Gln His Pro 180 185 190 Asp Arg Pro Ile Leu Phe His Cys Thr Leu Gly Lys Asp Arg Thr Gly 195 200 205 Val Phe Ala Ala Leu Leu Leu Ser Leu Cys Gly Val Pro Asp Glu Thr 210 215 220 Ile Val Glu Asp Tyr Ala Met Thr Thr Glu Gly Phe Gly Ala Trp Arg 225 230 235 240 Glu His Leu Ile Gln Arg Leu Leu Gln Arg Lys Asp Ala Ala Thr Arg 245 250 255 Glu Asp Ala Glu Ser Ile Ile Ala Ser Pro Pro Glu Thr Met Lys Ala 260 265 270 Phe Leu Glu Asp Val Val Ala Ala Lys Phe Gly Gly Ala Arg Asn Tyr 275 280 285 Phe Ile Gln His Cys Gly Phe Thr Glu Ala Glu Val Asp Lys Leu Ser 290 295 300 His Thr Leu Ala Ile Thr Asn 305 310 <210> 3 <211> 936 <212> DNA <213> Talaromyces verruculosus <400> 3 atgtctaatg acaccactac cacggcttct gccggaacag caacttcttc gcggtttctt 60 tccgtggggg gagttgtgaa cttccgtgaa ctgggcggtt acccatgtga ttctgtccct 120 cctgctcctg cctcaaacgg ctcaccggac aatgcatctg aagcgaccct ttgggttggc 180 cactcgtcca ttcggcctgg atttctgttt cgatcggcac agccgtctca gattaccccg 240 gccggtattg agacattgat ccgccagctt ggcatccaga caatttttga ctttcgttca 300 aggacggaaa ttgagcttgt tgccactcgc tatcctgatt cgctacttga gatacctggc 360 acgactcgct attccgtgcc cgtcttctcg gaaggcgact attccccagc gtcattagtc 420 aagaggtacg gagtgtcctc cgatactgca accgattcca cttcctccaa aagtgctaag 480 cctacaggat tcgtccacgc atatgaggct atcgcacgca gtgcagcaga aaacggcagt 540 tttcgtaaga taacggacca cataatacaa catccggacc ggcctattct gtttcactgt 600 acactgggga aagaccgaac cggtgtgttt gcagcattgt tattgagtct ttgcggggta 660 ccagacgaga cgatagttga agactatgct atgactaccg agggatttgg agcctggcgg 720 gaacatctaa ttcaacgctt gctacaaagg aaggatgcag ctacgcgcga ggatgcagaa 780 tccattattg ccagcccccc ggagactatg aaggcttttc tagaagatgt ggtagcagcc 840 aagttcgggg gtgctcgaaa ttactttatc cagcactgtg gatttacgga agctgaggtt 900 gataagttaa gccatacact ggccattacg aattga 936 <210> 4 <211> 961 <212> DNA <213> Talaromyces verruculosus <400> 4 ggtaccaagg aggtaaaaaa tgagcaatga cacgacgacc accgcgagcg ccggtactgc 60 aacttctagc cgttttctga gcgtcggcgg cgttgtgaat tttcgcgagc tgggtggcta 120 tccatgcgac agcgtgccgc cggctccggc aagcaacggt tcgcctgata atgcgtccga 180 ggcaacgctg tgggttggtc actccagcat tcgtccgggt ttcctgttcc gcagcgcgca 240 gccgagccag attacgccgg cgggtatcga aacgctgatc cgccaactgg gcatccagac 300 catttttgat ttccgtagcc gtaccgagat cgaactggtg gcgacccgtt acccggactc 360 tctgttggaa attccgggca ccacgcgcta ttccgtcccg gttttctccg agggtgacta 420 ttctccggcg agcctggtga agcgctatgg tgttagcagc gataccgcca cggacagcac 480 ctctagcaag agcgcgaagc cgaccggctt cgttcatgca tacgaagcca ttgcgcgcag 540 cgccgctgag aacggtagct tccgtaaaat taccgaccac atcatccagc atcctgatcg 600 tccaattttg ttccactgta ccctgggtaa agaccgtacg ggtgtctttg cggcgctgtt 660 gctgagcctg tgtggtgtgc cggacgaaac catcgtcgaa gattacgcga tgaccaccga 720 aggctttggt gcatggcgtg agcacctgat ccaacgtctg ctgcaacgta aagacgctgc 780 aacccgtgaa gatgccgaga gcatcattgc gtcgccgccg gagactatga aagcatttct 840 ggaagatgtt gtggcagcga aatttggtgg cgcgcgtaac tacttcattc aacattgcgg 900 cttcactgaa gctgaagtcg ataagctgag ccacaccctg gcgatcacga actaactcga 960 g 961 <210> 5 <211> 852 <212> DNA <213> Aspergillus wentii <220> <221> CDS <222> (1)..(852) <400> 5 atg gcg tct gtc cct gct cca ccg ttt gtt cat gtt gaa ggt atg tct 48 Met Ala Ser Val Pro Ala Pro Pro Phe Val His Val Glu Gly Met Ser 1 5 10 15 aat ttt cgt agc atc ggt ggc tac ccg ctg gag act gcc tcc acg aat 96 Asn Phe Arg Ser Ile Gly Gly Tyr Pro Leu Glu Thr Ala Ser Thr Asn 20 25 30 aac cat cgc tcg acc cgt caa ggc ttc gcg ttt cgt agc gcg gac ccg 144 Asn His Arg Ser Thr Arg Gln Gly Phe Ala Phe Arg Ser Ala Asp Pro 35 40 45 acg tat gtg acg cag aaa ggc ctg gaa acc att ctg tcc ctg gat att 192 Thr Tyr Val Thr Gln Lys Gly Leu Glu Thr Ile Leu Ser Leu Asp Ile 50 55 60 acc cgc gca ttt gac ttg cgt agc ttg gaa gaa gca aag gca caa cgt 240 Thr Arg Ala Phe Asp Leu Arg Ser Leu Glu Glu Ala Lys Ala Gln Arg 65 70 75 80 gcg aag ttg cag gcc gcg agc ggt tgt ctg gat tgc agc that agc caa 288 Ala Lys Leu Gln Ala Ala Ser Gly Cys Leu Asp Cys Ser Ile Ser Gln 85 90 95 cac atg atc cac caa ccg acc ccg ctg ttc ccg gat ggt gac tgg tcc 336 His Met Ile His Gln Pro Thr Pro Leu Phe Pro Asp Gly Asp Trp Ser 100 105 110 ccg gaa gcg gcg ggt gag cgc tac ttg cag tac gca caa gct gag ggt 384 Pro Glu Ala Ala Gly Glu Arg Tyr Leu Gln Tyr Ala Gln Ala Glu Gly 115 120 125 gat ggt atc agc ggt tat gtc gaa gtt tat ggt aat atg ctg gaa gag 432 Asp Gly Ile Ser Gly Tyr Val Glu Val Tyr Gly Asn Met Leu Glu Glu 130 135 140 ggc tgg atg gcg atc cgt gag att ctg ctg cac gtc cgt gac cgc ccg 480 Gly Trp Met Ala Ile Arg Glu Ile Leu Leu His Val Arg Asp Arg Pro 145 150 155 160 acc gaa gca ttc ctg tgc cac tgt tcc gcc ggt aaa gat cgt acg ggt 528 Thr Glu Ala Phe Leu Cys His Cys Ser Ala Gly Lys Asp Arg Thr Gly 165 170 175 atc gtg to gct gtt ctg ctc aaa gtc gcg ggt tgc agc gac gac ctg 576 Ile Val Ile Ala Val Leu Leu Lys Val Ala Gly Cys Ser Asp Asp Leu 180 185 190 gtg tgt cgt gag tac gaa ctg acc gag att ggc ctg gcg cgc cgt aga 624 Val Cys Arg Glu Tyr Glu Leu Thr Glu Ile Gly Leu Ala Arg Arg Arg 195 200 205 gag ttc atc gtt cag cat ctg ctg aag aaa ccg gaa atg aac ggc agc 672 Glu Phe Ile Val Gln His Leu Leu Lys Lys Pro Glu Met Asn Gly Ser 210 215 220 cgt gag ctg gcg gag cgc gtc gca ggc gcc cgt tac gag aac atg aaa 720 Arg Glu Leu Ala Glu Arg Val Ala Gly Ala Arg Tyr Glu Asn Met Lys 225 230 235 240 gaa acc ctg gaa atg gtg cag acc cgt tac cgc ggc atg cgc ggc tat 768 Glu Thr Leu Glu Met Val Gln Thr Arg Tyr Arg Gly Met Arg Gly Tyr 245 250 255 tgc aaa gaa atc ​​tgc ggt ctg acc gac gaa gat ctg agc att atc cag 816 Cys Lys Glu Ile Cys Gly Leu Thr Asp Glu Asp Leu Ser Ile Ile Gln 260 265 270 ggt aac ctg acg agc ccg gag agc ccg att ttc taa 852 Gly Asn Leu Thr Ser Pro Glu Ser Pro Ile Phe 275 280 <210> 6 <211> 283 <212> PRT <213> Aspergillus wentii <400> 6 Met Ala Ser Val Pro Ala Pro Pro Phe Val His Val Glu Gly Met Ser 1 5 10 15 Asn Phe Arg Ser Ile Gly Gly Tyr Pro Leu Glu Thr Ala Ser Thr Asn 20 25 30 Asn His Arg Ser Thr Arg Gln Gly Phe Ala Phe Arg Ser Ala Asp Pro 35 40 45 Thr Tyr Val Thr Gln Lys Gly Leu Glu Thr Ile Leu Ser Leu Asp Ile 50 55 60 Thr Arg Ala Phe Asp Leu Arg Ser Leu Glu Glu Ala Lys Ala Gln Arg 65 70 75 80 Ala Lys Leu Gln Ala Ala Ser Gly Cys Leu Asp Cys Ser Ile Ser Gln 85 90 95 His Met Ile His Gln Pro Thr Pro Leu Phe Pro Asp Gly Asp Trp Ser 100 105 110 Pro Glu Ala Ala Gly Glu Arg Tyr Leu Gln Tyr Ala Gln Ala Glu Gly 115 120 125 Asp Gly Ile Ser Gly Tyr Val Glu Val Tyr Gly Asn Met Leu Glu Glu 130 135 140 Gly Trp Met Ala Ile Arg Glu Ile Leu Leu His Val Arg Asp Arg Pro 145 150 155 160 Thr Glu Ala Phe Leu Cys His Cys Ser Ala Gly Lys Asp Arg Thr Gly 165 170 175 Ile Val Ile Ala Val Leu Leu Lys Val Ala Gly Cys Ser Asp Asp Leu 180 185 190 Val Cys Arg Glu Tyr Glu Leu Thr Glu Ile Gly Leu Ala Arg Arg Arg 195 200 205 Glu Phe Ile Val Gln His Leu Leu Lys Lys Pro Glu Met Asn Gly Ser 210 215 220 Arg Glu Leu Ala Glu Arg Val Ala Gly Ala Arg Tyr Glu Asn Met Lys 225 230 235 240 Glu Thr Leu Glu Met Val Gln Thr Arg Tyr Arg Gly Met Arg Gly Tyr 245 250 255 Cys Lys Glu Ile Cys Gly Leu Thr Asp Glu Asp Leu Ser Ile Ile Gln ​​​​​​​​​​​​​​​​​​​​ttcgcatttc gcagtgccga tccaacctac gtcacccaga aaggcctgga aaccatcctt 180 tcgctcgaca tcactcgagc ctttgacctc cgctcactgg aagaagcaaa ggcacagcgc 240 gcaaaactcc aggccgcctc aggatgtctc gactgcagca tcagccagca catgatccac 300 cagcccacac ccctatttcc agatggggac tggagtccag aggccgcagg ggagcggtat 360 ctgcagtacg cccaggctga gggagatggg atacgggct acgtggaggt ctacggaaac 420 atgctcgagg aaggttggat ggcgattcgc gagattctgc ttcatgtccg ggaccggcct 480 acagaggcgt ttctatgcca ttgtagtgca gggaaagatc gtacggggat tgtcattgcg 540 gttttgttga aggttgcagg gtgctcggat gatcttgtgt gcagagagta tgagttgacc 600 gagatcgggt tggctcgacg gagggagttt atcgtgcagc atctgcttaa gaagccggaa 660 atgaatggat cgagggaact ggccgaaaga gtggcggggg ccaggtatga gaatatgaag 720 gaaacgctgg agatggtgca aactagatat agagggatga ggggctattg caaggagatt 780 tgcggcttga ccgacgaaga tctatctatt atccagggga acttgactag tccggagagt 840 cctatcttct aa 852 <210> 8 <211> 877 <212> DNA <213> Aspergillus wentii <400> 8 ggtaccaagg aggtaaaaaa tggcgtctgt ccctgctcca ccgtttgttc atgttgaagg 60 tatgtctaat tttcgtagca tcggtggcta cccgctggag actgcctcca cgaataacca 120 tcgctcgacc cgtcaaggct tcgcgtttcg tagcgcggac ccgacgtatg tgacgcagaa 180 aggcctggaa accattctgt ccctggatat tacccgcgca tttgacttgc gtagcttgga 240 agaagcaaag gcacaacgtg cgaagttgca ggccgcgagc ggttgtctgg attgcagcat 300 tagccaacac atgatccacc aaccgacccc gctgttcccg gatggtgact ggtccccgga 360 agcggcgggt gagcgctact tgcagtacgc acaagctgag ggtgatggta tcagcggtta 420 tgtcgaagtt tatggtaata tgctggaaga gggctggatg gcgatccgtg agattctgct 480 gcacgtccgt gaccgcccga ccgaagcatt cctgtgccac tgttccgccg gtaaagatcg 540 tacgggtatc gtgattgctg ttctgctcaa agtcgcgggt tgcagcgacg acctggtgtg 600<000214tcgtgagtac gaactgaccg agattggcct ggcgcgccgt agagagttca tcgttcagca 660 tctgctgaag aaaccggaaa tgaacggcag ccgtgagctg gcggagcgcg tcgcaggcgc 720 ccgttacgag aacatgaaag aaaccctgga aatggtgcag acccgttacc gcggcatgcg 780 cggctattgc aaagaaatct gcggtctgac cgacgaagat ctgagcatta tccagggtaa 840 cctgacgagc ccggagagcc cgattttcta actcgag 877 <210> 9 <211> 828 <212> DNA <213> Helicocarpus griseus <220> <221> CDS <222> (1)..(828) <400> 9 atg gca tcc cca cca ggt cat ccg ttc gtt caa gtt gaa ggc gtt aat 48 Met Ala Ser Pro Pro Gly His Pro Phe Val Gln Val Glu Gly Val Asn 1 5 10 15 aat ttt cgc tct gtg ggt ggc tat ccg att acg cct agc agc gat gcg 96 Asn Phe Arg Ser Val Gly Gly Tyr Pro Ile Thr Pro Ser Ser Asp Ala 20 25 30 cgc ttc acg cgt gac aac ttt atc tac cgt agc gct gat ccg tgt tac 144 Arg Phe Thr Arg Asp Asn Phe Ile Tyr Arg Ser Ala Asp Pro Cys Tyr 35 40 45 att act ccg gaa ggc cgt agc aag att cgc agc ctg ggt atc acc acc 192 Ile Thr Pro Glu Gly Arg Ser Lys Ile Arg Ser Leu Gly Ile Thr Thr 50 55 60 gtg ttc gat ctg cgt agc cag ccg gag gtt gac aag caa ctg gcg aaa 240 Val Phe Asp Leu Arg Ser Gln Pro Glu Val Asp Lys Gln Leu Ala Lys 65 70 75 80 gac ccg agc agc ggt gtg ccg att gcg gat ggt gtc att cgt cgc ttc 288 Asp Pro Ser Ser Gly Val Pro Ile Ala Asp Gly Val Ile Arg Arg Phe 85 90 95 acc ccg gtt ttt agc cgc gag gat tgg ggt ccg gaa gca tcc gcg gtt 336 Thr Pro Val Phe Ser Arg Glu Asp Trp Gly Pro Glu Ala Ser Ala Val 100 105 110 cgt cac aac ctg tat gca gac gcg tcc ggt gct agc ggt tac gtc gat 384 Arg His Asn Leu Tyr Ala Asp Ala Ser Gly Ala Ser Gly Tyr Val Asp 115 120 125 gtg tac gcg gat atc ctg gaa aac ggt ggc gca gcg ttc cgt gag atc 432 Val Tyr Ala Asp Ile Leu Glu Asn Gly Gly Ala Ala Phe Arg Glu Ile 130 135 140 ctg ctg cac gtg cgt gac cgt ccg ggt gac gct ctg ttg tgc cac tgc 480 Leu Leu His Val Arg Asp Arg Pro Gly Asp Ala Leu Leu Cys His Cys 145 150 155 160 tcc gca gc aaa gac cgt acc ggc gtt gcg att gcg atc ctg ctc aaa 528 Ser Alpha Gly Lys Asp Arg Thr Gly Val Allele Ile Allele Leu Leu Lys 165 170 175 ctg gcc ggt tgc gaga gat gag tgc att tcg aaa gag tat gaa ctg acc 576 Leu Ala Gly Cys Glu Asp Glu Cys Ile Ser Lys Glu Tyr Glu Leu Thr 180 185 190 gag gtc ggt ctg gcc agc cgt aaa gaa ttt atc gag tac ctg att 624 Glu Val Gly Leu Can Be Arg Lys Glu Phe Ile Ile Glu Tyr Leu Ile 195 200 205 aag caa cct gag ctg gaa ggc gac cgt gcg aaa gcc gag aaa att gct 672 Lys Gln Pro Glu Leu Glu Gly Asp Arg Ala Lys Ala Glu Lys Ile Ala 210 215 220 ggc gcg aaa tac gaa aac atg ttg ggt acg ctg cag atg atg gaa cag 720 Gly Ala Lys Tyr Glu Asn Met Leu Gly Thr Leu Gln Met Met Glu Gln 225 230 235 240 aaa tat ggt ggc gtt gag ggc tac gtg aag gcc tac tgt aag ttg acg 768 Lys Tyr Gly Gly Val Glu Gly Tyr Val Lys Ala Tyr Cys Lys Leu Thr 245 250 255 gat aaa gac atc gca acc atc cgt cgc aat ctg gtc agc ggt gac aag 816 Asp Lys Asp Ile Ala Thr Ile Arg Arg Asn Leu Val Ser Gly Asp Lys 260 265 270 atg att gcg taa 828 Met Ile Ala 275 <210> 10 <211> 275 <212> PRT <213> Helicocarpus griseus <400> 10 Met Ala Ser Pro Pro Gly His Pro Phe Val Gln Val Glu Gly Val Asn 1 5 10 15 Asn Phe Arg Ser Val Gly Gly Tyr Pro Ile Thr Pro Ser Ser Asp Ala 20 25 30 Arg Phe Thr Arg Asp Asn Phe Ile Tyr Arg Ser Ala Asp Pro Cys Tyr 35 40 45 Ile Thr Pro Glu Gly Arg Ser Lys Ile Arg Ser Leu Gly Ile Thr Thr 50 55 60 Val Phe Asp Leu Arg Ser Gln Pro Glu Val Asp Lys Gln Leu Ala Lys 65 70 75 80 Asp Pro Ser Ser Gly Val Pro Ile Ala Asp Gly Val Ile Arg Arg Phe 85 90 95 Thr Pro Val Phe Ser Arg Glu Asp Trp Gly Pro Glu Ala Ser Ala Val 100 105 110 Arg His Asn Leu Tyr Ala Asp Ala Ser Gly Ala Ser Gly Tyr Val Asp 115 120 125 Val Tyr Ala Asp Ile Leu Glu Asn Gly Gly Ala Ala Phe Arg Glu Ile 130 135 140 Leu Leu His Val Arg Asp Arg Pro Gly Asp Ala Leu Leu Cys His Cys 145 150 155 160 Ser Ala Gly Lys Asp Arg Thr Gly Val Ala Ile Ala Ile Leu Leu Lys 165 170 175 Leu Ala Gly Cys Glu Asp Glu Cys Ile Ser Lys Glu Tyr Glu Leu Thr 180 185 190 Glu Val Gly Leu Ala Ser Arg Lys Glu Phe Ile Ile Glu Tyr Leu Ile 195 200 205 Lys Gln Pro Glu Leu Glu Gly Asp Arg Ala Lys Ala Glu Lys Ile Ala 210 215 220 Gly Ala Lys Tyr Glu Asn Met Leu Gly Thr Leu Gln Met Met Glu Gln 225 230 235 240 Lys Tyr Gly Gly Val Glu Gly Tyr Val Lys Ala Tyr Cys Lys Leu Thr 245 250 255 Asp Lys Asp Ile Ala Thr Ile Arg Arg Asn Leu Val Ser Gly Asp Lys 260 265 270 Met Ile Ala 275 <210> 11 <211> 828 <212> DNA <213> Helicocarpus griseus <400> 11 atggcatcac ccccagggca ccctttcgtg caagttgaag gcgtcaacaa cttccgctct 60 gtaggaggat atcccatcac cccatcctcc gacgcacgct tcacacgaga taacttcatc 120 tatcgcagcg ccgacccgtg ttacatcacg cccgaaggac gctccaaaat ccgctcactc 180 ggaatcacga ctgtttttga tctgcgctcc cagccagagg ttgacaagca gcttgccaaa 240 gacccttcct caggggttcc aatcgccgac ggcgtcatta gacgttttac gccggtattt 300 tcccgagagg attggggtcc ggaagcttcc gccgtccgcc ataatctgta tgctgatgcc 360 tctggggctt ctgggtacgt cgatgtgtat gccgacattc tggagaatgg aggggcggca 420 ttccgcgaga tcttgttgca cgtaagagac cggcctggtg atgcgctgct atgtcattgt 480 agtgccggaa aagatcgtac cggcgtggcg atagcgatac tgctcaagct tgcggggtgc 540 gaggatgaat gtatctcaaa ggagtacgag ctgaccgagg ttggtctagc ctcaagaaag 600 gagttcatta tagagtacct catcaagcag ccggaactag agggggatag agcaaaagct 660 gaaaaaattg cgggagccaa atatgagaac atgttaggga ccttgcaaat gatggaacag 720 aaatacgggg gtgttgaggg gtacgtgaaa gcgtattgca agttgacgga taaagatatt 780 gctacgatac gcaggaatct cgtctcaggt gacaaaatga ttgcctag 828 <210> 12 <211> 807 <212> DNA <213> Umbilicaria pustulata <220> <221> CDS <222> (1)..(807) <400> 12 atg tcc ctg ctg cct agc cca ccg ttt gtt cca gtt gaa ggt att cac 48 Met Ser Leu Leu Pro Ser Pro Pro Phe Val Pro Val Glu Gly Ile His 1 5 10 15 aat ttt cgc gat ctg ggc ggc tat ccg gtt agc acc agc ccg agc aag 96 Asn Phe Arg Asp Leu Gly Gly Tyr Pro Val Ser Thr Ser Pro Ser Lys 20 25 30 acc att cgt cgc aat atc atc ttt cgt tgt gcc gaa ccg tcg aaa atc ​​144 Thr Ile Arg Arg Asn Ile Ile Phe Arg Cys Ala Glu Pro Ser Lys Ile 35 40 45 acc ccg aac ggc att caa acg ctg cag agc ctg ggt gtg gcg acg ttc 192 Thr Pro Asn Gly Ile Gln Thr Leu Gln Ser Leu Gly Val Ala Thr Phe 50 55 60 ttt gac ctc cgt agc ggt ccg gaa atc ​​gag aaa atg aaa gcg cat gca 240 Phe Asp Leu Arg Ser Gly Pro Glu Ile Glu Lys Met Lys Ala His Ala 65 70 75 80 ccg gtc gtt gag atc aag ggt att gag cgt gtt ttc gtg ccg gtg ttc 288 Pro Val Val Glu Ile Lys Gly Ile Glu Arg Val Phe Val Pro Val Phe 85 90 95 gcg gat ggt gat tat agc ccg gaa caa att gcg ctg cgt tac aaa gac 336 Only Asp Gly Asp Tyr Ser Pro Glu Gln Ile Only Only Leu Arg Tyr Lys Asp 100 105 110 tat gcg tcc tct ggc act ggt ggc ttc acc cgt gcg tac cac gac att 384 Tyr Ala Ser Ser Gly Thr Gly Phe Thr Arg Ala Tyr His Asp Ile 115 120 125 ctg cgt tct gcc cct ccg agc tat cgt cgt atc ctg ctg cac ctg gca 432 Leu Arg Ser Wing Pro Ser Tyr Arg Arg 130 135 140 gag aag ccg aac cag ccg tgc gtg atc cac tgt acc gct gcc aaa gac 480 Glu Lys Pro Asn Gln Pro Cys Val Ile His Cys Thr Ala Gly Lys Asp 145 150 155 160 cgc acg ggt gtt ctg gca gcg ctg att ctg gaa ctg gcg ggt gtc gat 528 Arg Thr Gly Val Leu Ala Ala Leu Ile Leu Glu Leu Ala Gly Val Asp 165 170 175 caa gac acc atc gcg cat gag tac gcc ctg acc gag ctg ggc ctg aag 576 Gln Asp Thr Ile Ala His Glu Tyr Ala Leu Thr Glu Leu Gly Leu Lys 180 185 190 gca tgg cgt ccg acg gtt gtc gag cac tta ctg cag aat ccg gcg ctg 624 Ala Trp Arg Pro Thr Val Val Glu His Leu Leu Gln Asn Pro Ala Leu 195 200 205 gaa ggc aat cgc gag ggt gca ttg aat atg gtc agc gct cgt gcg gag 672 Glu Gly Asn Arg Glu Gly Ala Leu Asn Met Val Ser Ala Arg Ala Glu 210 215 220 aac atg ctg gcc gcc ttg gaa atg att cgc gag atc tac ggt ggt gct 720 Asn Met Leu Ala Ala Leu Glu Met Ile Arg Glu Ile Tyr Gly Gly Ala 225 230 235 240 gag gcg tac gtg aaa gaa aag tgc ggt ctg agc gac gaa gat att gca 768 Glu Ala Tyr Val Lys Glu Lys Cys Gly Leu Ser Asp Glu Asp Ile Ala 245 250 255 cgc att cgc cag aac att ttg cat acg ccg agc ccg taa 807 Arg Ile Arg Gln Asn Ile Leu His Thr Pro Ser Pro 260 265 <210> 13 <211> 268 <212> PRT <213> Umbilicaria pustulata <400> 13 Met Ser Leu Leu Pro Ser Pro Pro Phe Val Pro Val Glu Gly Ile His 1 5 10 15 Asn Phe Arg Asp Leu Gly Gly Tyr Pro Val Ser Thr Ser Pro Ser Lys 20 25 30 Thr Ile Arg Arg Asn Ile Ile Phe Arg Cys Ala Glu Pro Ser Lys Ile 35 40 45 Thr Pro Asn Gly Ile Gln Thr Leu Gln Ser Leu Gly Val Ala Thr Phe 50 55 60 Phe Asp Leu Arg Ser Gly Pro Glu Ile Glu Lys Met Lys Ala His Ala 65 70 75 80 Pro Val Val Glu Ile Lys Gly Ile Glu Arg Val Phe Val Pro Val Phe 85 90 95 Ala Asp Gly Asp Tyr Ser Pro Glu Gln Ile Ala Leu Arg Tyr Lys Asp 100 105 110 Tyr Ala Ser Ser Gly Thr Gly Gly Phe Thr Arg Ala Tyr His Asp Ile 115 120 125 Leu Arg Ser Ala Pro Pro Ser Tyr Arg Arg Ile Leu Leu His Leu Ala 130 135 140 Glu Lys Pro Asn Gln Pro Cys Val Ile His Cys Thr Ala Gly Lys Asp 145 150 155 160 Arg Thr Gly Val Leu Ala Ala Leu Ile Leu Glu Leu Ala Gly Val Asp 165 170 175 Gln Asp Thr Ile Ala His Glu Tyr Ala Leu Thr Glu Leu Gly Leu Lys 180 185 190 Ala Trp Arg Pro Thr Val Val Glu His Leu Leu Gln Asn Pro Ala Leu 195 200 205 Glu Gly Asn Arg Glu Gly Ala Leu Asn Met Val Ser Ala Arg Ala Glu 210 215 220 Asn Met Leu Ala Ala Leu Glu Met Ile Arg Glu Ile Tyr Gly Gly Ala 225 230 235 240 Glu Ala Tyr Val Lys Glu Lys Cys Gly Leu Ser Asp Glu Asp Ile Ala 245 250 255 Arg Ile Arg Gln Asn Ile Leu His Thr Pro Ser Pro 260 265 <210> 14 <211> 807 <212> DNA <213> Umbilicaria pustulata <400> 14 atgtctctgc taccgtcacc tcccttcgta cccgttgagg gtatccacaa cttccgggac 60 ctaggcggct accccgtctc gacttcccct tccaagacca tacgtcgcaa catcatcttt 120 cgctgcgccg aaccctcgaa aatcactccc aatggcatcc agacgctcca atctttgggc 180 gtcgctacgt tcttcgacct ccgctccggc ccggaaatcg agaagatgaa agcacatgca 240 cctgtcgtcg agattaaggg catcgagcgt gtgttcgttc ccgtcttcgc cgacggggat 300 tactcgcccg aacaaatcgc tctgcgatac aaagactacg cttccagcgg aacggggggt 360 tttaccaggg cgtaccatga tatcctccga agtgcccctc cgagctatcg gcgcatacta 420 ttacatctgg cggagaagcc caaccagcca tgcgtcattc attgcacggc cgggaaagat 480 aggacgggcg tattggcggc gttgatactc gagttggccg gggttgatca ggatacaatt 540 gcgcacgagt acgcattgac ggaactgggg ttgaaggcct ggcgtcccac tgtggtggag 600 cacctcttgc agaatccagc gttggaggga aatcgggaag gggcattgaa catggtcagc 660 gcgagggcag agaacatgct ggcagccttg gagatgatcc gggagatcta tggcggcgcc 720 gaagcatatg tgaaggagaa gtgtggcctc agcgacgaag acattgcgcg gatacggcag 780 aatattctac acacgccatc tccgtga 807 <210> 15<00​​​​​​​​​​​​​​​​​​​​​​​​​ ggt ggc tat ccg att acc gat ctg ctg agc acc cgt cgc aat ttc gtt 144 Gly Gly Tyr Pro Ile Thr Asp Leu Leu Ser Thr Arg Arg Asn Phe Val 35 40 45 tat cgc tcc gca gtt cct acc cgc atc acc cca acg ggc ctg cag acg 192 Tyr Arg Ser Ala Val Pro Thr Arg Ile Thr Pro Thr Gly Leu Gln Thr 50 55 60 ctg acc caa gat ctg cag att acg acg gtc tac gac tta cgt tcg aat 240 Leu Thr Gln Asp Leu Gln Ile Thr Thr Val Tyr Asp Leu Arg Ser Asn 65 70 75 80 gct gag ctg cgt aaa gat cct atc gcg agc agc ccg ttg gac acc cac 288 Ala Glu Leu Arg Lys Asp Pro Ile Ala Ser Ser Pro Leu Asp Thr His 85 90 95 gac agc gtg act gtc ctg cat acc ccg gtt ttc ccg gag cgc gat tct 336 Asp Ser Val Thr Val Leu His Thr Pro Val Phe Pro Glu Arg Asp Ser 100 105 110 agc ccg gaa cag ctg gca aag cgt ttt gcc aac tat atg agc gcg aac 384 Ser Pro Glu Gln Leu Alpha Lys Arg Phe Alone Asn Tyr Met Ser Al Asn 115 120 125 ggt tcc gag ggt ttc gtt gcg gcg tac gca gag att ctg cgt gat ggt 432 Gly Ser Glu Gly Phe Val Ala Ala Tyr Ala Glu Ile Leu Arg Asp Gly 130 135 140 gtg gat gcc tac cgc aag gtt ttt gaa cac gtg cgt gac cgt ccg cgt 480 Val Asp Ala Tyr Arg Lys Val Phe Glu His Val Arg Asp Arg Pro Arg 145 150 155 160 gat gcg ttt ctg gtg cac tgc acc ggt ggc aaa gac cgt acg ggt gtg 528 Asp Ala Phe Leu Val His Cys Thr Gly Gly Lys Asp Arg Thr Gly Val 165 170 175 ttg gtt gcg ctg atg ctg ttg gtg gca ggc gtc aaa gac cgt gac gtt 576 Lion Val Wing Lew Met Lion Val Wing Gly Val Lys Asp Arg Asp Val 180 185 190 att gcc gat gag tac agc ctg acg gaa aag ggt ttt gcg gct gtc atc 624 Ile Ala Asp Glu Tyr Ser Leu Thr Glu Lys Gly Phe Ala Ala Val Ile 195 200 205 aaa gcc gat gct gcg gaa aag atc atc aaa gac atg ggt gtt gac ggt 672 Lys Ala Asp Ala Ala Glu Lys Ile Ile Lys Asp Met Gly Val Asp Gly 210 215 220 gcc aat cgt gcg ggc atc gag cgt ctg ttg agc gca cgc aaa gaa aac 720 Ala Asn Arg Ala Gly Ile Glu Arg Leu Leu Ser Ala Arg Lys Glu Asn 225 230 235 240 atg agc gcg acc ctg gag tac att gag aag caa ttt ggt ggc gca gag 768 Met Ser Ala Thr Leu Glu Tyr Ile Glu Lys Gln Phe Gly Gly Ala Glu 245 250 255 ggc tat ctg cgc gac caa ctg ggt ttc ggc gac gaa gat gtg gaa cag 816 Gly Tyr Leu Arg Asp Gln Leu Gly Phe Gly Asp Glu Asp Val Glu Gln 260 265 270 atc cgt aag agc ctg gtc gtt gag gat aaa ggc ctg ttc taa 858 Ile Arg Lys Ser Leu Val Val Glu Asp Lys Gly Leu Phe 275 280 285 <210> 16 <211> 285 <212> PRT <213> Talaromyces verruculosus <400> 16 Met Ser Val Thr Glu His Val Val Glu Ala Ser Thr Pro Ser Thr Leu 1 5 10 15 Pro Pro Pro Phe Ile His Val Asp Gly Val Pro Asn Phe Arg Asp Ile 20 25 30 Gly Gly Tyr Pro Ile Thr Asp Leu Leu Ser Thr Arg Arg Asn Phe Val 35 40 45 Tyr Arg Ser Ala Val Pro Thr Arg Ile Thr Pro Thr Gly Leu Gln Thr 50 55 60 Leu Thr Gln Asp Leu Gln Ile Thr Thr Val Tyr Asp Leu Arg Ser Asn 65 70 75 80 Ala Glu Leu Arg Lys Asp Pro Ile Ala Ser Ser Pro Leu Asp Thr His 85 90 95 Asp Ser Val Thr Val Leu His Thr Pro Val Phe Pro Glu Arg Asp Ser 100 105 110 Ser Pro Glu Gln Leu Ala Lys Arg Phe Ala Asn Tyr Met Ser Ala Asn 115 120 125 Gly Ser Glu Gly Phe Val Ala Ala Tyr Ala Glu Ile Leu Arg Asp Gly 130 135 140 Val Asp Ala Tyr Arg Lys Val Phe Glu His Val Arg Asp Arg Pro Arg 145 150 155 160 Asp Ala Phe Leu Val His Cys Thr Gly Gly Lys Asp Arg Thr Gly Val 165 170 175 Leu Val Ala Leu Met Leu Leu Val Ala Gly Val Lys Asp Arg Asp Val 180 185 190 Ile Ala Asp Glu Tyr Ser Leu Thr Glu Lys Gly Phe Ala Ala Val Ile 195 200 205 Lys Ala Asp Ala Ala Glu Lys Ile Ile Lys Asp Met Gly Val Asp Gly 210 21​​​​​​​​​​​​​​​​​​​​​​​​​​​atgagcgtca cagaacatgt agtcgaagcc tcgacaccat caacccttcc accacccttc 60 atccatgtcg acggcgtccc caacttccgc gacatcggcg gctaccccat cacagactta 120 ctgtcaacac gacgaaactt cgtgtatcgc tccgcagtcc caacacgcat cactcccaca 180 ggtctacaga cactcaccca agacctccaa atcacaacag tctacgacct acgctccaac 240 gctgaactgc gcaaggatcc cattgcctcc agccctctag acacccatga ctctgtaacg 300 gtgctacaca cccccgtctt tcccgaacgg gactcaagtc ccgaacaact cgcaaagagg 360 tttgcgaatt acatgtccgc caacggctcg gaagggtttg tagccgccta cgccgagatt 420 ttgcgtgatg gcgttgatgc ataccgcaag gtgtttgagc atgtccgtga tcggccccgg 480 gatgcgtttt tggtgcattg tactggtggg aaggatagaa cgggtgtcct tgtagcgctc 540 atgttacttg ttgcgggtgt caaggataga gatgtgattg ccgacgagta ctcgttgacg 600 gagaaggggt ttgctgctgt tattaaggcg gatgcggcgg agaagattat aaaggatatg 660 ggagtggatg gggcgaatag ggcgggcatt gagagattgc tgtcggcgag gaaggagaat 720 atgagtgcta cgttggagta tatcgagaaa cagtttggtg gggcggaggg ttatttgagg 780 gatcagttag ggtttggtga tgaggatgtt gagcagatta ggaagagtct tgtcgtggag 840 gataagggtt tattttag 858 <210> 18 <211> 852 <212> DNA <213> Hydnomerulius pinastri <220> <221> CDS <222> (1)..(852) <400> 18 atg act gca acc gac aat ggc tta gaa ccg ctg gac cct gca tac gtt 48 Met Thr Ala Thr Asp Asn Gly Leu Glu Pro Leu Asp Pro Ala Tyr Val 1 5 10 15 gct gat gtg ttg agc cgt ccg ccg ttt gtc cag atc tcc ggc gtg tgt 96 Ala Asp Val Leu Ser Arg Pro Pro Phe Val Gln Ile Ser Gly Val Cys 20 25 30 aac gtc aga gat ctg ggc agc tat ccg acc gct acc ccg aat gtg att 144 Asn Val Arg Asp Leu Gly Ser Tyr Pro Thr Ala Thr Pro Asn Val Ile 35 40 45 acc aag cct ggt tat gca tac cgt ggt gcc gaa gtt tcc aat atc acc 192 Thr Lys Pro Gly Tyr Ala Tyr Arg Gly Ala Glu Val Ser Asn Ile Thr 50 55 60 gaa gag ggc agc caa caa atg aaa gca ctg ggt att acc acg atc ttt 240 Glu Glu Gly Ser Gln Gln Met Lys Ala Leu Gly Ile Thr Thr Ile Phe 65 70 75 80 gat ctg cgt tct gac cca gag atg cag aag tac agc acg ccg att ccg 288 Asp Leu Arg Ser Asp Pro Glu Met Gln Lys Tyr Ser Thr Pro Ile Pro 85 90 95 cat atc gag ggt gtc ctg att ctg cgt acc ccg gtg ttc gcc acc gag 336 His Ile Glu Gly Val Leu Ile Leu Arg Thr Pro Val Phe Ala Thr Glu 100 105 110 gac tat agc ccg gag tcg atg gcg aag cgt ttt gag ctg tac gcg tct 384 Asp Tyr Ser Pro Glu Ser Met Ala Lys Arg Phe Glu Leu Tyr Ala Ser 115 120 125 ggt acg acc gaa gca ttc atg aag ctg tat agc cag att ctg gac cac 432 Gly Thr Thr Glu Ala Phe Met Lys Leu Tyr Ser Gln Ile Leu Asp His 130 135 140 ggc ggc aaa gcg ttc ggt act att ctg cgt cat gtt cgt gac cgc ccg 480 Gly Gly Lys Ala Phe Gly Thr Ile Leu Arg His Val Arg Asp Arg Pro 145 150 155 160 aac agc gtt ttt ctg ttt cac tgc acg gcc ggt aaa gat cgc acg ggc 528 Asn Ser Val Phe Leu Phe His Cys Thr Ala Gly Lys Asp Arg Thr Gly 165 170 175 that that gcg gcc atc ctg ttc aaa ttg gcg ggt gtg gat gat cac ttg 576 Ile Ile Ala Ala Ile Leu Phe Lys Leu Ala Gly Val Asp Asp His Leu 180 185 190 atc tgt cag gac tac agc ctg acg cgc atc ggt cgt gag cca gac cgt 624 Ile Cys Gln Asp Tyr Ser Leu Thr Arg Ile Gly Arg Glu Pro Asp Arg 195 200 205 gaa aaa gtt ctg cgc cgt ctg ctg aat gaa ccg ctg ttc gcg gcg aat 672 Glu Lys Val Leu Arg Arg Leu Leu Asn Glu Pro Leu Phe Ala Ala Asn 210 215 220 acc gag ctt gcg ctg cgc atg ttg acg agc cgc tac gaa acc atg caa 720 Thr Glu Leu Ala Leu Arg Met Leu Thr Ser Arg Tyr Glu Thr Met Gln 225 230 235 240 gcg acc ctg ggt ctg ttg agc gac aaa tat ggc ggt gtg gaa gca tac 768 Ala Thr Leu Gly Leu Leu Ser Asp Lys Tyr Gly Gly Val Glu Ala Tyr 245 250 255 gtc aag aac ttc tgc ggt ctg acc gat aac gac atc agc gtt atc cgt 816 Val Lys Asn Phe Cys Gly Leu Thr Asp Asn Asp Ile Ser Val Ile Arg 260 265 270 acc aac ctg gtt gtg ccg acg aaa gcg cgt atg taa 852 Thr Asn Leu Val Val Pro Thr Lys Ala Arg Met 275 280 <210> 19 <211> 283 <212> PRT <213> Hydnomerulius pinastri <400> 19 Met Thr Ala Thr Asp Asn Gly Leu Glu Pro Leu Asp Pro Ala Tyr Val 1 5 10 15 Ala Asp Val Leu Ser Arg Pro Pro Phe Val Gln Ile Ser Gly Val Cys 20 25 30 Asn Val Arg Asp Leu Gly Ser Tyr Pro Thr Ala Thr Pro Asn Val Ile 35 40 45 Thr Lys Pro Gly Tyr Ala Tyr Arg Gly Ala Glu Val Ser Asn Ile Thr 50 55 60 Glu Glu Gly Ser Gln Gln Met Lys Ala Leu Gly Ile Thr Thr Ile Phe 65 70 75 80 Asp Leu Arg Ser Asp Pro Glu Met Gln Lys Tyr Ser Thr Pro Ile Pro 85 90 95 His Ile Glu Gly Val Leu Ile Leu Arg Thr Pro Val Phe Ala Thr Glu 100 105 110 Asp Tyr Ser Pro Glu Ser Met Ala Lys Arg Phe Glu Leu Tyr Ala Ser 115 120 125 Gly Thr Thr Glu Ala Phe Met Lys Leu Tyr Ser Gln Ile Leu Asp His 130 135 140 Gly Gly Lys Ala Phe Gly Thr Ile Leu Arg His Val Arg Asp Arg Pro 145 150 155 160 Asn Ser Val Phe Leu Phe His Cys Thr Ala Gly Lys Asp Arg Thr Gly 165 170 175 Ile Ile Ala Ala Ile Leu Phe Lys Leu Ala Gly Val Asp Asp His Leu 180 185 190 Ile Cys Gln Asp Tyr Ser Leu Thr Arg Ile Gly Arg Glu Pro Asp Arg 195 200 205 Glu Lys Val Leu Arg Arg Leu Leu Asn Glu Pro Leu Phe Ala Ala Ala Asn 210 215 220 Thr Glu Leu Ala Leu Arg Met Leu Thr Ser Arg Tyr Glu Thr Met Gln 225 230 235 240 Only Thr Leu Gly Leu Leu Served Asp Lys Tyr Gly Gly Val Glu Ala Tyr 245 250 255 Val Lys Asn Phe Cys Gly Leu Thr Asp Asn Asp Ile Ser Val Ile Arg 260 265 270 Thr Asn Leu Val Val Pro Thr Lys Ala Arg Met 275,280 <210> 20 <211> 852 <212> DNA <213> Hydnomerulius pinastri <400> 20 atgaccgcaa cagacaacgg actagaaccc ttagaccctg catatgtcgc agatgtgctc 60 tcaagaccac cattcgtaca atatctggt gtttgcaacg tccgtctct aggatcctac 120 cctaccgcca ctcccaatgt cataacaag ccggtatg cataccgggg cgcagaggtc 180 tctaacatta ccgaagagg tagccagca atgaggcgc taggcataac gactatattt 240 gatcttagat cggatccaga gatgcagaaa tacagcactc caatacccca cattgaaggc 300 gtactgatat tgcgcacgcc tgtcttcgcg accgaggatt atagtccgga aagtatggcc 360 aagagatttg agctatacgc aagtggtact actgaagcat tttgaaact atactctcaa 420 atactagacc atggaggcaa agccttcgga acaattctcc ggcacgttcg ggacaggcca 480 aattctgtct ttcttttcca ttgcactgcg gggaaagacc ggaccggcat cattgctgca 540 attctgttca agctcgccgg cgtagacgac catctcatat gtcaagatta ctccctcaca 600 cgaataggtc gcgagcctga tcgtgaaaag gtcctccggc gactcttgaa tgaacctcta 660 tttgccgcca acacggaact tgcactacga atgctcacgt ctcgatatga aactatgcaa 720 gcaacgttgg ggcttcttag cgataagtat ggcggggtgg aggcgtatgt gaagaatttc 780 tgtgggctca cggataatga tatatcggtc atacgaacaa atctcgttgt acctacaaag 840 gcgcggatgt ag 852 <210> 21 <211> 936 <212> DNA <213> Talaromyces cellulolyticus <220> <221> CDS <222> (1)..(936) <400> 21 atg agc aac gac acg acc agc acc gca tcc gca ggc acc gca act tct 48 Met Ser Asn Asp Thr Thr Ser Thr Ala Ser Ala Gly Thr Ala Thr Ser 1 5 10 15 tcg cgc ttt ctg agc gtc ggt ggc gtg gtt aac ttc cgt gag ttg ggt 96 Ser Arg Phe Leu Ser Val Gly Gly Val Val Asn Phe Arg Glu Leu Gly 20 25 30 ggc tac ccg tgc gac agc gtt cct cct gca cca gca agc aat ggt agc 144 Gly Tyr Pro Cys Asp Ser Val Pro Pro Ala Pro Ala Ser Asn Gly Ser 35 40 45 ccg gac aat gcg agc gaa gcg att ctg tgg gtt ggt cac agc agc att 192 Pro Asp Asn Ala Ser Glu Ala Ile Leu Trp Val Gly His Ser Ser Ile 50 55 60 cgt ccg cgc ttc ttg ttt cgt agc gca cag ccg tcc cag atc acc ccg 240 Arg Pro Arg Phe Leu Phe Arg Ser Ala Gln Pro Ser Gln Ile Thr Pro 65 70 75 80 gcc ggt to go acg ctg to cgc caa ctc ggt to caa gcg atc ttt 288 Ala Gly Ile Glu Thr Leu Ile Arg Gln Leu Gly Ile Gln Ala Ile Phe 85 90 95 gac ttt cgt tcc cgt acc gag atc caa ctg gtg gca acc cgc tac cca 336 Asp Phe Arg Ser Arg Thr Glu Ile Gln Leu Val Ala Thr Arg Tyr Pro 100 105 110 gat agc ctg ctg gaa att ccg ggc acg act cgt tac tct gtt ccg gtc 384 Asp Ser Leu Leu Glu Ile Pro Gly Thr Thr Arg Tyr Ser Val Pro Val 115 120 125 ttt acc gag ggc gac tac agc ccg gct tct ctg gtt aag cgt tat ggt 432 Phe Thr Glu Gly Asp Tyr Ser Pro Ala Ser Leu Val Lys Arg Tyr Gly 130 135 140 gtc tct agc gac acg gca acg gat agc acc agc tca aag tgc gcg aaa 480 Val Ser Ser Asp Thr Ala Thr Asp Ser Thr Ser Ser Lys Cys Ala Lys 145 150 155 160 ccg acc ggc ttt gtg cat gct tat gaa gcg that gct cgt tct gcc gcg 528 Pro Thr Gly Phe Val His Ala Tyr Glu Ala Ile Ala Arg Ser Ala Ala 165 170 175 gag aac ggt agc ttc cgc aag atc acc gac cac att atc caa cat ccg 576 Glu Asn Gly Ser Phe Arg Lys Ile Thr Asp His Ile Ile Gln His Pro 180 185 190 gat cgc ccg atc ctg ttt cac tgc acg ctg ggc aaa gac cgt acc ggt 624 Asp Arg Pro Ile Leu Phe His Cys Thr Leu Gly Lys Asp Arg Thr Gly 195 200 205 gtt ttc gca gcg ctg ctg ctg agc ttg tgt ggt gtc ccg aat gac acc 672 Val Phe Ala Ala Leu Leu Leu Ser Leu Cys Gly Val Pro Asn Asp Thr 210 215 220 atc gtg gaa gat tat gcg atg acg acc gaa ggc ttc ggt gtg tgg cgt 720 Ile Val Glu Asp Tyr Ala Met Thr Thr Glu Gly Phe Gly Val Trp Arg 225 230 235 240 gag cac ttg att cag cgt ctg ctg cag cgc aaa gat gcg gct acg cgt 768 Glu His Leu Ile Gln Arg Leu Leu Gln Arg Lys Asp Ala Ala Thr Arg 245 250 255 gaa gat gcc gag ttc att atc gcg agc cat ccg gag agc atg aaa gcg 816 Glu Asp Ala Glu Phe Ile Ile Ala Ser His Pro Glu Ser Met Lys Ala 260 265 270 ttc ctg gaa gat gtc gtt gcg acc aaa ttc ggt gac gcc cgc aac tac 864 Phe Leu Glu Asp Val Val Ala Thr Lys Phe Gly Asp Ala Arg Asn Tyr 275 280 285 ttt atc cag cac tgt ggt ctg acc gaa gcc gaa gtg gat aag ctg atc 912 Phe Ile Gln His Cys Gly Leu Thr Glu Ala Glu Val Asp Lys Leu Ile 290 295 300 cgt acg ctg gtg atc gcg aat taa 936 Arg Thr Leu Val Ile Ala Asn 305 310 <210> 22 <211> 311 <212> PRT <213> Talaromyces cellulolyticus <400> 22 Met Ser Asn Asp Thr Thr Ser Thr Ala Ser Ala Gly Thr Ala Thr Ser 1 5 10 15 Ser Arg Phe Leu Ser Val Gly Gly Val Val Asn Phe Arg Glu Leu Gly 20 25 30 Gly Tyr Pro Cys Asp Ser Val Pro Pro Ala Pro Ala Ser Asn Gly Ser 35 40 45 Pro Asp Asn Ala Ser Glu Ala Ile Leu Trp Val Gly His Ser Ser Ile 50 55 60 Arg Pro Arg Phe Leu Phe Arg Ser Ala Gln Pro Ser Gln Ile Thr Pro 65 70 75 80 Ala Gly Ile Glu Thr Leu Ile Arg Gln Leu Gly Ile Gln Ala Ile Phe 85 90 95 Asp Phe Arg Ser Arg Thr Glu Ile Gln Leu Val Ala Thr Arg Tyr Pro 100 105 110 Asp Ser Leu Leu Glu Ile Pro Gly Thr Thr Arg Tyr Ser Val Pro Val 115 120 125 Phe Thr Glu Gly Asp Tyr Ser Pro Ala Ser Leu Val Lys Arg Tyr Gly 130 135 140 Val Ser Ser Asp Thr Ala Thr Asp Ser Thr Ser Ser Lys Cys Ala Lys 145 150 155 160 Pro Thr Gly Phe Val His Ala Tyr Glu Ala Ile Ala Arg Ser Ala Ala 165 170 175 Glu Asn Gly Ser Phe Arg Lys Ile Thr Asp His Ile Ile Gln His Pro 180 185 190 Asp Arg Pro is characterized by Cys Thr Gly and Asp Arg Thr Gly 195 200 205 Val Phe Ala Ala Leu Leu Leu Ser Leu Cys Gly Val Pro Asn Asp Thr 210 215 220 Ile Val Glu Asp Tyr Ala Met Thr Thr Glu Gly Phe Gly Val Trp Arg 225 230 235 240 Glu His With Gln Arg With Gln Arg With Gln Arg With Thr Arg 245 250 255 Glu Asp Ala Glu Phe Ile Ile Ala Ser His Pro Glu Ser Met Lys Ala 260 265 270 Phe Leu Glu Asp Val Val Ala Thr Lys Phe Gly Asp Ala Arg Asn Tyr 275 280 285 Phe Ile Gln His Cys Gly Leu Thr Glu Ala Glu Val Asp Lys Leu Ile 290,295,300 Arg Thr Lion Valley With Asn 305 310 <210> 23 <211> 936 <212> DNA <213> Talaromyces cellulolyticus (Talaromyces cellulolyticus) <400> 23 atgtctaatg acaccactag cacggcttct gccggaacag caacttctc gcggttctt 60 tctgtgggcg gagttgtgaa tttccgtgaa ctgggcggtt atccatgtga ttctgtccct 120 cctgctcctg cctcaaacgg ctcaccggac aacgcatctg aagcgatcct ttgggttggc 180 cactcgtcca ttcggcctag gtttctcttt cgatcggcac agccgtctca gattaccccg 240 gccggtattg agacattgat ccgccagctt ggcatccagg caatttttga ctttcgttca 300 cggacggaaa ttcagcttgt cgccactcgc tatcctgatt cgctactcga gatacctggt 360 acgactcgct attccgtgcc cgtcttcacg gagggcgact attccccggc gtcattagtc 420 aagaggtacg gagtgtcctc cgatactgca actgattcca cttcctccaa atgtgccaag 480 cctacaggat tcgtccacgc atatgaggct atcgcacgca gcgcagcaga aaacggcagt 540 tttcgtaaaa taacggacca cataatacaa catccggacc ggcctatcct gtttcactgt 600 acattgggaa aagaccgaac cggtgtattt gcagcattgt tattgagtct ttgcggggta 660 ccaaacgaca cgatagttga agactatgct atgactaccg agggatttgg ggtctggcga 720 gaacatctaa ttcaacgcct gttacaaaga aaggatgcag ctacgcgtga ggatgcagaa 780 ttcattattg ccagccaccc ggagagtatg aaggcttttc tagaagatgt ggtagcaacc 840 aagttcgggg atgctcgaaa ttactttatc cagcactgtg gattgacgga agcggaggtt 900 gataagctaa ttcggacact ggtcattgcg aattga 936 <210> 24 <211> 990 <212> DNA <213> Talaromyces marneffei <220><s <221> CDS <222> (1)..(990) <400> 24 atg tgg aat ttg cac tat tat att ccg ggc tct gca cca gtt aat ttg 48 Met Trp Asn Leu His Tyr Tyr Ile Pro Gly Ser Ala Pro Val Asn Leu 1 5 10 15 aac gac atg ccg aac gat acg gcg acg acg gct tcc gca ggc act agc 96 Asn Asp Met Pro Asn Asp Thr Ala Thr Thr Ala Ser Ala Gly Thr Ser 20 25 30 gcc acg agc cgc ttc ctc tgt gtc agc ggt gtt gcg aac ttc cgt gaa 144 Ala Thr Ser Arg Phe Leu Cys Val Ser Gly Val Ala Asn Phe Arg Glu 35 40 45 ctg ggt ggc tat ccg tgc gac acc gtt cct cca gca ccg gcg agc aat 192 Leu Gly Gly Tyr Pro Cys Asp Thr Val Pro Pro Ala Pro Ala Ser Asn 50 55 60 ggt agc ccg cat aat gca tcc gag gcc acg ctg caa ggt tcc cac tct 240 Gly Ser Pro His Asn Ala Ser Glu Ala Thr Leu Gln Gly Ser His Ser 65 70 75 80 agc att cgt ccg ggc ttc atc ttc cgt agc gcg caa ccg agc cag atc 288 Ser Ile Arg Pro Gly Phe Ile Phe Arg Ser Ala Gln Pro Ser Gln Ile 85 90 95 aat ccg gca ggc atc gcg acg ctg gcg cat gaa ctg tct att caa gtc 336 Asn Pro Ala Gly Ile Ala Thr Leu Ala His Glu Leu Ser Ile Gln Val 100 105 110 atc ttc gac ttc cgt tcg cag acc gag atc cag ctg gtc acc acc cac 384 Ile Phe Asp Phe Arg Ser Gln Thr Glu Ile Gln Leu Val Thr Thr His 115 120 125 tac ccg gat agc ctg ttg gag atc ccg tgt acc acc cgt tac agc gtg 432 Tyr Pro Asp Ser Leu Leu Glu Ile Pro Cys Thr Thr Arg Tyr Ser Val 130 135 140 ccg gtg ttt aac gag ggt gac tat agc ccg gct tcg ctg gtc aag aaa 480 Pro Val Phe Asn Glu Gly Asp Tyr Ser Pro Ala Ser Leu Val Lys Lys 145 150 155 160 tac ggt gtg agc ccg gac cca gtg acg cat tcc gct agc agc acc agc 528 Tyr Gly Val Ser Pro Asp Pro Val Thr His Ser Ala Ser Ser Thr Ser 165 170 175 gcg aat cct gcc ggc ttt gtg ccg gcc tac gaa gca atc gct cgt agc 576 Ala Asn Pro Ala Gly Phe Val Pro Ala Tyr Glu Ala Ile Ala Arg Ser 180 185 190 gca gcc gaa aac ggt agc ttt cgc aaa atc acc gag cac att att cag 624 Ala Ala Glu Asn Gly Ser Phe Arg Lys Ile Thr Glu His Ile Ile Gln 195 200 205 cac ccg gat cag ccg att ttg ttt cat tgc acc ctg ggt aaa gat cgc 672 His Pro Asp Gln Pro Ile Leu Phe His Cys Thr Leu Gly Lys Asp Arg 210 215 220 acg ggt gtg ttt gcg gcc ctg ctg ctg agc ctg tgc ggt gtt tcc acc 720 Thr Gly Val Phe Ala Ala Leu Leu Leu Ser Leu Cys Gly Val Ser Thr 225 230 235 240 gaa aag atc gtg gaa gat tac gcg atg acc acc gag ggt ttc ggt gct 768 Glu Lys Ile Val Glu Asp Tyr Ala Met Thr Thr Glu Gly Phe Gly Ala 245 250 255 tgg cgt gag cac ctg att aag cgc ctg ctg cag cgt aaa gat gcg gca 816 Trp Arg Glu His With Lys Arg With Gln Arg Lys Asp Ala Ala 260 265 270 acc cgc caa gac gct gag ttc atc att gcc agc cac ccg gaa acc atg 864 Thr Arg Gln Asp With Glu Phe Ile Ile Ala Ser His Pro Glu Thr Met 275 280 285 aaa tct ttt ctg gac gac gtt gtt cgt gcg aag ttt ggc tcc gcg cgt 912 Lys Phe Gly Ser Ala Arg 290,295,300 aac tat ttc gtg caa cag tgc ggt ctg act gag tac gaa gtt gat aag 960 Asn Tyr Phe Val Gln Gln Cys Gly Leu Thr Glu Tyr Glu Val Asp Lys 305 310 315 320 ctg att cat acg ctg gtc att atc aag taa 990 Leu Ile His Thr Leu Val Ile Ile Lys 325 <210> 25 <211> 329 <212> PRT <213> Talaromyces marneffei <400> 25 Met Trp Asn Leu His Tyr Tyr Ile Pro Gly Ser Ala Pro Val Asn Leu 1 5 10 15 Asn Asp Met Pro Asn Asp Thr Ala Thr Thr Ala Ser Ala Gly Thr Ser 20 25 30 Ala Thr Ser Arg Phe Leu Cys Val Ser Gly Val Ala Asn Phe Arg Glu 35 40 45 Leu Gly Gly Tyr Pro Cys Asp Thr Val Pro Pro Ala Pro Ala Ser Asn 50 55 60 Gly Ser Pro His Asn Ala Ser Glu Ala Thr Leu Gln Gly Ser His Ser 65 70 75 80 Ser Ile Arg Pro Gly Phe Ile Phe Arg Ser Ala Gln Pro Ser Gln Ile 85 90 95 Asn Pro Ala Gly Ile Ala Thr Leu Ala His Glu Leu Ser Ile Gln Val 100 105 110 Ile Phe Asp Phe Arg Ser Gln Thr Glu Ile Gln Leu Val Thr Thr His 115 120 125 Tyr Pro Asp Ser Leu Leu Glu Ile Pro Cys Thr Thr Arg Tyr Ser Val 130 135 140 Pro Val Phe Asn Glu Gly Asp Tyr Ser Pro Ala Ser Leu Val Lys Lys 145 150 155 160 Tyr Gly Val Ser Pro Asp Pro Val Thr His Ser Ala Ser Ser Thr Ser 165 170 175 Ala Asn Pro Ala Gly Phe Val Pro Ala Tyr Glu Ala Ile Ala Arg Ser 180 185 190 Ala Ala Glu Asn Gly Ser Phe Arg Lys Ile Thr Glu His Ile Ile Gln 195 200 205 His Pro Asp Gln Pro Ile Leu Phe His Cys Thr Leu Gly Lys Asp Arg 210 215 220 Thr Gly Val Phe Ala Ala Leu Leu Leu Ser Leu Cys Gly Val Ser Thr 225 230 235 240 Glu Lys Ile Val Glu Asp Tyr Ala Met Thr Thr Glu Gly Phe Gly Ala 245 250 255 Trp Arg Glu His With Lys Arg With Gln Arg Lys Asp Ala Ala 260 265 270 Thr Arg Gln Asp With Glu Phe Ile Ile Ala Ser His Pro Glu Thr Met 275 280 285 Lys Phe Gly Ser Ala Arg 290,295,300 Asn Tyr Phe Will Gln Gln Cys Gly Leu Thr Glu Tyr Glu Will Asp Lys 305 310 315 320 Lion Goes His Thr Lion Goes To Lys 325 <210> 26 <211> 990 <212> DNA <213> Talaromyces marneffei <400> 26 atgtggaacc tacactacta tattcctgga tcagcaccag tcaacttgaa cgacatgcct aatgacaccg ctaccacggc ttctgccgga acatcagcaa cttcacggtt tctttgcgtg 120 agcggagtgg cgaatttccg tgaactgggc ggttaccat gcgatactgt ccctcctgct 180 cctgcgtcaa acggttcacc gcacaatgca tctgaagcga ccctccaggg tagtcattcg 240 tctattcggc ctggatttat ctttcgatcg gctcagccgt cgcagattaa cccggctggt 300 attgccacat tagcacacga gcttagcatc caggtgattt ttgactttcg ttcgcaaacc gaaattcagc ttgtcactac tcattatcct gattcgctac ttgagatacc ttgcacgact cgctattccg tgccggtctt caatgagggc gactattccc cagcgtcgtt agtcaagaag 480 tacggggtat cccccgatcc tgtaacacat tccgcttcct ccacgagtgc caatcctgca 540 ggatttgtcc ccgcgtatga agccatcgca cgaagcgcag cagaaaacgg cagtttccgt aaaataacag agcacataat acagcatccg gaccagccga tcctgtttca ttgtactctg ggaaaggacc ggaccggagt ttttgcagca ttgctattga gcctttgcgg tgtttcgact 720 gagagatag ttgaagacta tgctatgact accgagggtt tcggagcctg gcgggaacat 780 ctaattaac gcctgctgca aaggaagat gcagcaacac gccaggatgc ggaattcatt atcgccagcc acccggagac tatgaagtct ttcctagcg atgtcgtgcg agctagttc ggaagtgctc gaaattactt tgtccagcag tgtggattga cagaatga ggttgataag ttaatccata cactcgtgat tataaaatga 990 <210> 27 <211> 906 <212> DNA <213> Talaromyces atroroseus <220> <221> CDS <222> (1)..(906) <400> 27 atg tcc acc aat gca gat ccg acc acg ttt tcc gat aag tcc ccg ttc 48 Met Ser Thr Asn Ala Asp Pro Thr Thr Phe Ser Asp Lys Ser Pro Phe 1 5 10 15 atc aat gtc agc ggc gtg gtg aat ttt cgt gac ctg ggc ggc tac agc 96 Ile Asn Val Ser Gly Val Val Asn Phe Arg Asp Leu Gly Gly Tyr Ser 20 25 30 tgc ttg acc ccg ttg acg cca gtc agc aac ggc agc ccg gta att gcg 144 Cys Leu Thr Pro Leu Thr Pro Val Ser Asn Gly Ser Pro Val Ile Ala 35 40 45 tcg aag ggt agc cct tct agc tat atc cgt cca ggt ttc ctg ttt cgc 192 Ser Lys Gly Ser Pro Ser Ser Tyr Ile Arg Pro Gly Phe Leu Phe Arg 50 55 60 tct gct cag ccg agc cag att acc gaa acc ggt atc gag gtc ctg acc 240 Ser Ala Gln Pro Ser Gln Ile Thr Glu Thr Gly Ile Glu Val Leu Thr 65 70 75 80 cac aag ctg aat atc ggt gcg att ttt gac ttc cgt tcc caa acc gag 288 His Lys Leu Asn Ile Gly Ala Ile Phe Asp Phe Arg Ser Gln Thr Glu 85 90 95 atc caa ctg gtt gcg acg cgt tac ccg gac agc ctg ctg gaa att ccg 336 Ile Gln Leu Val Ala Thr Arg Tyr Pro Asp Ser Leu Leu Glu Ile Pro 100 105 110 ttt acc tct cgt tat gca gtc ccg gtt ttc gag cat tgt gat ttc agc 384 Phe Thr Ser Arg Tyr Ala Val Pro Val Phe Glu His Cys Asp Phe Ser 115 120 125 ccg gtt agc ttg agc aag aaa tat ggt gcg ccg agc aac gca ccg cct 432 Pro Val Ser Leu Ser Lys Lys Tyr Gly Ala Pro Ser Asn Ala Pro Pro 130 135 140 acc gaa gcg gag cac ggt agc ttt gtg cag gcg tac gaa gat to gcc 480 Thr Glu Ala Glu His Gly Ser Phe Val Gln Ala Tyr Glu Asp Ile Ala 145 150 155 160 cgt agc gca gca gag aac ggc agc ttc cgc agc atc acg gac cac att 528 Arg Ser Ala Ala Glu Asn Gly Ser Phe Arg Ser Ile Thr Asp His Ile 165 170 175 ttg cgc tac ccg gat atg ccg atc ctg ttc cac tgc acc gtg ggc aaa 576 Leu Arg Tyr Pro Asp Met Pro Ile Leu Phe His Cys Thr Val Gly Lys 180 185 190 gac cgc acc ggc gtt ttt gcg gcg ctg ctg ctg aaa ctg tgt ggt gtg 624 Asp Arg Thr Gly Val Phe Ala Ala Leu Leu Leu Lys Leu Cys Gly Val 195 200 205 agc gac gaa gtt gtg att cag gac tat gcc ctg act acg caa ggt ctg 672 Ser Asp Glu Val Val Ile Gln Asp Tyr Ala Leu Thr Thr Gln Gly Leu 210 215 220 ggt gcc tgg aga gag cat ctg atc caa cgc ctg ctg cag cgt aat gac 720 Gly Ala Trp Arg Glu His Leu Ile Gln Arg Leu Leu Gln Arg Asn Asp 225 230 235 240 gtc gcg acg cgt gaa gat gca gag ttt atc ctg gct agc cgt ccg gag 768 Val Ala Thr Arg Glu Asp Ala Glu Phe Ile Leu Ala Ser Arg Pro Glu 245 250 255 act atg aaa tcg ttc ctg gcc gat gtt gtg gaa acc aag ttc ggt ggc 816 Thr Met Lys Ser Phe Leu Ala Asp Val Val Glu Thr Lys Phe Gly Gly 260 265 270 gct cgc aac tac ttc acg ctg ctg tgc ggt ctg acc gaa gat gat gtt 864 Ala Arg Asn Tyr Phe Thr Leu Leu Cys Gly Leu Thr Glu Asp Asp Val 275 280 285 aac aac ctg att agc ctg gtt gtc att cat aac acg aat taa 906 Asn Asn Leu Ile Ser Leu Val Val Ile His Asn Thr Asn 290 295 300 <210> 28 <211> 301 <212> PRT <213> Talaromyces atroroseus <400> 28 Met Ser Thr Asn Ala Asp Pro Thr Thr Phe Ser Asp Lys Ser Pro Phe 1 5 10 15 Ile Asn Val Ser Gly Val Val Asn Phe Arg Asp Leu Gly Gly Tyr Ser 20 25 30 Cys Leu Thr Pro Leu Thr Pro Val Ser Asn Gly Ser Pro Val Ile Ala 35 40 45 Ser Lys Gly Ser Pro Ser Ser Tyr Ile Arg Pro Gly Phe Leu Phe Arg 50 55 60 Ser Ala Gln Pro Ser Gln Ile Thr Glu Thr Gly Ile Glu Val Leu Thr 65 70 75 80 His Lys Leu Asn Ile Gly Ala Ile Phe Asp Phe Arg Ser Gln Thr Glu 85 90 95 Ile Gln Leu Val Ala Thr Arg Tyr Pro Asp Ser Leu Leu Glu Ile Pro 100 105 110 Phe Thr Ser Arg Tyr Ala Val Pro Val Phe Glu His Cys Asp Phe Ser 115 120 125 Pro Val Ser Leu Ser Lys Lys Tyr Gly Ala Pro Ser Asn Ala Pro Pro 130 135 140 Thr Glu Ala Glu His Gly Ser Phe Val Gln Ala Tyr Glu Asp Ile Ala 145 150 155 160 Arg Ser Ala Ala Glu Asn Gly Ser Phe Arg Ser Ile Thr Asp His Ile 165 170 175 ...

Claims

1. A biocatalytic method for producing a terpene alcohol compound of general formula (1), in R represents H or a cyclic or acyclic, linear or branched, saturated or unsaturated hydrocarbon residue with or without substitution, The Method The following steps are involved: (1) contacting the corresponding terpene diphosphate precursor of the terpene compound of the general formula (1) with a polypeptide having terpene diphosphate phosphatase activity to form the terpene alcohol, wherein the polypeptide having terpene diphosphate phosphatase activity is selected from diphosphate removal enzyme members of the protein tyrosine phosphatase family, And wherein the polypeptide having terpene diphosphate phosphatase activity is selected from the group consisting of the following polypeptides: a) TalVeTPP, the amino acid sequence of which is SEQ ID NO: 2, b) AspWeTPP, the amino acid sequence of which is SEQ ID NO: 6, c) HelGriTPP, whose amino acid sequence is SEQ ID NO: 10, d) UmbPiTPP1, whose amino acid sequence is SEQ ID NO: 13, e) TalVeTPP2, the amino acid sequence of which is SEQ ID NO: 16, f) HydPiTPP1, whose amino acid sequence is SEQ ID NO: 19, g) TalCeTPP1, whose amino acid sequence is SEQ ID NO: 22, h) TalMaTPP1, whose amino acid sequence is SEQ ID NO: 25, i) TalAstroTPP1, whose amino acid sequence is SEQ ID NO: 28, and j) PeSubTPP1, whose amino acid sequence is SEQ ID NO:

31.

2. The method according to claim 1, The following steps are involved: (1) contacting the corresponding terpene diphosphate precursor of the terpene compound of the general formula (1) with a polypeptide having terpene diphosphate phosphatase activity to form the terpene alcohol; and (2) Separating the terpene alcohol from step (1).

3. A biocatalytic method for producing bicyclic diterpene alcohol compounds, The following steps are involved: (1) contacting a corresponding bicyclic diterpene diphosphate precursor of the bicyclic diterpene compound with a polypeptide having terpene diphosphate phosphatase activity to form the bicyclic diterpene alcohol, wherein the polypeptide having terpene diphosphate phosphatase activity is selected from diphosphate removal enzyme members of the protein tyrosine phosphatase family, And wherein the polypeptide having terpene diphosphate phosphatase activity is selected from the group consisting of the following polypeptides: a) TalVeTPP, the amino acid sequence of which is SEQ ID NO: 2, b) AspWeTPP, the amino acid sequence of which is SEQ ID NO: 6, c) HelGriTPP, whose amino acid sequence is SEQ ID NO: 10, d) UmbPiTPP1, whose amino acid sequence is SEQ ID NO: 13, e) TalVeTPP2, the amino acid sequence of which is SEQ ID NO: 16, f) HydPiTPP1, whose amino acid sequence is SEQ ID NO: 19, g) TalCeTPP1, whose amino acid sequence is SEQ ID NO: 22, h) TalMaTPP1, whose amino acid sequence is SEQ ID NO: 25, i) TalAstroTPP1, whose amino acid sequence is SEQ ID NO: 28, and j) PeSubTPP1, whose amino acid sequence is SEQ ID NO:

31.

4. The method according to claim 3, The following steps are involved: (1) contacting a corresponding bicyclic diterpene diphosphate precursor of the bicyclic diterpene compound with a polypeptide having terpene diphosphate phosphatase activity to form the bicyclic diterpene alcohol; and (2) separating the bicyclic diterpene alcohol from step (1).

5. The process according to claim 1 or 2, wherein a terpene alcohol compound of the general formula (1) is prepared, wherein R represents H or an acyclic, linear or branched, saturated or unsaturated hydrocarbon residue.

6. The method according to claim 5, wherein the terpene alcohol of general formula (1) is selected from farnesol and geranylgeraniol.

7. The method according to claim 3 or 4, wherein step (1) further comprises contacting the acyclic terpene diphosphate precursor with a polypeptide having bicyclic diterpene diphosphate synthase activity to form the bicyclic diterpene diphosphate precursor.

8. The method according to claim 7, wherein the bicyclic diterpene diphosphate synthase is selected from: a) SmCPS2, the amino acid sequence of which is SEQ ID NO: 34, b) TaTps1-del59, whose amino acid sequence is SEQ ID NO: 40, and c) SsLPS, whose amino acid sequence is SEQ ID NO:

38.

9. The method according to any one of claims 3 and 8, wherein the biocatalytically produced bicyclic diterpene alcohol is selected from copalol and lisdendiolate, each of which is in the form of a substantially pure stereoisomer or in the form of a mixture of at least two stereoisomers.

10. The method according to claim 7, wherein the biocatalytically produced bicyclic diterpene alcohol is selected from copalol and lisdendiolate, each of which is in the form of a substantially pure stereoisomer or in the form of a mixture of at least two stereoisomers.

11. The method according to claim 1, 2, 3 or 4, further comprising processing the terpene alcohol of step (1) or step (2) into a terpene alcohol derivative using chemical or biocatalytic synthesis or a combination of both as step (3), wherein the derivative is a hydrocarbon, diol, triol, aldehyde, acid, ether, amide, ketone, epoxide, glycoside and / or ester.

12. The method according to claim 11, wherein the derivative is an acetal, a ketal, a lactone and / or an acetate.

13. The method of claim 11, wherein the terpene alcohol is oxidized biocatalytically.

14. The method of claim 13, wherein the terpene alcohol is converted by contacting with an alcohol dehydrogenase (ADH).

15. The method according to claim 14, wherein the ADH is selected from: a) CymB, the amino acid sequence of which is SEQ ID NO:42; b) AspWeADH1, whose amino acid sequence is SEQ ID NO: 44; c) PsAeroADH1, whose amino acid sequence is SEQ ID NO: 46; d) AzTolADH1, whose amino acid sequence is SEQ ID NO: 48; e) AroAroADH1, whose amino acid sequence is SEQ ID NO: 50; f) ThTerpADH1, whose amino acid sequence is SEQ ID NO: 52; g) CdGeoA, whose amino acid sequence is SEQ ID NO: 54; h) VoADH1, whose amino acid sequence is SEQ ID NO: 56; i) SCH23-ADH1, whose amino acid sequence is SEQ ID NO: 68; and j) SCH24-ADH1a, the amino acid sequence of which is SEQ ID NO:

70.

16. A method for preparing an ambroxol-like compound of the following general formula, The Method include: (1) Providing a lisdendioic acid or copal compound by carrying out the biocatalytic method defined in any one of claims 1 to 15; and (2) converting the lisdendialol or copal compound of step (1) into an ambroxan-like compound by chemical synthesis and / or biochemical synthesis.

17. The method according to claim 16, wherein step (1) of the method comprises: (1) providing a lisdendioic acid or copal compound by performing the biocatalytic method defined in any one of claims 1 to 15, and isolating the lisdendioic acid or copal compound.